AnatomyOrganismsDiseasesChemicals and DrugsAnalytical, Diagnostic and Therapeutic Techniques and EquipmentPhenomena and ProcessesNamed GroupsHealth Care
Lupus Erythematosus, SystemicLupus Erythematosus, DiscoidLupus Erythematosus, CutaneousLupus NephritisAntibodies, AntinuclearAutoantibodiesLupus Vasculitis, Central Nervous SystemHydroxychloroquineAntibodies, AnticardiolipinMice, Inbred NZBAntibodies, AntiphospholipidAutoantigensAntiphospholipid SyndromeAutoimmune DiseasesImmunoglobulin GMice, Inbred MRL lprComplement C4Lupus Coagulation InhibitorsnRNP Core ProteinsAntigen-Antibody ComplexPanniculitis, Lupus ErythematosusRheumatic DiseasesAutoimmunityArthritis, RheumatoidSjogren's SyndromeComplement C1qNephritisPhotosensitivity DisordersSeverity of Illness IndexPrednisoloneComplement C3RNA, Small CytoplasmicB-LymphocytesDNAImmunosuppressive AgentsConnective Tissue DiseasesImmunoglobulin MCase-Control StudiesEnzyme-Linked Immunosorbent AssayGenetic Predisposition to DiseaseB-Cell Activating FactorCardiolipinsCollagen DiseasesMixed Connective Tissue DiseaseComplement C4aSerositisScleroderma, SystemicLupus VulgarisGlomerulonephritisRibonucleoproteinsRibonucleoproteins, Small Nuclearbeta 2-Glycoprotein IBiological MarkersComplement System ProteinsVasculitisAntibody SpecificityT-LymphocytesCryoglobulinsProteinuriaAdrenal Cortex HormonesReceptors, IgGPlasmapheresisAzathioprineMethylprednisoloneInterferon Regulatory FactorsB-Lymphocyte SubsetsPolymorphism, Single NucleotideComplement C4bPrednisoneAntibodiesComplement C2Lymphocyte ActivationGlucocorticoidsAntibodies, MonoclonalMyelitis, TransverseKidneyAntibodies, Anti-IdiotypicSkin DiseasesRisk FactorsGenotypeKidney GlomerulusAnemia, Hemolytic, AutoimmuneInterferon-alphaDisease Models, AnimalCohort StudiesFlow CytometryTumor Necrosis Factor Ligand Superfamily Member 13ThrombocytopeniaAllelesPolymorphism, GeneticReceptors, Complement 3bEuropean Continental Ancestry GroupBlood SedimentationLymphocytesLeukocytes, MononuclearBiopsyGene FrequencyImmunoglobulin IdiotypesFluorescent Antibody TechniqueComplement C3c
Lupus Erythematosus, Systemic
A chronic, relapsing, inflammatory, and often febrile multisystemic disorder of connective tissue, characterized principally by involvement of the skin, joints, kidneys, and serosal membranes. It is of unknown etiology, but is thought to represent a failure of the regulatory mechanisms of the autoimmune system. The disease is marked by a wide range of system dysfunctions, an elevated erythrocyte sedimentation rate, and the formation of LE cells in the blood or bone marrow.
Lupus Erythematosus, Discoid
A chronic form of cutaneous lupus erythematosus (LUPUS ERYTHEMATOSUS, CUTANEOUS) in which the skin lesions mimic those of the systemic form but in which systemic signs are rare. It is characterized by the presence of discoid skin plaques showing varying degrees of edema, erythema, scaliness, follicular plugging, and skin atrophy. Lesions are surrounded by an elevated erythematous border. The condition typically involves the face and scalp, but widespread dissemination may occur.
Lupus Erythematosus, Cutaneous
A form of lupus erythematosus in which the skin may be the only organ involved or in which skin involvement precedes the spread into other body systems. It has been classified into three forms - acute (= LUPUS ERYTHEMATOSUS, SYSTEMIC with skin lesions), subacute, and chronic (= LUPUS ERYTHEMATOSUS, DISCOID).
Lupus Nephritis
Glomerulonephritis associated with autoimmune disease SYSTEMIC LUPUS ERYTHEMATOSUS. Lupus nephritis is histologically classified into 6 classes: class I - normal glomeruli, class II - pure mesangial alterations, class III - focal segmental glomerulonephritis, class IV - diffuse glomerulonephritis, class V - diffuse membranous glomerulonephritis, and class VI - advanced sclerosing glomerulonephritis (The World Health Organization classification 1982).
Antibodies, Antinuclear
Autoantibodies directed against various nuclear antigens including DNA, RNA, histones, acidic nuclear proteins, or complexes of these molecular elements. Antinuclear antibodies are found in systemic autoimmune diseases including systemic lupus erythematosus, Sjogren's syndrome, scleroderma, polymyositis, and mixed connective tissue disease.
Autoantibodies
Antibodies that react with self-antigens (AUTOANTIGENS) of the organism that produced them.
Lupus Vasculitis, Central Nervous System
Central nervous system vasculitis that is associated with SYSTEMIC LUPUS ERYTHEMATOSUS. Clinical manifestations may include DEMENTIA; SEIZURES; CRANIAL NERVE DISEASES; HEMIPARESIS; BLINDNESS; DYSPHASIA; and other neurological disorders.
Hydroxychloroquine
A chemotherapeutic agent that acts against erythrocytic forms of malarial parasites. Hydroxychloroquine appears to concentrate in food vacuoles of affected protozoa. It inhibits plasmodial heme polymerase. (From Gilman et al., Goodman and Gilman's The Pharmacological Basis of Therapeutics, 9th ed, p970)
Antibodies, Anticardiolipin
Antiphospholipid antibodies found in association with systemic lupus erythematosus (LUPUS ERYTHEMATOSUS, SYSTEMIC;), ANTIPHOSPHOLIPID SYNDROME; and in a variety of other diseases as well as in healthy individuals. The antibodies are detected by solid-phase IMMUNOASSAY employing the purified phospholipid antigen CARDIOLIPIN.
Mice, Inbred NZB
Antibodies, Antiphospholipid
Autoantibodies directed against phospholipids. These antibodies are characteristically found in patients with systemic lupus erythematosus (LUPUS ERYTHEMATOSUS, SYSTEMIC;), ANTIPHOSPHOLIPID SYNDROME; related autoimmune diseases, some non-autoimmune diseases, and also in healthy individuals.
Autoantigens
Endogenous tissue constituents that have the ability to interact with AUTOANTIBODIES and cause an immune response.
Antiphospholipid Syndrome
The presence of antibodies directed against phospholipids (ANTIBODIES, ANTIPHOSPHOLIPID). The condition is associated with a variety of diseases, notably systemic lupus erythematosus and other connective tissue diseases, thrombopenia, and arterial or venous thromboses. In pregnancy it can cause abortion. Of the phospholipids, the cardiolipins show markedly elevated levels of anticardiolipin antibodies (ANTIBODIES, ANTICARDIOLIPIN). Present also are high levels of lupus anticoagulant (LUPUS COAGULATION INHIBITOR).
Autoimmune Diseases
Disorders that are characterized by the production of antibodies that react with host tissues or immune effector cells that are autoreactive to endogenous peptides.
Immunoglobulin G
The major immunoglobulin isotype class in normal human serum. There are several isotype subclasses of IgG, for example, IgG1, IgG2A, and IgG2B.
Mice, Inbred MRL lpr
A mouse substrain that is genetically predisposed to the development of systemic lupus erythematosus-like syndrome, which has been found to be clinically similar to the human disease. It has been determined that this mouse strain carries a mutation in the fas gene. Also, the MRL/lpr is a useful model to study behavioral and cognitive deficits found in autoimmune diseases and the efficacy of immunosuppressive agents.
Complement C4
A glycoprotein that is important in the activation of CLASSICAL COMPLEMENT PATHWAY. C4 is cleaved by the activated COMPLEMENT C1S into COMPLEMENT C4A and COMPLEMENT C4B.
Lupus Coagulation Inhibitor
An antiphospholipid antibody found in association with systemic lupus erythematosus (LUPUS ERYTHEMATOSUS, SYSTEMIC;), ANTIPHOSPHOLIPID SYNDROME; and in a variety of other diseases as well as in healthy individuals. In vitro, the antibody interferes with the conversion of prothrombin to thrombin and prolongs the partial thromboplastin time. In vivo, it exerts a procoagulant effect resulting in thrombosis mainly in the larger veins and arteries. It further causes obstetrical complications, including fetal death and spontaneous abortion, as well as a variety of hematologic and neurologic complications.
snRNP Core Proteins
The protein components that constitute the common core of small nuclear ribonucleoprotein particles. These proteins are commonly referred as Sm nuclear antigens due to their antigenic nature.
Antigen-Antibody Complex
The complex formed by the binding of antigen and antibody molecules. The deposition of large antigen-antibody complexes leading to tissue damage causes IMMUNE COMPLEX DISEASES.
Panniculitis, Lupus Erythematosus
A type of lupus erythematosus characterized by deep dermal or subcutaneous nodules, most often on the head, face, or upper arms. It is generally chronic and occurs most often in women between the ages of 20 and 45.
Rheumatic Diseases
Disorders of connective tissue, especially the joints and related structures, characterized by inflammation, degeneration, or metabolic derangement.
Autoimmunity
Process whereby the immune system reacts against the body's own tissues. Autoimmunity may produce or be caused by AUTOIMMUNE DISEASES.
Arthritis, Rheumatoid
A chronic systemic disease, primarily of the joints, marked by inflammatory changes in the synovial membranes and articular structures, widespread fibrinoid degeneration of the collagen fibers in mesenchymal tissues, and by atrophy and rarefaction of bony structures. Etiology is unknown, but autoimmune mechanisms have been implicated.
Sjogren's Syndrome
Chronic inflammatory and autoimmune disease in which the salivary and lacrimal glands undergo progressive destruction by lymphocytes and plasma cells resulting in decreased production of saliva and tears. The primary form, often called sicca syndrome, involves both KERATOCONJUNCTIVITIS SICCA and XEROSTOMIA. The secondary form includes, in addition, the presence of a connective tissue disease, usually rheumatoid arthritis.
Complement C1q
A subcomponent of complement C1, composed of six copies of three polypeptide chains (A, B, and C), each encoded by a separate gene (C1QA; C1QB; C1QC). This complex is arranged in nine subunits (six disulfide-linked dimers of A and B, and three disulfide-linked homodimers of C). C1q has binding sites for antibodies (the heavy chain of IMMUNOGLOBULIN G or IMMUNOGLOBULIN M). The interaction of C1q and immunoglobulin activates the two proenzymes COMPLEMENT C1R and COMPLEMENT C1S, thus initiating the cascade of COMPLEMENT ACTIVATION via the CLASSICAL COMPLEMENT PATHWAY.
Nephritis
Inflammation of any part of the KIDNEY.
Photosensitivity Disorders
Abnormal responses to sunlight or artificial light due to extreme reactivity of light-absorbing molecules in tissues. It refers almost exclusively to skin photosensitivity, including sunburn, reactions due to repeated prolonged exposure in the absence of photosensitizing factors, and reactions requiring photosensitizing factors such as photosensitizing agents and certain diseases. With restricted reference to skin tissue, it does not include photosensitivity of the eye to light, as in photophobia or photosensitive epilepsy.
Severity of Illness Index
Levels within a diagnostic group which are established by various measurement criteria applied to the seriousness of a patient's disorder.
Prednisolone
A glucocorticoid with the general properties of the corticosteroids. It is the drug of choice for all conditions in which routine systemic corticosteroid therapy is indicated, except adrenal deficiency states.
Complement C3
A glycoprotein that is central in both the classical and the alternative pathway of COMPLEMENT ACTIVATION. C3 can be cleaved into COMPLEMENT C3A and COMPLEMENT C3B, spontaneously at low level or by C3 CONVERTASE at high level. The smaller fragment C3a is an ANAPHYLATOXIN and mediator of local inflammatory process. The larger fragment C3b binds with C3 convertase to form C5 convertase.
RNA, Small Cytoplasmic
Small RNAs found in the cytoplasm usually complexed with proteins in scRNPs (RIBONUCLEOPROTEINS, SMALL CYTOPLASMIC).
B-Lymphocytes
Lymphoid cells concerned with humoral immunity. They are short-lived cells resembling bursa-derived lymphocytes of birds in their production of immunoglobulin upon appropriate stimulation.
DNA
A deoxyribonucleotide polymer that is the primary genetic material of all cells. Eukaryotic and prokaryotic organisms normally contain DNA in a double-stranded state, yet several important biological processes transiently involve single-stranded regions. DNA, which consists of a polysugar-phosphate backbone possessing projections of purines (adenine and guanine) and pyrimidines (thymine and cytosine), forms a double helix that is held together by hydrogen bonds between these purines and pyrimidines (adenine to thymine and guanine to cytosine).
Immunosuppressive Agents
Agents that suppress immune function by one of several mechanisms of action. Classical cytotoxic immunosuppressants act by inhibiting DNA synthesis. Others may act through activation of T-CELLS or by inhibiting the activation of HELPER CELLS. While immunosuppression has been brought about in the past primarily to prevent rejection of transplanted organs, new applications involving mediation of the effects of INTERLEUKINS and other CYTOKINES are emerging.
Connective Tissue Diseases
A heterogeneous group of disorders, some hereditary, others acquired, characterized by abnormal structure or function of one or more of the elements of connective tissue, i.e., collagen, elastin, or the mucopolysaccharides.
Immunoglobulin M
A class of immunoglobulin bearing mu chains (IMMUNOGLOBULIN MU-CHAINS). IgM can fix COMPLEMENT. The name comes from its high molecular weight and originally being called a macroglobulin.
Case-Control Studies
Studies which start with the identification of persons with a disease of interest and a control (comparison, referent) group without the disease. The relationship of an attribute to the disease is examined by comparing diseased and non-diseased persons with regard to the frequency or levels of the attribute in each group.
Enzyme-Linked Immunosorbent Assay
An immunoassay utilizing an antibody labeled with an enzyme marker such as horseradish peroxidase. While either the enzyme or the antibody is bound to an immunosorbent substrate, they both retain their biologic activity; the change in enzyme activity as a result of the enzyme-antibody-antigen reaction is proportional to the concentration of the antigen and can be measured spectrophotometrically or with the naked eye. Many variations of the method have been developed.
Genetic Predisposition to Disease
A latent susceptibility to disease at the genetic level, which may be activated under certain conditions.
B-Cell Activating Factor
A tumor necrosis factor superfamily member that plays a role in the regulation of B-LYMPHOCYTE survival. It occurs as a membrane-bound protein that is cleaved to release an biologically active soluble form with specificity to TRANSMEMBRANE ACTIVATOR AND CAML INTERACTOR PROTEIN; B-CELL ACTIVATION FACTOR RECEPTOR; and B-CELL MATURATION ANTIGEN.
Cardiolipins
Acidic phospholipids composed of two molecules of phosphatidic acid covalently linked to a molecule of glycerol. They occur primarily in mitochondrial inner membranes and in bacterial plasma membranes. They are the main antigenic components of the Wassermann-type antigen that is used in nontreponemal SYPHILIS SERODIAGNOSIS.
Collagen Diseases
Historically, a heterogeneous group of acute and chronic diseases, including rheumatoid arthritis, systemic lupus erythematosus, progressive systemic sclerosis, dermatomyositis, etc. This classification was based on the notion that "collagen" was equivalent to "connective tissue", but with the present recognition of the different types of collagen and the aggregates derived from them as distinct entities, the term "collagen diseases" now pertains exclusively to those inherited conditions in which the primary defect is at the gene level and affects collagen biosynthesis, post-translational modification, or extracellular processing directly. (From Cecil Textbook of Medicine, 19th ed, p1494)
Mixed Connective Tissue Disease
A syndrome with overlapping clinical features of systemic lupus erythematosus, scleroderma, polymyositis, and Raynaud's phenomenon. The disease is differentially characterized by high serum titers of antibodies to ribonuclease-sensitive extractable (saline soluble) nuclear antigen and a "speckled" epidermal nuclear staining pattern on direct immunofluorescence.
Complement C4a
The smaller fragment formed when complement C4 is cleaved by COMPLEMENT C1S. It is an anaphylatoxin that causes symptoms of immediate hypersensitivity (HYPERSENSITIVITY, IMMEDIATE) but its activity is weaker than that of COMPLEMENT C3A or COMPLEMENT C5A.
Serositis
Inflammation of a serous membrane.
Scleroderma, Systemic
A chronic multi-system disorder of CONNECTIVE TISSUE. It is characterized by SCLEROSIS in the SKIN, the LUNGS, the HEART, the GASTROINTESTINAL TRACT, the KIDNEYS, and the MUSCULOSKELETAL SYSTEM. Other important features include diseased small BLOOD VESSELS and AUTOANTIBODIES. The disorder is named for its most prominent feature (hard skin), and classified into subsets by the extent of skin thickening: LIMITED SCLERODERMA and DIFFUSE SCLERODERMA.
Lupus Vulgaris
A form of cutaneous tuberculosis. It is seen predominantly in women and typically involves the NASAL MUCOSA; BUCCAL MUCOSA; and conjunctival mucosa.
Glomerulonephritis
Inflammation of the renal glomeruli (KIDNEY GLOMERULUS) that can be classified by the type of glomerular injuries including antibody deposition, complement activation, cellular proliferation, and glomerulosclerosis. These structural and functional abnormalities usually lead to HEMATURIA; PROTEINURIA; HYPERTENSION; and RENAL INSUFFICIENCY.
Ribonucleoproteins
Complexes of RNA-binding proteins with ribonucleic acids (RNA).
Ribonucleoproteins, Small Nuclear
Highly conserved nuclear RNA-protein complexes that function in RNA processing in the nucleus, including pre-mRNA splicing and pre-mRNA 3'-end processing in the nucleoplasm, and pre-rRNA processing in the nucleolus (see RIBONUCLEOPROTEINS, SMALL NUCLEOLAR).
beta 2-Glycoprotein I
A 44-kDa highly glycosylated plasma protein that binds phospholipids including CARDIOLIPIN; APOLIPOPROTEIN E RECEPTOR; membrane phospholipids, and other anionic phospholipid-containing moieties. It plays a role in coagulation and apoptotic processes. Formerly known as apolipoprotein H, it is an autoantigen in patients with ANTIPHOSPHOLIPID ANTIBODIES.
Biological Markers
Measurable and quantifiable biological parameters (e.g., specific enzyme concentration, specific hormone concentration, specific gene phenotype distribution in a population, presence of biological substances) which serve as indices for health- and physiology-related assessments, such as disease risk, psychiatric disorders, environmental exposure and its effects, disease diagnosis, metabolic processes, substance abuse, pregnancy, cell line development, epidemiologic studies, etc.
Complement System Proteins
Serum glycoproteins participating in the host defense mechanism of COMPLEMENT ACTIVATION that creates the COMPLEMENT MEMBRANE ATTACK COMPLEX. Included are glycoproteins in the various pathways of complement activation (CLASSICAL COMPLEMENT PATHWAY; ALTERNATIVE COMPLEMENT PATHWAY; and LECTIN COMPLEMENT PATHWAY).
Vasculitis
Inflammation of any one of the blood vessels, including the ARTERIES; VEINS; and rest of the vasculature system in the body.
Antibody Specificity
The property of antibodies which enables them to react with some ANTIGENIC DETERMINANTS and not with others. Specificity is dependent on chemical composition, physical forces, and molecular structure at the binding site.
T-Lymphocytes
Lymphocytes responsible for cell-mediated immunity. Two types have been identified - cytotoxic (T-LYMPHOCYTES, CYTOTOXIC) and helper T-lymphocytes (T-LYMPHOCYTES, HELPER-INDUCER). They are formed when lymphocytes circulate through the THYMUS GLAND and differentiate to thymocytes. When exposed to an antigen, they divide rapidly and produce large numbers of new T cells sensitized to that antigen.
Cryoglobulins
Abnormal immunoglobulins, especially IGG or IGM, that precipitate spontaneously when SERUM is cooled below 37 degrees Celsius. It is characteristic of CRYOGLOBULINEMIA.
Proteinuria
The presence of proteins in the urine, an indicator of KIDNEY DISEASES.
Adrenal Cortex Hormones
Receptors, IgG
Specific molecular sites on the surface of various cells, including B-lymphocytes and macrophages, that combine with IMMUNOGLOBULIN Gs. Three subclasses exist: Fc gamma RI (the CD64 antigen, a low affinity receptor), Fc gamma RII (the CD32 antigen, a high affinity receptor), and Fc gamma RIII (the CD16 antigen, a low affinity receptor).
Plasmapheresis
Procedure whereby plasma is separated and extracted from anticoagulated whole blood and the red cells retransfused to the donor. Plasmapheresis is also employed for therapeutic use.
Azathioprine
An immunosuppressive agent used in combination with cyclophosphamide and hydroxychloroquine in the treatment of rheumatoid arthritis. According to the Fourth Annual Report on Carcinogens (NTP 85-002, 1985), this substance has been listed as a known carcinogen. (Merck Index, 11th ed)
Methylprednisolone
A PREDNISOLONE derivative with similar anti-inflammatory action.
Interferon Regulatory Factors
A family of transcription factors that share an N-terminal HELIX-TURN-HELIX MOTIF and bind INTERFERON-inducible promoters to control GENE expression. IRF proteins bind specific DNA sequences such as interferon-stimulated response elements, interferon regulatory elements, and the interferon consensus sequence.
B-Lymphocyte Subsets
A classification of B-lymphocytes based on structurally or functionally different populations of cells.
Polymorphism, Single Nucleotide
A single nucleotide variation in a genetic sequence that occurs at appreciable frequency in the population.
Complement C4b
The large fragment formed when COMPLEMENT C4 is cleaved by COMPLEMENT C1S. The membrane-bound C4b binds COMPLEMENT C2A, a SERINE PROTEASE, to form C4b2a (CLASSICAL PATHWAY C3 CONVERTASE) and subsequent C4b2a3b (CLASSICAL PATHWAY C5 CONVERTASE).
Prednisone
A synthetic anti-inflammatory glucocorticoid derived from CORTISONE. It is biologically inert and converted to PREDNISOLONE in the liver.
Antibodies
Immunoglobulin molecules having a specific amino acid sequence by virtue of which they interact only with the ANTIGEN (or a very similar shape) that induced their synthesis in cells of the lymphoid series (especially PLASMA CELLS).
Complement C2
A component of the CLASSICAL COMPLEMENT PATHWAY. C2 is cleaved by activated COMPLEMENT C1S into COMPLEMENT C2B and COMPLEMENT C2A. C2a, the COOH-terminal fragment containing a SERINE PROTEASE, combines with COMPLEMENT C4B to form C4b2a (CLASSICAL PATHWAY C3 CONVERTASE) and subsequent C4b2a3b (CLASSICAL PATHWAY C5 CONVERTASE).
Lymphocyte Activation
Morphologic alteration of small B LYMPHOCYTES or T LYMPHOCYTES in culture into large blast-like cells able to synthesize DNA and RNA and to divide mitotically. It is induced by INTERLEUKINS; MITOGENS such as PHYTOHEMAGGLUTININS, and by specific ANTIGENS. It may also occur in vivo as in GRAFT REJECTION.
Glucocorticoids
A group of CORTICOSTEROIDS that affect carbohydrate metabolism (GLUCONEOGENESIS, liver glycogen deposition, elevation of BLOOD SUGAR), inhibit ADRENOCORTICOTROPIC HORMONE secretion, and possess pronounced anti-inflammatory activity. They also play a role in fat and protein metabolism, maintenance of arterial blood pressure, alteration of the connective tissue response to injury, reduction in the number of circulating lymphocytes, and functioning of the central nervous system.
Antibodies, Monoclonal
Antibodies produced by a single clone of cells.
Myelitis, Transverse
Inflammation of a transverse portion of the spinal cord characterized by acute or subacute segmental demyelination or necrosis. The condition may occur sporadically, follow an infection or vaccination, or present as a paraneoplastic syndrome (see also ENCEPHALOMYELITIS, ACUTE DISSEMINATED). Clinical manifestations include motor weakness, sensory loss, and incontinence. (Adams et al., Principles of Neurology, 6th ed, pp1242-6)
Kidney
Body organ that filters blood for the secretion of URINE and that regulates ion concentrations.
Antibodies, Anti-Idiotypic
Antibodies which react with the individual structural determinants (idiotopes) on the variable region of other antibodies.
Skin Diseases
Risk Factors
An aspect of personal behavior or lifestyle, environmental exposure, or inborn or inherited characteristic, which, on the basis of epidemiologic evidence, is known to be associated with a health-related condition considered important to prevent.
Genotype
The genetic constitution of the individual, comprising the ALLELES present at each GENETIC LOCUS.
Kidney Glomerulus
A cluster of convoluted capillaries beginning at each nephric tubule in the kidney and held together by connective tissue.
Anemia, Hemolytic, Autoimmune
Acquired hemolytic anemia due to the presence of AUTOANTIBODIES which agglutinate or lyse the patient's own RED BLOOD CELLS.
Interferon-alpha
One of the type I interferons produced by peripheral blood leukocytes or lymphoblastoid cells. In addition to antiviral activity, it activates NATURAL KILLER CELLS and B-LYMPHOCYTES, and down-regulates VASCULAR ENDOTHELIAL GROWTH FACTOR expression through PI-3 KINASE and MAPK KINASES signaling pathways.
Disease Models, Animal
Naturally occurring or experimentally induced animal diseases with pathological processes sufficiently similar to those of human diseases. They are used as study models for human diseases.
Cohort Studies
Studies in which subsets of a defined population are identified. These groups may or may not be exposed to factors hypothesized to influence the probability of the occurrence of a particular disease or other outcome. Cohorts are defined populations which, as a whole, are followed in an attempt to determine distinguishing subgroup characteristics.
Flow Cytometry
Technique using an instrument system for making, processing, and displaying one or more measurements on individual cells obtained from a cell suspension. Cells are usually stained with one or more fluorescent dyes specific to cell components of interest, e.g., DNA, and fluorescence of each cell is measured as it rapidly transverses the excitation beam (laser or mercury arc lamp). Fluorescence provides a quantitative measure of various biochemical and biophysical properties of the cell, as well as a basis for cell sorting. Other measurable optical parameters include light absorption and light scattering, the latter being applicable to the measurement of cell size, shape, density, granularity, and stain uptake.
Tumor Necrosis Factor Ligand Superfamily Member 13
A member of tumor necrosis factor superfamily found on MACROPHAGES; DENDRITIC CELLS and T-LYMPHOCYTES. It occurs as transmembrane protein that can be cleaved to release a secreted form that specifically binds to TRANSMEMBRANE ACTIVATOR AND CAML INTERACTOR PROTEIN; and B CELL MATURATION ANTIGEN.
Thrombocytopenia
A subnormal level of BLOOD PLATELETS.
Alleles
Variant forms of the same gene, occupying the same locus on homologous CHROMOSOMES, and governing the variants in production of the same gene product.
Polymorphism, Genetic
The regular and simultaneous occurrence in a single interbreeding population of two or more discontinuous genotypes. The concept includes differences in genotypes ranging in size from a single nucleotide site (POLYMORPHISM, SINGLE NUCLEOTIDE) to large nucleotide sequences visible at a chromosomal level.
Receptors, Complement 3b
Molecular sites on or in some B-lymphocytes and macrophages that recognize and combine with COMPLEMENT C3B. The primary structure of these receptors reveal that they contain transmembrane and cytoplasmic domains, with their extracellular portion composed entirely of thirty short consensus repeats each having 60 to 70 amino acids.
European Continental Ancestry Group
Individuals whose ancestral origins are in the continent of Europe.
Blood Sedimentation
Measurement of rate of settling of erythrocytes in anticoagulated blood.
Lymphocytes
White blood cells formed in the body's lymphoid tissue. The nucleus is round or ovoid with coarse, irregularly clumped chromatin while the cytoplasm is typically pale blue with azurophilic (if any) granules. Most lymphocytes can be classified as either T or B (with subpopulations of each), or NATURAL KILLER CELLS.
Leukocytes, Mononuclear
Mature LYMPHOCYTES and MONOCYTES transported by the blood to the body's extravascular space. They are morphologically distinguishable from mature granulocytic leukocytes by their large, non-lobed nuclei and lack of coarse, heavily stained cytoplasmic granules.
Biopsy
Removal and pathologic examination of specimens in the form of small pieces of tissue from the living body.
Gene Frequency
The proportion of one particular in the total of all ALLELES for one genetic locus in a breeding POPULATION.
Immunoglobulin Idiotypes
Unique genetically-controlled determinants present on ANTIBODIES whose specificity is limited to a single group of proteins (e.g., another antibody molecule or an individual myeloma protein). The idiotype appears to represent the antigenicity of the antigen-binding site of the antibody and to be genetically codetermined with it. The idiotypic determinants have been precisely located to the IMMUNOGLOBULIN VARIABLE REGION of both immunoglobin polypeptide chains.
Fluorescent Antibody Technique
Test for tissue antigen using either a direct method, by conjugation of antibody with fluorescent dye (FLUORESCENT ANTIBODY TECHNIQUE, DIRECT) or an indirect method, by formation of antigen-antibody complex which is then labeled with fluorescein-conjugated anti-immunoglobulin antibody (FLUORESCENT ANTIBODY TECHNIQUE, INDIRECT). The tissue is then examined by fluorescence microscopy.
Complement C3c
A 206-amino-acid fragment in the alpha chain (672-1663) of C3b. It is generated when C3b is inactivated (iC3b) and its alpha chain is cleaved by COMPLEMENT FACTOR I into C3c (749-954), and C3dg (955-1303) in the presence COMPLEMENT FACTOR H.
Rheumatoid Factor
Antibodies found in adult RHEUMATOID ARTHRITIS patients that are directed against GAMMA-CHAIN IMMUNOGLOBULINS.
Immunoglobulins
Multi-subunit proteins which function in IMMUNITY. They are produced by B LYMPHOCYTES from the IMMUNOGLOBULIN GENES. They are comprised of two heavy (IMMUNOGLOBULIN HEAVY CHAINS) and two light chains (IMMUNOGLOBULIN LIGHT CHAINS) with additional ancillary polypeptide chains depending on their isoforms. The variety of isoforms include monomeric or polymeric forms, and transmembrane forms (B-CELL ANTIGEN RECEPTORS) or secreted forms (ANTIBODIES). They are divided by the amino acid sequence of their heavy chains into five classes (IMMUNOGLOBULIN A; IMMUNOGLOBULIN D; IMMUNOGLOBULIN E; IMMUNOGLOBULIN G; IMMUNOGLOBULIN M) and various subclasses.
Haplotypes
The genetic constitution of individuals with respect to one member of a pair of allelic genes, or sets of genes that are closely linked and tend to be inherited together such as those of the MAJOR HISTOCOMPATIBILITY COMPLEX.
Thrombosis
Formation and development of a thrombus or blood clot in the blood vessel.
Complement Activating Enzymes
Enzymes that activate one or more COMPLEMENT PROTEINS in the complement system leading to the formation of the COMPLEMENT MEMBRANE ATTACK COMPLEX, an important response in host defense. They are enzymes in the various COMPLEMENT ACTIVATION pathways.
Cyclophosphamide
Precursor of an alkylating nitrogen mustard antineoplastic and immunosuppressive agent that must be activated in the LIVER to form the active aldophosphamide. It has been used in the treatment of LYMPHOMA and LEUKEMIA. Its side effect, ALOPECIA, has been used for defleecing sheep. Cyclophosphamide may also cause sterility, birth defects, mutations, and cancer.
Mycophenolic Acid
An antibiotic substance derived from Penicillium stoloniferum, and related species. It blocks de novo biosynthesis of purine nucleotides by inhibition of the enzyme inosine monophosphate dehydrogenase. Mycophenolic acid is important because of its selective effects on the immune system. It prevents the proliferation of T-cells, lymphocytes, and the formation of antibodies from B-cells. It also may inhibit recruitment of leukocytes to inflammatory sites. (From Gilman et al., Goodman and Gilman's The Pharmacological Basis of Therapeutics, 9th ed, p1301)
OX40 Ligand
A membrane-bound tumor necrosis family member that is expressed on activated antigen-presenting cells such as B-LYMPHOCYTES and MACROPHAGES. It signals T-LYMPHOCYTES by binding the OX40 RECEPTOR.
STAT4 Transcription Factor
A signal transducer and activator of transcription that mediates cellular responses to INTERLEUKIN-12 in T-LYMPHOCYTES. Stat4 is an important signaling molecule for differentiation in TH1 CELLS.
Retrospective Studies
Studies used to test etiologic hypotheses in which inferences about an exposure to putative causal factors are derived from data relating to characteristics of persons under study or to events or experiences in their past. The essential feature is that some of the persons under study have the disease or outcome of interest and their characteristics are compared with those of unaffected persons.
Pregnancy Complications
Conditions or pathological processes associated with pregnancy. They can occur during or after pregnancy, and range from minor discomforts to serious diseases that require medical interventions. They include diseases in pregnant females, and pregnancies in females with diseases.
Antibodies, Monoclonal, Murine-Derived
Antibodies obtained from a single clone of cells grown in mice or rats.
Kidney Diseases
Pathological processes of the KIDNEY or its component tissues.
Toll-Like Receptor 7
A pattern recognition receptor that binds several forms of imidazo-quinoline including the antiviral compound Imiquimod.
Blood Coagulation Factors
Endogenous substances, usually proteins, that are involved in the blood coagulation process.
Protein-Losing Enteropathies
Pathological conditions in the INTESTINES that are characterized by the gastrointestinal loss of serum proteins, including SERUM ALBUMIN; IMMUNOGLOBULINS; and at times LYMPHOCYTES. Severe condition can result in HYPOGAMMAGLOBULINEMIA or LYMPHOPENIA. Protein-losing enteropathies are associated with a number of diseases including INTESTINAL LYMPHANGIECTASIS; WHIPPLE'S DISEASE; and NEOPLASMS of the SMALL INTESTINE.
Central Nervous System Diseases
Diseases of any component of the brain (including the cerebral hemispheres, diencephalon, brain stem, and cerebellum) or the spinal cord.
Antirheumatic Agents
Drugs that are used to treat RHEUMATOID ARTHRITIS.
Toll-Like Receptor 9
A pattern recognition receptor that binds unmethylated CPG CLUSTERS. It mediates cellular responses to bacterial pathogens by distinguishing between self and bacterial DNA.
Asian Continental Ancestry Group
Individuals whose ancestral origins are in the southeastern and eastern areas of the Asian continent.
Raynaud Disease
An idiopathic vascular disorder characterized by bilateral Raynaud phenomenon, the abrupt onset of digital paleness or CYANOSIS in response to cold exposure or stress.
Cells, Cultured
Cells propagated in vitro in special media conducive to their growth. Cultured cells are used to study developmental, morphologic, metabolic, physiologic, and genetic processes, among others.
Disease Progression
The worsening of a disease over time. This concept is most often used for chronic and incurable diseases where the stage of the disease is an important determinant of therapy and prognosis.
Mice, Congenic
Mouse strains constructed to possess identical genotypes except for a difference at a single gene locus.
Interferon Type I
Interferon secreted by leukocytes, fibroblasts, or lymphoblasts in response to viruses or interferon inducers other than mitogens, antigens, or allo-antigens. They include alpha- and beta-interferons (INTERFERON-ALPHA and INTERFERON-BETA).
Prospective Studies
Observation of a population for a sufficient number of persons over a sufficient number of years to generate incidence or mortality rates subsequent to the selection of the study group.
Oral Ulcer
A loss of mucous substance of the mouth showing local excavation of the surface, resulting from the sloughing of inflammatory necrotic tissue. It is the result of a variety of causes, e.g., denture irritation, aphthous stomatitis (STOMATITIS, APHTHOUS); NOMA; necrotizing gingivitis (GINGIVITIS, NECROTIZING ULCERATIVE); TOOTHBRUSHING; and various irritants. (From Jablonski, Dictionary of Dentistry, 1992, p842)
Complement Hemolytic Activity Assay
A screening assay for circulating COMPLEMENT PROTEINS. Diluted SERUM samples are added to antibody-coated ERYTHROCYTES and the percentage of cell lysis is measured. The values are expressed by the so called CH50, in HEMOLYTIC COMPLEMENT units per milliliter, which is the dilution of serum required to lyse 50 percent of the erythrocytes in the assay.
Age of Onset
The age, developmental stage, or period of life at which a disease or the initial symptoms or manifestations of a disease appear in an individual.
Follow-Up Studies
Studies in which individuals or populations are followed to assess the outcome of exposures, procedures, or effects of a characteristic, e.g., occurrence of disease.
Receptors, Complement
Molecules on the surface of some B-lymphocytes and macrophages, that recognize and combine with the C3b, C3d, C1q, and C4b components of complement.
Protein Tyrosine Phosphatase, Non-Receptor Type 22
A subtype of non-receptor protein tyrosine phosphatases that is characterized by the presence of an N-terminal catalytic domain and a C-terminal PROLINE-rich domain. The phosphatase subtype is predominantly expressed in LYMPHOCYTES and plays a key role in the inhibition of downstream T-LYMPHOCYTE activation. Polymorphisms in the gene that encodes this phosphatase subtype are associated with a variety of AUTOIMMUNE DISEASES.
Facial Dermatoses
Anti-Inflammatory Agents
Substances that reduce or suppress INFLAMMATION.
Immunologic Factors
Biologically active substances whose activities affect or play a role in the functioning of the immune system.
Complement Activation
The sequential activation of serum COMPLEMENT PROTEINS to create the COMPLEMENT MEMBRANE ATTACK COMPLEX. Factors initiating complement activation include ANTIGEN-ANTIBODY COMPLEXES, microbial ANTIGENS, or cell surface POLYSACCHARIDES.
HLA-DR3 Antigen
An HLA-DR antigen which is associated with HLA-DRB1 CHAINS encoded by DRB1*03 alleles.
African Americans
Persons living in the United States having origins in any of the black groups of Africa.
Epitopes
Sites on an antigen that interact with specific antibodies.
Histiocytic Necrotizing Lymphadenitis
Development of lesions in the lymph node characterized by infiltration of the cortex or paracortex by large collections of proliferating histiocytes and complete or, more often, incomplete necrosis of lymphoid tissue.
Skin
The outer covering of the body that protects it from the environment. It is composed of the DERMIS and the EPIDERMIS.
Treatment Outcome
Evaluation undertaken to assess the results or consequences of management and procedures used in combating disease in order to determine the efficacy, effectiveness, safety, and practicability of these interventions in individual cases or series.

Fitzgerald factor (high molecular weight kininogen) clotting activity in human plasma in health and disease in various animal plasmas. (1/6365)

Fitzgerald factor (high molecular weight kininogen) is an agent in normal human plasma that corrects the impaired in vitro surface-mediated plasma reactions of blood coagulation, fibrinolysis, and kinin generation observed in Fitzgerald trait plasma. To assess the possible pathophysiologic role of Fitzgerald factor, its titer was measured by a functional clot-promoting assay. Mean +/- SD in 42 normal adults was 0.99+/-0.25 units/ml, one unit being the activity in 1 ml of normal pooled plasma. No difference in titer was noted between normal men and women, during pregnancy, or after physical exercise. Fitzgerald factor activity was significantly reduced in the plasmas of eight patients with advanced hepatic cirrhosis (0.40+/-0.09 units/ml) and of ten patients with disseminated intravascular coagulation (0.60+/-0.30 units/ml), but was normal in plasmas of patients with other congenital clotting factor deficiencies, nephrotic syndrome, rheumatoid arthritis, systemic lupus erythematosus, or sarcoidosis, or under treatment with warfarin. The plasmas of 21 mammalian species tested appeared to contain Fitzgerald factor activity, but those of two avian, two repitilian, and one amphibian species did not correct the coagulant defect in Fitzgerald trait plasmas.  (+info)

Fine specificity of the autoimmune response to the Ro/SSA and La/SSB ribonucleoproteins. (2/6365)

The fine specificity of the Ro and La proteins has been studied by several techniques. In general, there is agreement in a qualitative sense that autoantibodies bind multiple epitopes. For some specific antibody binding, different studies agree quantitatively, for instance, the binding of the carboxyl terminus of 60-kd Ro as described by 2 studies using different techniques and the presence of an epitope within the leucine zipper of 52-kd Ro. In addition, there is general agreement about the location of a prominent epitope at the RRM motif region of the La molecule. On the other hand, the many specific epitope regions of the molecules differ among these studies. These discrepancies are likely the result of using different techniques, sera, and peptide constructs as well as a result of inherent advantages and disadvantages in the individual approaches. Several theories concerning the origin of not only the antibodies, but also the diseases themselves, have been generated from studies of the fine specificity of antibody binding. These include a theory of a primordial foreign antigen for anti-Ro autoimmunity, molecular mimicry with regard to La and CCHB, as well as the association of anti-Ro with HLA. These remain unproven, but are of continuing interest. An explanation for the association of anti-60-kd Ro and anti-52-kd Ro in the sera of patients has sprung from evaluating antibody binding. Data demonstrating multiple epitopes are part of a large body of evidence that strongly suggests an antigen-driven immune response. This means that the autoantigens are directly implicated in initiating and sustaining autoimmunity in their associated diseases. A number of studies have investigated the possibility of differences in the immune response to these antigens in SS and SLE sera. While several differences have been reported, none have been reproduced in a second cohort of patients. Furthermore, none of the reported differences may be sufficiently robust for clinical purposes, such as distinguishing between SS with systemic features and mild SLE, although some might be promising. For instance, in at least 3 groups of SLE patients, no binding of residues spanning amino acids 21-41 of 60-kd Ro has been found. Meanwhile, 1 of those studies found that 41% of sera from patients with primary SS bound the 60-kd Ro peptide 21-41. Perhaps future studies will elaborate a clinical role of such a difference among SS and SLE patients. Study of the epitopes of these autoantigens has, in part, led to a new animal model of anti-Ro and anti-La. Non-autoimmune-prone animals are immunized with proteins or peptides that make up the Ro/La RNP. Such animals develop an autoimmune response to the entire particle, not just the immunogen. This response has been hypothesized to arise from autoreactive B cells. In another, older animal model of disease, the MRL-lpr/lpr mouse, B cells have recently been shown to be required for the generation of abnormal, autoreactive T cells. Thus, there are now powerful data indicating that B cells that produce autoantibodies are directly involved in the pathogenesis of disease above and beyond the formation of immune complexes. Given that the autoreactive B cell is potentially critical to the underlying pathogenesis of disease, then studying these cells will be crucial to further understanding the origin of diseases associated with Ro and La autoimmunity. Hopefully, an increased understanding will eventually lead to improved treatment of patients. Progress in the area of treatment will almost surely be incremental, and studies of the fine specificity of autoantibody binding will be a part of the body of basic knowledge contributing to ultimate advancement. In the future, the animal models will need to be examined with regard to immunology and immunochemistry as well as genetics. The development of these autoantibodies has not been studied extensively because upon presentation to medical care, virtually all patients have a full-  (+info)

Associations of anti-beta2-glycoprotein I autoantibodies with HLA class II alleles in three ethnic groups. (3/6365)

OBJECTIVE: To determine any HLA associations with anti-beta2-glycoprotein I (anti-beta2GPI) antibodies in a large, retrospectively studied, multiethnic group of 262 patients with primary antiphospholipid antibody syndrome (APS), systemic lupus erythematosus (SLE), or another connective tissue disease. METHODS: Anti-beta2GPI antibodies were detected in sera using an enzyme-linked immunosorbent assay. HLA class II alleles (DRB1, DQA1, and DQB1) were determined by DNA oligotyping. RESULTS: The HLA-DQB1*0302 (DQ8) allele, typically carried on HLA-DR4 haplotypes, was associated with anti-beta2GPI when compared with both anti-beta2GPI-negative SLE patients and ethnically matched normal controls, especially in Mexican Americans and, to a lesser extent, in whites. Similarly, when ethnic groups were combined, HLA-DQB1*0302, as well as HLA-DQB1*03 alleles overall (DQB1*0301, *0302, and *0303), were strongly correlated with anti-beta2GPI antibodies. The HLA-DR6 (DR13) haplotype DRB1*1302; DQB1*0604/5 was also significantly increased, primarily in blacks. HLA-DR7 was not significantly increased in any of these 3 ethnic groups, and HLA-DR53 (DRB4*0101) was increased in Mexican Americans only. CONCLUSION: Certain HLA class II haplotypes genetically influence the expression of antibodies to beta2GPI, an important autoimmune response in the APS, but there are variations in HLA associations among different ethnic groups.  (+info)

Estrogen enhancement of anti-double-stranded DNA antibody and immunoglobulin G production in peripheral blood mononuclear cells from patients with systemic lupus erythematosus. (4/6365)

OBJECTIVE: To study the in vitro effect of estrogen on IgG anti-double-stranded DNA (anti-dsDNA) antibody and total IgG production in peripheral blood mononuclear cells (PBMC) from patients with systemic lupus erythematosus (SLE), in order to elucidate its regulatory role in SLE. METHODS: PBMC from SLE patients and normal donors were cultured with 17beta-estradiol (E2). IgG anti-dsDNA antibodies, total IgG, and cytokine activity in the culture supernatants were measured by enzyme-linked immunosorbent assay. RESULTS: E2 enhanced production of IgG anti-dsDNA antibodies as well as total IgG in PBMC from SLE patients. Anti-dsDNA production in patients with inactive disease was less responsive to E2 than that in patients with active disease. E2 also enhanced total IgG, but not anti-dsDNA, production in the PBMC of normal donors. Antibody production was increased by E2 to a lesser extent in patients' B cells than in their PBMC. Anti-interleukin-10 (anti-IL-10) antibodies partially blocked the E2-induced increase in antibody production in patients' PBMC, but anti-IL-10 had no effect on B cells. E2 increased IL-10 production by patients' monocytes. Exogenous IL-10 acted additively with E2 in increasing antibody production in patients' B cells. CONCLUSION: These results suggest that E2 may polyclonally increase the production of IgG, including IgG anti-dsDNA, in SLE patients' PBMC by enhancing B cell activity and by promoting IL-10 production in monocytes. These findings support the involvement of E2 in the pathogenesis of SLE.  (+info)

Premature morbidity from cardiovascular and cerebrovascular diseases in women with systemic lupus erythematosus. (5/6365)

OBJECTIVE: To determine rates of morbidity due to cardiovascular and cerebrovascular diseases among women with systemic lupus erythematosus (SLE). METHODS: I used the California Hospital Discharge Database, which contains information on all discharges from acute care hospitals in California, to identify women with SLE who had been hospitalized for treatment of either acute myocardial infarction (AMI), congestive heart failure (CHF), or cerebrovascular accident (CVA) from 1991 to 1994. I compared the proportions of hospitalizations for each cause among women with SLE with those in a group of women without SLE, for 3 age strata (18-44 years, 45-64 years, and > or =65 years). RESULTS: Compared with young women without SLE, young women with SLE were 2.27 times more likely to be hospitalized because of AMI (95% confidence interval [95% CI] 1.08-3.46), 3.80 times more likely to be hospitalized because of CHF (95% CI 2.41-5.19), and 2.05 times more likely to be hospitalized because of CVA (95% CI 1.17-2.93). Among middle-aged women with SLE, the frequencies of hospitalization for AMI and CVA did not differ from those of the comparison group, but the risk of hospitalization for CHF was higher (odds ratio [OR] 1.39, 95% CI 1.05-1.73). Among elderly women with SLE, the risk of hospitalization for AMI was significantly lower (OR 0.70, 95% CI 0.51-0.89), the risk of hospitalization for CHF was higher (OR 1.25, 95% CI 1.01-1.49), and the risk of hospitalization for CVA was not significantly different from those in the comparison group. CONCLUSION: Young women with SLE are at substantially increased risk of AMI, CHF, and CVA. The relative odds of these conditions decrease with age among women with SLE.  (+info)

Unilateral cataplexy associated with systemic lupus erythematosus. (6/6365)

A patient with systemic lupus erythematosus (SLE) developed attacks of unilateral cataplexy precipitated by laughter. Unilateral cataplexy has not been described previously in detail and its association with SLE is unique. The clinical details, investigations, and diagnostic criteria are discussed and a causal relationship between cataplexy and SLE is suggested.  (+info)

Autoreactive human T cell lines recognizing ribosomal protein L7. (7/6365)

Sera of patients suffering from systemic lupus erythematosus (SLE) frequently contain oligoclonal IgG autoantibodies with high affinity for the ribosomal protein L7 (rpL7). The humoral autoimmune response to rpL7 apparently is driven by antigen and T cell dependent. In order to analyze the T cell response to rpL7 we cultured peripheral blood lymphocytes of healthy individuals and SLE patients in the presence of recombinant rpL7. After 10 days, the cytokine response to re-stimulation with rpL7 was examined using a spot-ELISA. Measuring IFN-gamma secretion, the T cells of two patients and four healthy donors showed a significant increase in the number of spots as compared to control cells. Secretion of IL-4 or IL-10 was not detected. From the antigen-stimulated primary cultures we established by limiting dilution cloning six rpL7-reactive, IFN-gamma-secreting T cell lines which show a CD3+CD4+CD8- phenotype. One line additionally was shown to be positive for HLA-DR and CD45R0, but negative for CD27 and CD31. The cell lines carry alphabeta TCR chains which differ from each other in sequence and specificity. rpL7 fragments rich in basic amino acids could be identified as epitopes recognized by the TCR of three cell lines. Recognition of rpL7 is HLA-DR6 restricted or respectively HLA-DP restricted in the two cell lines analyzed.  (+info)

Genome-wide screen for systemic lupus erythematosus susceptibility genes in multiplex families. (8/6365)

Systemic lupus erythematosus (SLE) is the prototype of human autoimmune diseases. Its genetic component has been suggested by familial aggregation (lambdas = 20) and twin studies. We have screened the human genome to localize genetic intervals that may contain lupus susceptibility loci in a sample of 188 lupus patients belonging to 80 lupus families with two or more affected relatives per family using the ABI Prism linkage mapping set which includes 350 polymorphic markers with an average spacing of 12 cM. Non-parametric multipoint linkage analysis suggests evidence for predisposing loci on chromosomes 1 and 18. However, no single locus with overwhelming evidence for linkage was found, suggesting that there are no 'major' susceptibility genes segregating in families with SLE, and that the genetic etiology is more likely to result from the action of several genes of moderate effect. Furthermore, the support for a gene in the 1q44 region as well as in the 1p36 region is clearly found only in the Mexican American families with SLE but not in families of Caucasian ethnicity, suggesting that consideration of each ethnic group separately is crucial.  (+info)

Flares in pediatric systemic lupus erythematosus<...Flares in pediatric systemic lupus erythematosus<...
TY - JOUR. T1 - Flares in pediatric systemic lupus erythematosus. AU - Weiss, Jennifer E.. AU - Sison, Cristina P.. AU - Ilowite, Norman T.. AU - Gottlieb, Beth S.. AU - Eberhard, Barbara A.. PY - 2007/6/1. Y1 - 2007/6/1. N2 - Objective. To determine the flare rate and the change in Safety of Estrogens in Lupus Erythematosus: National Assessment Systemic Lupus Erythematosus Disease Activity Index (SELENA SLEDAI) score with disease flare in pediatric systemic lupus erythematosus (pSLE). Methods. A retrospective chart review of 62 patients with pSLE (ages 5-20 yrs). A flare was defined as the start of, or increase in, the dose of corticosteroids and/or the addition of an immunosuppressive medication. All pre-flare, flare, and post-flare visits were recorded with a SELENA SLEDAI score calculated for each visit. The flare rate was calculated by dividing the total number of flares in the cohort by the total followup years. Results. Sixty-two patients were eligible. Forty-seven patients had 112 ...
https://einstein.pure.elsevier.com/en/publications/flares-in-pediatric-systemic-lupus-erythematosus-2
Systemic lupus erythematosus disease activity index 2000. | The Journal of RheumatologySystemic lupus erythematosus disease activity index 2000. | The Journal of Rheumatology
OBJECTIVE: To describe the Systemic Lupus Erythematosus Disease Activity Index 2000 (SLEDAI-2K), a modification of SLEDAI to reflect persistent, active disease in those descriptors that had previously only considered new or recurrent occurrences, and to validate SLEDAI-2K against the original SLEDAI as a predictor for mortality and as a measure of global disease activity in the clinic. METHODS: All visits in our cohort of 960 patients were used to correlate SLEDAI-2K against the original SLEDAI, and the whole cohort was used to validate SLEDAI-2K as a predictor of mortality. A subgroup of 212 patients with SLE followed at the Lupus Clinic who had 5 regular visits, 3-6 months apart, in 1991-93 was also included. An uninvolved clinician evaluated each patient record and assigned a clinical activity level. The SLEDAI score was calculated from the database according to both the original and modified definitions. RESULTS: SLEDAI-2K correlated highly (r = 0.97) with SLEDAI. Both methods for SLEDAI ...
https://www.jrheum.org/content/29/2/288?ijkey=fa1a9e262e9d8f203fac95b7542a2030a391d9d2&keytype2=tf_ipsecsha
Patients with the autoimmune disease systemic lupus erythematosus (SLE) develop pathogenic - PI3K Signaling in B and T...Patients with the autoimmune disease systemic lupus erythematosus (SLE) develop pathogenic - PI3K Signaling in B and T...
Patients with the autoimmune disease systemic lupus erythematosus (SLE) develop pathogenic antibodies against their own self-antigens. U1-70(131-150):I-Ek (without phosphorylation) correlates with disease intensity and antiCU1-70 autoantibody creation. These T cells express RORt and produce IL-17A also. Furthermore, the U1-70Cparticular Compact disc4+ T cells that generate IL-17A are discovered within a subset of sufferers Dovitinib with SLE and so are significantly elevated in sufferers with blended connective tissues disease. These scholarly research offer equipment for learning antigen-specific POLDS Compact disc4+ T cells in lupus, and show an Dovitinib antigen-specific way to obtain IL-17A in autoimmune disease. Systemic lupus erythematosus (SLE) can be an autoimmune disease where sufferers develop high-titer, specific highly, isotype-switched autoantibodies against DNA- and RNA- filled with autoantigens (1). U1-70, U1-A, and U1-C, with U1-RNA as well as the seven Smith proteins jointly, ...
http://health-e-nc.org/2017/06/15/patients-with-the-autoimmune-disease-systemic-lupus-erythematosus-sle-develop-pathogenic/
Subclinical impairment of ovarian reserve in juvenile systemic lupus erythematosus after cyclophosphamide therapy.
OBJECTIVES: To perform systematic assessment of ovarian reserve markers using a combination of tests in juvenile systemic lupus erythematosus (JSLE) patients without amenorrhoea. METHODS: Twenty-seven consecutive JSLE female patients and 13 healthy c
http://www.biomedsearch.com/nih/Subclinical-impairment-ovarian-reserve-in/22703605.html
Novel evidence-based systemic lupus erythematosus responder index - Furie - 2009 - Arthritis Care & Research - Wiley Online...Novel evidence-based systemic lupus erythematosus responder index - Furie - 2009 - Arthritis Care & Research - Wiley Online...
Data from a randomized, double-blind, placebo-controlled study in 449 patients of 3 doses of belimumab (1, 4, 10 mg/kg) or placebo plus standard of care therapy (SOC) over a 56-week period were analyzed. The Safety of Estrogens in Lupus Erythematosus: National Assessment (SELENA) version of the Systemic Lupus Erythematosus Disease Activity Index (SLEDAI) and British Isles Lupus Assessment Group (BILAG) SLE disease activity instruments, the Short Form 36 health survey, and biomarker analyses were used to create a novel SRI. Response to treatment in a subset of 321 serologically active SLE patients (antinuclear antibodies ≥1:80 and/or anti-double-stranded DNA antibodies ≥30 IU/ml) at baseline was retrospectively evaluated using the SRI. ...
http://onlinelibrary.wiley.com/doi/10.1002/art.24698/abstract
Study of the Safety and Efficacy of GDC-0853 in Participants With Moderate to Severe Active Systemic Lupus Erythematosus |...Study of the Safety and Efficacy of GDC-0853 in Participants With Moderate to Severe Active Systemic Lupus Erythematosus |...
Clinical trial for SYSTEMIC LUPUS ERYTHEMATOSUS , Study of the Safety and Efficacy of GDC-0853 in Participants With Moderate to Severe Active Systemic Lupus Erythematosus
http://www.centerwatch.com/clinical-trials/listings/101634/systemic-lupus-erythematosus-study-safety-efficacy-gdc-0853/?&radius=50
Altered peripheral lymphocyte subsets in untreated systemic lupus erythematosus patients with infectionsAltered peripheral lymphocyte subsets in untreated systemic lupus erythematosus patients with infections
LU, Zhimin et al. Altered peripheral lymphocyte subsets in untreated systemic lupus erythematosus patients with infections. Braz J Med Biol Res [online]. 2019, vol.52, n.4, e8131. Epub 15-Abr-2019. ISSN 1414-431X. https://doi.org/10.1590/1414-431x20198131.. The leading cause of death in systemic lupus erythematosus (SLE) patients is infection. The objective of this study was to evaluate the distribution of lymphocyte subsets in untreated SLE patients with infections. This was a cross-sectional study. Data from January 2017 to May 2018 were collected. Flow cytometry was used to measure the peripheral lymphocyte subsets including CD3+T cells, CD4+T cells, CD8+T cells, CD19+B cells, CD3-CD16+CD56NK cells, and CD3+CD16+CD56NKT cells in 25 healthy controls and 52 treatment-naive SLE patients, among whom 13 were complicated with infections. Association between the lymphocyte subsets and infections was further analyzed. SLE patients with infections (n=13) showed a significantly higher incidence rate of ...
https://www.scielo.br/scielo.php?script=sci_abstract&pid=S0100-879X2019000400609&lng=pt&nrm=iso
Accelerated damage accrual among men with systemic lupus erythematosus: XLIV. Results from a multiethnic US cohort | Read by...Accelerated damage accrual among men with systemic lupus erythematosus: XLIV. Results from a multiethnic US cohort | Read by...
OBJECTIVE: To determine the impact of the patients sex on the manifestations and outcome of systemic lupus erythematosus (SLE).. METHODS: We studied SLE patients who were ages 16 years or older and had a disease duration of , or =5 years at the time of enrollment in the LUpus in MInorities, NAture versus nurture cohort, a multiethnic cohort consisting of Hispanic, African American, and Caucasian patients. Socioeconomic/demographic, clinical, and serologic features, as well as disease activity (by the Systemic Lupus Activity Measure, Revised) and damage accrual (by the Systemic Lupus International Collaborating Clinics/American College of Rheumatology Damage Index) were compared between male and female patient groups. Multivariable analyses using male sex and damage accrual as dependent variables were then performed.. RESULTS: Sixty-three male SLE patients (10.2%) from all ethnic groups were included. The mean ages of the male and female patients were comparable. Factors that were either more ...
https://read.qxmd.com/read/17265497/accelerated-damage-accrual-among-men-with-systemic-lupus-erythematosus-xliv-results-from-a-multiethnic-us-cohort
Possible triggering effect of cytomegalovirus infection on systemic lupus erythematosus<...
TY - JOUR. T1 - Possible triggering effect of cytomegalovirus infection on systemic lupus erythematosus. AU - Nawata, M.. AU - Seta, N.. AU - Yamada, M.. AU - Sekigawa, I.. AU - Iida, N.. AU - Hashimoto, H.. PY - 2001. Y1 - 2001. N2 - We report on a patient with systemic lupus erythematosus (SLE) who showed elevated titers of IgM antibodies to cytomegalovirus (CMV), suggesting CMV infection at the onset of SLE. Serum CMV antigens were also detected in the patient. These findings raise the possibility that CMV infection may be related to the onset of SLE in certain patients.. AB - We report on a patient with systemic lupus erythematosus (SLE) who showed elevated titers of IgM antibodies to cytomegalovirus (CMV), suggesting CMV infection at the onset of SLE. Serum CMV antigens were also detected in the patient. These findings raise the possibility that CMV infection may be related to the onset of SLE in certain patients.. KW - Cytomegalovirus. KW - Proteinuria. KW - Systemic lupus ...
https://keio.pure.elsevier.com/en/publications/possible-triggering-effect-of-cytomegalovirus-infection-on-system
Autoimmune reactivity to malondialdehyde adducts in systemic lupus erythematosus is associated with disease activity and...Autoimmune reactivity to malondialdehyde adducts in systemic lupus erythematosus is associated with disease activity and...
Immunoglobulin M (IgM) autoreactivity to malondialdehyde (MDA) protein modifications is part of the natural antibody repertoire in health and may have beneficial functions. In contrast, IgG anti-MDA are increased in chronic inflammation and autoimmunity and may instead have pathogenic properties. Herein, we investigated serum IgG anti-MDA levels by enzyme-linked immunosorbent assay (ELISA) in 398 systemic lupus erythematosus (SLE) patients in the Swedish Karolinska SLE cohort and compared these to findings in 225 US SLE patients from New York University and Johns Hopkins University. In two independent cohorts, IgG anti-MDA levels correlated positively with disease activity by the Systemic Lupus Erythematosus Disease Activity Index (SLEDAI; p | 0.0001, Spearman R = 0.3). Meta-analysis found an odds ratio of 2.7 (confidence interval (CI) 1.9-3.9; p | 0.0001) for high anti-MDA IgG levels with active disease (SLEDAI ≥ 6). Furthermore, IgG anti-MDA correlated directly with erythrocyte sedimentation rate
https://arthritis-research.biomedcentral.com/articles/10.1186/s13075-018-1530-2/tables/1
A Long-Term Study of the Safety and Tolerability of Repeated Administration of CEP-33457 in Patients With Systemic Lupus...A Long-Term Study of the Safety and Tolerability of Repeated Administration of CEP-33457 in Patients With Systemic Lupus...
An SRI response is defined as a reduction from baseline in the Systemic Lupus Erythematosus Disease Activity Index 2000 (SLEDAI 2K) score of at least 4 points, no worsening in Physicians Global Assessment (PhGA) (with worsening defined as an increase in PhGA of more than 0.30 point from baseline), no British Isles Lupus Assessment Group A (BILAG A) organ domain score, and no more than 1 new BILAG B organ domain score from baseline ...
https://clinicaltrials.gov/ct2/show/NCT01240694
Systemic lupus erythematosus symptoms, treatments & forums | PatientsLikeMeSystemic lupus erythematosus symptoms, treatments & forums | PatientsLikeMe
Systemic lupus erythematosus: Find the most comprehensive real-world symptom and treatment data on systemic lupus erythematosus at PatientsLikeMe. 37842 patients with systemic lupus erythematosus experience muscle pain, joint swelling, skin sensitivity to sun (photosensitivity), joint pain, and chest pain and use Hydroxychloroquine, Prednisone, Methotrexate, Belimumab, and Azathioprine to treat their systemic lupus erythematosus and its symptoms.
https://www.patientslikeme.com/conditions/34-lupus
Vaccine antibodies and T- and B-cell interaction in juvenile systemic lupus erythematosusVaccine antibodies and T- and B-cell interaction in juvenile systemic lupus erythematosus
Both systemic lupus erythematosus (SLE) and its treatment can cause immunosuppression and a decreased response to vaccination. We evaluated 30 children and adolescents with SLE, and 14 age-matched healthy subjects (control group) regarding immunophenotyping and lymphocyte apoptosis by flow cytometry …
https://pubmed.ncbi.nlm.nih.gov/21505013/?dopt=Abstract
Delineation of the human systemic lupus erythematosus anti-Smith antibody response using phage-display combinatorial libraries<...Delineation of the human systemic lupus erythematosus anti-Smith antibody response using phage-display combinatorial libraries<...
TY - JOUR. T1 - Delineation of the human systemic lupus erythematosus anti-Smith antibody response using phage-display combinatorial libraries. AU - Del Rincon, I.. AU - Zeidel, M.. AU - Rey, E.. AU - Harley, J. B.. AU - James, J. A.. AU - Fischbach, M.. AU - Sanz, I.. PY - 2000/12/15. Y1 - 2000/12/15. N2 - The anti-Smith (Sm) autoantibody response is highly specific for systemic lupus erythematosus and is predominantly targeted to the Sm-B/B and -D1 polypeptides. In all animal species thus far studied, anti-Sm Abs initially recognize proline-rich epitopes in the carboxyl terminus of the Sm-B/B protein and subsequently to multiple other epitopes in B/B and D. The absence of appropriate mAbs has limited our understanding of the genetic and structural basis of this autoimmune response. Using phage-display technology and lymphocytes from a systemic lupus erythematosus patient we have generated the first and only panel of human IgG anti-Sm mAbs thus far available. These Abs reproduced to a ...
https://scholars.uthscsa.edu/en/publications/delineation-of-the-human-systemic-lupus-erythematosus-anti-smith-
133 Soluble cxcl16 in juvenile systemic lupus erythematosus | Lupus Science & Medicine133 Soluble cxcl16 in juvenile systemic lupus erythematosus | Lupus Science & Medicine
Results The serum levels of sCXCL16 in jSLE patients were higher than controls (p,0.001), they were also siginificantly higher in patients with alopecia or malar rash than other jSLE .Positive correlation was identified between serum levels of sCXCL16 and SLEDAI score. There was a significant positive correlation between sCXCL16 levels and severity of lupus nephritis as assessed by renal biopsy. Serum levels of sCXCL16 were positively significantly correlated with the 24 hour urine protein,ANA, SBP, DBP AND ESR 1st hour. Serum sCXCL16 level was significanly negatively correlated with C3 serum level. ...
http://lupus.bmj.com/content/4/Suppl_1/A59.3
Glucocorticoid for Systemic Lupus Erythematosus Market Global Analysis, Opportunities And Segmentation 2019-2024 - Investor...Glucocorticoid for Systemic Lupus Erythematosus Market Global Analysis, Opportunities And Segmentation 2019-2024 - Investor...
Global Glucocorticoid for Systemic Lupus Erythematosus Status and Trend Report offers a comprehensive analysis of Glucocorticoid for Systemic Lupus Erythematosus industry, standing on the readers perspective, delivering detailed market data and penetrating insights. No matter the client is industry insider, potential entrant or investor, the report will provide useful data and information.. The Asia-Pacific will occupy more market share in the following years, especially in China, also fast growing India and Southeast Asia regions. North America, especially The United States, will still play an important role which cannot be ignored. Any changes from the United States might affect the development trend of Glucocorticoid for Systemic Lupus Erythematosus. Europe also plays important roles in the global market, with market size of xx million USD in 2019 and will be xx million USD in 2024, with a CAGR of xx%. This report studies the Glucocorticoid for Systemic Lupus Erythematosus market status and ...
https://investoropinion.co.uk/2020/04/01/glucocorticoid-for-systemic-lupus-erythematosus-market-global-analysis-opportunities-and-segmentation-2019-2024/
Presence of anti-Porphyromonas gingivalis-peptidylarginine deiminase antibodies in serum from juvenile systemic lupus...Presence of anti-Porphyromonas gingivalis-peptidylarginine deiminase antibodies in serum from juvenile systemic lupus...
View more ,Periodontal disease is a group of chronic inflammatory diseases affecting tooth-supporting tissues. The early stage is the presence of biofilm-associated gingival inflammation which, in patients having juvenile systemic lupus erythematosus (SLE), might function as a reservoir of anaerobic Gram-negative bacteria such as Porphyromonas gingivalis. Porphyromonas gingivalis has been associated with an increased level of anticardiolipin and anti-b2-glycoprotein antibodies in patients with SLE, which implies periodontal disease as a modifiable risk factor for SLE morbility1 . Besides, Porphyromonas gingivalis also express functional endogenous Peptidylarginine deiminase (PAD) enzymes, which catalyzes a citrullination reaction that can lead to formation of citrullinated peptides. PAD can frequently be recognized in sera of patients with rheumatoid arthritis, systemic lupus erythematosusand primary Sjögren syndrome2 . Laugisch et al. 3 reported that PAD secreted by Porphyromonas gingivalis ...
https://research-repository.griffith.edu.au/handle/10072/389983
Autoantibodies against C1q in systemic lupus erythematosus are antigen-driven - edocAutoantibodies against C1q in systemic lupus erythematosus are antigen-driven - edoc
Autoantibodies against complement C1q (anti-C1q Abs) were shown to strongly correlate with the occurrence of severe nephritis in patients with systemic lupus erythematosus (SLE), suggesting a potential pathogenic role by interfering with the complement cascade. To analyze the humoral immune response against C1q at the molecular level, we screened a bone marrow-derived IgGkappa/IgGlambda Fab phage display library from a SLE patient with high anti-C1q Ab titer against purified human C1q. Six Fabs that exhibited strong binding to C1q in ELISA were isolated. The anti-C1q Fabs recognized neoepitopes that were only exposed on bound C1q and not present on soluble C1q mapping to different regions of the collagen-like region of C1q. Analysis of the genes encoding the variable H and L chains of the IgG-derived anti-C1q Fab revealed that all the variable H and L chain regions were highly mutated, with nucleotide and amino acid homologies to the closest germline in the range of 71-97% (average 85 +/- 4) and ...
https://edoc.unibas.ch/25275/
Cardiac pathology of systemic lupus erythematosus<...
TY - JOUR. T1 - Cardiac pathology of systemic lupus erythematosus. AU - Jain, D.. AU - Halushka, Marc K. PY - 2009/7. Y1 - 2009/7. N2 - Systemic lupus erythematosus is a common chronic autoimmune disorder causing injury to many organ systems. Cardiac complications of lupus affect most parts of the heart. These include pericarditis, myocarditis, endocarditis and coronary artery disease. While many histopathological findings in lupus-related cardiac diseases are non-specific, there are a few important findings which pathologists should be aware of. This review provides pathological descriptions of these entities.. AB - Systemic lupus erythematosus is a common chronic autoimmune disorder causing injury to many organ systems. Cardiac complications of lupus affect most parts of the heart. These include pericarditis, myocarditis, endocarditis and coronary artery disease. While many histopathological findings in lupus-related cardiac diseases are non-specific, there are a few important findings which ...
https://jhu.pure.elsevier.com/en/publications/cardiac-pathology-of-systemic-lupus-erythematosus-3
A longitudinal PRINTO study on growth and puberty in juvenile systemic lupus erythematosus | Annals of the Rheumatic DiseasesA longitudinal PRINTO study on growth and puberty in juvenile systemic lupus erythematosus | Annals of the Rheumatic Diseases
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Centers RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.. ...
https://ard.bmj.com/content/71/4/511.share
AB0533 Juvenile and juvenile-onset systemic lupus erythematosus patients: clinical characteristics, disease activity and damage...AB0533 Juvenile and juvenile-onset systemic lupus erythematosus patients: clinical characteristics, disease activity and damage...
Results The mean age of the JSLE children was 13.25±2.09 years and 23.17±4.26 years for JO-SLE cases. JO-SLE cases were older at disease onset with a higher female-to-male ratio. There were no noticeable gender differences. There was a significantly higher frequency of serositis, nephritis and hematological involvement in the JO-SLE (57.7%, 76.9% and 73.1%) compared to the JSLE cases (15.4%; 30.8% and 30.8%) (p,0.001 for all). The erythrocyte sedimentation rate, creatinine and proteinuria were significantly increased in JO-SLE while alkaline phosphatase was higher in JSLE cases. In JO-SLE cases, SLEDAI significantly increased (5.96±6.18 vs 3.12±1.97; p=0.003) and the SLICC tended to increase compared to the JSLE children. More JO-SLE cases received hydroxychloroquine and azathioprine. ...
http://ard.bmj.com/content/76/Suppl_2/1237.3
Systemic Lupus Erythematosus - Lahey HealthSystemic Lupus Erythematosus - Lahey Health
Fanouriakis A, Kostopoulou M, et al. 2019 update of the EULAR recommendations for the management of systemic lupus erythematosus. Ann Rheum Dis. 2019 Jun;78(6):736-745. Systemic lupus erythematosus (lupus). National Institute of Arthritis and Musculoskeletal and Skin Diseases website. Available at: http://www.niams.nih.gov/Health%5FInfo/Lupus/default.asp. Accessed January 8, 2021. Systemic lupus erythematosus (SLE). EBSCO DynaMed website. Available at: https://www.dynamed.com/condition/systemic-lupus-erythematosus-sle. Accessed January 8, 2021. Understanding lupus. Lupus Foundation of America website. Available at: http://www.lupus.org/answers/topic/understanding-lupus. Accessed January 8, 2021. ...
https://www.lahey.org/health-library/systemic-lupus-erythematosus/
Systemic lupus erythematosus | Lima Memorial Health SystemSystemic lupus erythematosus | Lima Memorial Health System
Amital H, Szekanecz Z, Szücs G, et al. Serum concentrations of 25-OH vitamin D in patients with systemic lupus erythematosus (SLE) are inversely related to disease activity: is it time to routinely supplement patients with SLE with vitamin D? Ann Rheum Dis. 2010 Jun;69(6):1155-7. (Epub ahead of print). Bast A, Haenen GR. Lipoic acid: a multifunctional antioxidant. Biofactors. 2003;17(1-4):207-13.. Chang DM, Lan JL, Lin HY, Luo SF. Dehydroepiandrosterone treatment of women with mild-to-moderate systemic lupus erythematosus: a multicenter randomized, double-blind, placebo-controlled trial. Arthritis Rheum. 2002 Nov;46(11):2924-7.. Costenbader KH, Kang JH, Karlson EW. Antioxidant Intake and Risks of Rheumatoid Arthritis and Systemic Lupus Erythematosus in Women. Am J Epidemiol. 2010 Jun 9. [Epub ahead of print]. Dryden GW Jr, Deaciuc I, Arteel G, McClain CJ. Clinical implications of oxidative stress and antioxidant therapy. Curr Gastroenterol Rep. 2005;7(4):308-16.. El-Badri NS, Hakki A, Ferrari ...
https://www.limamemorial.org/health-library/Complementary%20and%20Alternative%20Medicine/33/000161
Is melasma a symptom of systemic lupus erythematosus sle - Things You Didnt KnowIs melasma a symptom of systemic lupus erythematosus sle - Things You Didnt Know
Is melasma a symptom of systemic lupus erythematosus sle - Is there a cure for systemic lupus erythematosus (sle)? SLE treatment. Systemic lupus erythematosus (sle) is a long-term autoimmune disorder that may affect the skin, joints, kidneys, brain, and other organs. There is no cure for sle. The goal of treatment is to control symptoms.
https://www.healthtap.com/topics/is-melasma-a-symptom-of-systemic-lupus-erythematosus-sle
Systemic lupus erythematosusSystemic lupus erythematosus
Arntfield RT, Hicks CM. Systemic lupus erythematosus and the vasculitides. In: Walls RM, Hockberger RS, Gausche-Hill M, eds. Rosens Emergency Medicine: Concepts and Clinical Practice. 9th ed. Philadelphia, PA: Elsevier; 2018:chap 108.. Crow MK. Etiology and pathogenesis of systemic lupus erythematosus. In: Firestein GS, Budd RC, Gabriel SE, McInnes IB, ODell JR, eds. Kelley and Firesteins Textbook of Rheumatology. 10th ed. Philadelphia, PA: Elsevier; 2017:chap 79.. Fanouriakis A, Kostopoulou M, Alunno A, et al. 2019 update of the EULAR recommendations for the management of systemic lupus erythematosus. Ann Rheum Dis. 2019;78(6) :736-745. PMID: 30926722 pubmed.ncbi.nlm.nih.gov/30926722/.. Hahn BH, McMahon MA, Wilkinson A, et al. American College of Rheumatology guidelines for screening, treatment, and management of lupus nephritis. Arthritis Care Res (Hoboken). 2012;64(6):797-808. PMID: 22556106 pubmed.ncbi.nlm.nih.gov/22556106/.. van Vollenhoven RF, Mosca M, Bertsias G, et al. Treat-to-target ...
http://nch.adam.com/content.aspx?productid=117&pid=1&gid=000435
Pediatric Systemic Lupus Erythematosus Medication: Antimalarial agents, Corticosteroids, Immunosuppressive agents, BLyS...Pediatric Systemic Lupus Erythematosus Medication: Antimalarial agents, Corticosteroids, Immunosuppressive agents, BLyS...
Systemic lupus erythematosus (SLE) is a rheumatic disease characterized by autoantibodies directed against self-antigens, immune complex formation, and immune dysregulation, resulting in damage to essentially any organ. The disease can affect, for example, the kidneys, skin, blood cells, and nervous system.
https://emedicine.medscape.com/article/1008066-medication
Systemic Lupus Erythematosus, Pipeline Review, H1 2015Systemic Lupus Erythematosus, Pipeline Review, H1 2015
Table of Contents. Table of Contents 2. List of Tables 7. List of Figures 9. Introduction 10. Global Markets Direct Report Coverage 10. Systemic Lupus Erythematosus Overview 11. Therapeutics Development 12. Pipeline Products for Systemic Lupus Erythematosus-Overview 12. Pipeline Products for Systemic Lupus Erythematosus-Comparative Analysis 13. Systemic Lupus Erythematosus-Therapeutics under Development by Companies 14. Systemic Lupus Erythematosus-Therapeutics under Investigation by Universities/Institutes 19. Systemic Lupus Erythematosus-Pipeline Products Glance 20. Late Stage Products 20. Clinical Stage Products 21. Early Stage Products 22. Unknown Stage Products 23. Systemic Lupus Erythematosus-Products under Development by Companies 24. Systemic Lupus Erythematosus-Products under Investigation by Universities/Institutes 29. Systemic Lupus Erythematosus-Companies Involved in Therapeutics Development 30. 4SC AG 30. AbbVie Inc. 31. Ablynx NV 32. Actelion Ltd 33. AiCuris GmbH & Co. KG 34. Amgen ...
https://www.kenresearch.com/healthcare/pharmaceuticals/systemic-lupus-erythematosus-pipeline/9985-91.html
Echocardiographic observation of acute myocarditis with systemic lupus erythematosus<...
TY - JOUR. T1 - Echocardiographic observation of acute myocarditis with systemic lupus erythematosus. AU - Ueda, Takashi. AU - Mizushige, Katsufumi. AU - Aoyama, Tohru. AU - Tokuda, Michiaki. AU - Kiyomoto, Hideyasu. AU - Matsuo, Hirohide. PY - 2000/2/1. Y1 - 2000/2/1. N2 - Although myocarditis from a series of autopsies of patients with systemic lupus erythematosus was frequently observed, the incidence of clinically apparent myocardial dysfunction was low. A 30-year-old woman with systemic lupus erythematosus was examined by echocardiography. An acoustic densitometry was followed at the left ventricular posterior wall throughout the clinical course. A decrease in the magnitude of cyclic variation of integrated backscatter (IB) was observed before treatment. Following the combined treatment, steroid and cyclophosphamide, a repeated ultrasonic tissue characterization showed an increase in the magnitude of cyclic variation of IB. It is thought that ultrasonic tissue characterization may be a ...
https://tohoku.pure.elsevier.com/en/publications/echocardiographic-observation-of-acute-myocarditis-with-systemic-
Systemic lupus erythematosus - Treatment with chinese herbs for Systemic lupus erythematosus symptoms
Systemic lupus erythematosus Bluish complexion, Bluish skin, Blue-tinge to the skin, Cough with cloudy, fishy-smelling mucus, Cough with cloudy, fishy-smelling sputum, , Chronic constipation (elderly people), , systemic lupus erythematosus
http://www.tcmassistant.com/symptoms/systemic-lupus-erythematosus.html
Systemic Lupus Erythematosus facts, information, pictures | Encyclopedia.com articles about Systemic Lupus Erythematosus
Get information, facts, and pictures about Systemic Lupus Erythematosus at Encyclopedia.com. Make research projects and school reports about Systemic Lupus Erythematosus easy with credible articles from our FREE, online encyclopedia and dictionary.
http://www.encyclopedia.com/medicine/diseases-and-conditions/pathology/systemic-lupus-erythematosus
Low dynamic muscle strength and its associations with fatigue, functional performance, and quality of life in premenopausal...Low dynamic muscle strength and its associations with fatigue, functional performance, and quality of life in premenopausal...
The purpose of the present study was to compare dynamic muscle strength, functional performance, fatigue, and quality of life in premenopausal systemic lupus erythematosus (SLE) patients with low disease activity versus matched-healthy controls and to determine the association of dynamic muscle strength with fatigue, functional performance, and quality of life in SLE patients. We evaluated premenopausal (18-45 years) SLE patients with low disease activity (Systemic lupus erythematosus disease activity index [SLEDAI]: mean 1.5 ± 1.2). The control (n = 25) and patient (n = 25) groups were matched by age, physical characteristics, and the level of physical activities in daily life (International Physical Activity Questionnaire IPAQ). Both groups had not participated in regular exercise programs for at least six months prior to the study. Dynamic muscle strength was assessed by one-repetition maximum (1-RM) tests. Functional performance was assessed by the Timed Up and Go (TUG), in 30-s test a chair stand
https://bmcmusculoskeletdisord.biomedcentral.com/articles/10.1186/1471-2474-14-263
Lack of patient education is risk factor of disease flare in patients with systemic lupus erythematosus in China | BMC Health...Lack of patient education is risk factor of disease flare in patients with systemic lupus erythematosus in China | BMC Health...
To explore the inadequacies of health service and its impact on clinical outcomes of patients with systemic lupus erythematosus (SLE) in China. A total of 210 SLE patients were randomly recruited between January 2017 and January 2018. Each patient received self-report questionnaires to assess medication adherence [Compliance Questionnaire for Rheumatology (CQR)], beliefs about medicines [Beliefs about Medicines Questionnaire (BMQ)] and satisfaction about medicine information [the Satisfaction with Information about Medicines Scale (SIMS)]. Associations between SLE disease activity index (SLEDAI-2 K) and observed factors were analyzed by multiple logistic regression. Based on CQR, only 28.10% patients were adherent. The score of BMQ was 2.85 ± 5.42, and merely 32.38% patients were satisfied with the information about their prescribed medicines. Disease activity was associated with SIMS, EuroQol five-dimensions [EQ5D], Systemic Lupus International Collaborating Clinics (SLICC), depression, use of NSAID
https://0-bmchealthservres-biomedcentral-com.brum.beds.ac.uk/articles/10.1186/s12913-019-4206-y
Plus itPlus it
Systemic lupus erythematosus (SLE) is an autoimmune inflammatory disease that significantly affects health-related quality of life (HRQOL): physical, psychologic, mental, and social aspects of well-being that are influenced by disease, in the context of life experiences and expectations specific to each patient1. A relapsing, remitting chronic disease, SLE results in disability in 20%-40% of afflicted young and middle-aged women and men2. In patients with SLE, HRQOL is influenced by disease activity and symptoms of fatigue, depression, pain, sleep disturbances, and cognitive dysfunction3. Across 5 randomized controlled trials (RCT) in SLE, baseline HRQOL scores were low and were similar to those of subjects following myocardial infarction or with chronic congestive heart failure4. Lower scores were highly correlated with history of renal disease, presence of anti-dsDNA antibodies, higher disease activity scores by Systemic Lupus Erythematosus Disease Activity Index (SLEDAI) and/or Safety of ...
https://www.jrheum.org/content/38/9/1821
Biomarkers of Lupus Disease: Serial Biomarker Sampling in Patients With Active Systemic Lupus Erythematosus (SLE) - Study...Biomarkers of Lupus Disease: Serial Biomarker Sampling in Patients With Active Systemic Lupus Erythematosus (SLE) - Study...
Group A only: patients on immunosuppressive treatments had them withdrawn at baseline. All patients were allowed up to 160 mg depomedrol at baseline which could be repeated within two weeks up to a total of 4 shots maximum or until satisfactory improvement. Time to flare was calculated from baseline. moderate disease at baseline was defined as up to 3 BILAG B (moderate disease) organ scores, no BILAG A (severe disease) score and a SLEDAI ,/= 10. Severe disease required ,3 BILAG B, OR at least one BILAG A OR SLEDAI , 10 or meeting criteria for a severe flare on the SELENA SLEDAI flare index. At baseline 25 patients with moderate disease. 16 patients had severe disease. Note: severe rash with A on BILAG is only SLEDAI=2, explaining some discrepancies in measures ...
https://clinicaltrials.gov/ct2/show/results/NCT00987831?term=BOLD&cond=SLE&rank=1
Systemic lupus erythematosus (SLE) is usually a chronic autoimmune multisystem disease - Role of adrenergic receptors in human...
Keywords: Panretinal photocoagulation Retinal vascular occlusion Systemic lupus erythematosus Intro Systemic lupus erythematosus can be a multisystem disease of unfamiliar etiology seen as a several autoimmune phenomena with lesions in multiple body organ systems. Ocular manifestations of systemic BML-275 lupus erythematosus (SLE) consist of mucocutaneous involvement from the eyelids supplementary Sjogrens symptoms optic neuropathy. The retinopathy includes cotton wool spots with or without retinal hemorrhages generally.1-3 Vaso-occlusive disease particularly in the current presence of antiphospholipid antibodies usually trigger devastating and long term damage to visible function regardless of strenuous treatment and requires treatment with anticoagulation and proliferative retinopathy is treated with laser beam therapy.2 3 Case record A 35-year-old female was admitted due to sudden loss of visual acuity in the still left attention. She have been diagnosed as experiencing systemic lupus ...
http://researchreportone.com/?p=1627
High Prevalence of Metabolic Syndrome in South African Systemic Lupus Erythematosus Patients | AbstractHigh Prevalence of Metabolic Syndrome in South African Systemic Lupus Erythematosus Patients | Abstract
Introduction: Patients with systemic lupus erythematosus (SLE) are at increased risk of metabolic syndrome (MetS) and its complications. In absence of..
https://www.longdom.org/abstract/high-prevalence-of-metabolic-syndrome-in-south-african-systemic-lupus-erythematosus-patients-44155.html
Association of Systemic Lupus Erythematosus (SLE) Genetic Susceptibility Loci with Lupus Nephritis in Children and Adults with...Association of Systemic Lupus Erythematosus (SLE) Genetic Susceptibility Loci with Lupus Nephritis in Children and Adults with...
Background/Purpose: Systemic lupus erythematosus (SLE) is a complex, chronic, autoimmune disease. Genome-wide association studies (GWAS) have identified multiple risk SNPs in HLA and non-HLA gene regions. There is evidence that genetics are also important in lupus nephritis (LN) risk. LN is one of the most common and severe manifestations of SLE. The purpose of this study was to determine the association of known SLE risk SNPs with LN in both childhood-onset (cSLE) and adult-onset SLE (aSLE) populations. Methods: The study population included two tertiary care SLE cohorts; one with cSLE and the other with aSLE. Participants met American College of Rheumatology (ACR) and/or Systemic Lupus International Collaborating Clinics (SLICC) classification criteria for SLE, with prospectively collected clinical and laboratory data. Participants were genotyped on the Illumina MEGA or Omni1 arrays. Principal components were calculated in reference to the 1000 genomes project, and ancestry was genetically ...
https://acrabstracts.org/abstract/association-of-systemic-lupus-erythematosus-sle-genetic-susceptibility-loci-with-lupus-nephritis-in-children-and-adults-with-sle/
Immunology: Systemic Lupus Erythematosus Juvenile | Free EssayImmunology: Systemic Lupus Erythematosus Juvenile | Free Essay
This paper will explore juvenile Systemic Lupus Erythematosus. It will also explore its signs, symptoms, diagnosis, prognosis, statistics, treatment, complications, risk factors, and diet.
https://studycorgi.com/immunology-systemic-lupus-erythematosus-juvenile/
T Lymphocyte Apoptosis in Systemic Lupus Erythematosus PatientsT Lymphocyte Apoptosis in Systemic Lupus Erythematosus Patients
Objective(s): Apoptosis is a tightly regulated process and plays a crucial role in autoimmune diseases. Because abnormalities in apoptosis are considered to be involved in the pathogenesis of systemic lupus erythematosus (SLE), in present study we studied the apoptosis in T lymphocytes from Iranian SLE patientsat protein and gene expression levels for some molecules which are involved in apoptosis pathways. Materials and Methods: Thirty five SLE patients (23 female, 12 male), and 20 age matched controls (10 female, 10 male) participated in this study. T lymphocytes were isolated from peripheral blood mononuclear cells (PBMCs) using MACS method. Apoptosis rate was studied at protein level by flow cytometer using Annexin V, and at gene expression level using semi-quantitative RT-PCR method for detection of Fas, FasL, Bcl-2, caspase 8, and caspase 9 genes. Results: The percentage of apoptotic cells in SLE patients was not different in comparison with controls (20.2% ± 1.4 vs 21.1% ± 1.0), but the
http://ijbms.mums.ac.ir/article_1353.html
Genetic ancestry, serum interferon- αactivity, and autoantibodies in systemic lupus erythematosus<...
TY - JOUR. T1 - Genetic ancestry, serum interferon- αactivity, and autoantibodies in systemic lupus erythematosus. AU - Ko, Kichul. AU - Franek, Beverly S.. AU - Marion, Miranda. AU - Kaufman, Kenneth M.. AU - Langefeld, Carl D.. AU - Harley, John B.. AU - Niewold, Timothy B.. PY - 2012/6. Y1 - 2012/6. N2 - Objective. To investigate and refine the relationships among systemic lupus erythematosus (SLE) and related autoantibodies, interferon-α (IFN-α), and various ancestral backgrounds. Methods. We investigated quantitatively defined genetic ancestry through principal component analysis in place of self-reported ancestry. Results. African ancestry was found to be associated with presence of anti-RNP antibody (p = 0.0026), and anti-RNP was correlated with high levels of IFN-α (p = 2.8 × 10 -5). Conclusion. Our data support a model in which African ancestry increases the likelihood of SLE-associated autoantibody formation, which subsequently results in higher levels of serum IFN-α. The Journal ...
https://mayoclinic.pure.elsevier.com/en/publications/genetic-ancestry-serum-interferon-%CE%B1activity-and-autoantibodies-in
Recent corticosteroid use and recent disease activity: independent determinants of coronary heart disease risk factors in...
Data abstracted retrospectively from the charts at 11,359 clinic visits for 310 patients with SLE to the Montreal General Hospital were used to investigate the associations of recent corticosteroid dose and recent Systemic Lupus Erythematosus Disease Activity Index (SLEDAI) score with 8 CHD risk factors (total serum cholesterol, high-density lipoprotein [HDL] cholesterol, low-density lipoprotein cholesterol, apolipoprotein B [Apo B], triglycerides, systolic blood pressure [BP], body mass index, and blood glucose) and the aggregate estimate of 2-year CHD risk. Separate multivariable linear regression models estimated the mutually-adjusted effects of average daily corticosteroid dose and average SLEDAI score within the past year on the current level of each risk factor while adjusting for age, sex, cumulative damage score, disease duration, and, where appropriate, use of relevant medications ...
https://espace.library.uq.edu.au/view/UQ:315681
PLOS ONE: Further Evidence of Subphenotype Association with Systemic Lupus Erythematosus Susceptibility Loci: A European Cases...PLOS ONE: Further Evidence of Subphenotype Association with Systemic Lupus Erythematosus Susceptibility Loci: A European Cases...
Introduction Systemic Lupus Erythematosus (SLE) shows a spectrum of clinical manifestations that complicate its diagnosis, treatment and research. This variability is likely related with environmental exposures and genetic factors among which known SLE susceptibility loci are prime candidates. The first published analyses seem to indicate that this is the case for some of them, but results are still inconclusive and we aimed to further explore this question. Methods European SLE patients, 1444, recruited at 17 centres from 10 countries were analyzed. Genotypes for 26 SLE associated SNPs were compared between patients with and without each of 11 clinical features: ten of the American College of Rheumatology (ACR) classification criteria (except ANAs) and age of disease onset. These analyses were adjusted for centre of recruitment, top ancestry informative markers, gender and time of follow-up. Overlap of samples with previous studies was excluded for assessing replication. Results There were three
http://journals.plos.org/plosone/article/comments?id=10.1371/journal.pone.0045356&imageURI=info:doi/10.1371/journal.pone.0045356.t003
Systemic lupus erythematosus (SLE): sustained clinical benefit and reduction in severe flares with Stelara® (ustekinumab) ...Systemic lupus erythematosus (SLE): sustained clinical benefit and reduction in severe flares with Stelara® (ustekinumab) ...
The Janssen Pharmaceutical Companies of Johnson & Johnson presented this week results of two analyses from a Phase 2 study of Stelara®*(ustekinumab) in systemic lupus erythematosus (SLE). The studies highlight not only the sustained clinical benefit of ustekinumab - an anti-interleukin (IL) IL-12/23 p40 neutralising monoclonal antibody - on SLE disease activity at one-year, but also show a reduction in the rate of severe flares.. They also provide new insights into the possible pathway through which ustekinumab is acting in SLE patients who respond to IL-12/23 p40 blockade.1,2. The Phase 2 study, presented by lead study investigator Ronald van Vollenhoven MD PhD and colleagues, is a global randomized, placebo-controlled trial in 102 adults with seropositive SLE by Systemic Lupus International Collaborating Clinics (SLICC) criteria and active disease despite ongoing standard of care therapy (steroid, antimalarial and/or immunosuppressive therapies).1Patients were randomized (3:2) to receive ...
https://www.portalediabete.org/systemic-lupus-erythematosus-sle-sustained-clinical-benefit-and-reduction-in-severe-flares-with-stelarar-ustekinumab-eular2019/
Increased interleukin-23 receptor + T cells in peripheral blood mononuclear cells of patients with systemic lupus erythematosus...Increased interleukin-23 receptor + T cells in peripheral blood mononuclear cells of patients with systemic lupus erythematosus...
Systemic lupus erythematosus (SLE) is an autoimmune disorder characterized by production of autoantibodies and immune complex deposition in various organs. Aberrations in the T lymphocyte compartment and dysregulated cytokine production are key features of SLE pathogenesis and disease progression. Recently, the role of the interleukin (IL)-17/IL-23 axis in the pathogenesis of SLE has been reported. IL-23 and IL-23R are essential for expansion of pathogenic IL-17-producing T lymphocytes and have been shown to be important in the pathogenesis of lupus in animal models. In this study, the expression of IL-23R and IL-17 in CD4+ and CD8+ T lymphocytes in peripheral blood mononuclear cells (PBMCs) of SLE patients and control subjects were examined by flow cytometry. Twenty-nine SLE patients and 10 control subjects were recruited in this study. Patients were divided into active and inactive groups based on the SLE disease activity index (SLEDAI). As another disease control population, five psoriatic patients
https://arthritis-research.biomedcentral.com/articles/10.1186/ar3194/email/correspondent/c2/new
Federal Agency Grants Award to Fast Track Research of New Lupus Disease Activity Measurement Tests | Lupus Foundation of AmericaFederal Agency Grants Award to Fast Track Research of New Lupus Disease Activity Measurement Tests | Lupus Foundation of America
The National Institute of Allergy and Infectious Diseases has awarded a grant to Progentec to fast-track research into new tests for measuring systemic lupus erythematosus disease activity.
https://www.lupus.org/news/federal-agency-grants-award-to-fast-track-research-of-new-lupus-disease-activity-measurement
Successful pregnancy in pulmonary arterial hypertension associated with systemic lupus erythematosus: a case report - Zurich...Successful pregnancy in pulmonary arterial hypertension associated with systemic lupus erythematosus: a case report - Zurich...
INTRODUCTION: Pulmonary arterial hypertension is a complication of systemic lupus erythematosus. Mortality in pregnant patients with pulmonary arterial hypertension related to connective tissue disease is as high as 56%. The authors report the first case of a successful maternal-fetal outcome in a pregnant patient with systemic lupus erythematosus-associated pulmonary arterial hypertension treated with sildenafil and inhaled iloprost during pregnancy and until several weeks after caesarean section. CASE PRESENTATION: The case presented is of a 29-year-old woman with systemic lupus erythematosus and associated severe pulmonary arterial hypertension. Vasodilator therapy with bosentan and sildenafil, immunosuppressive therapy with prednisone, hydroxychloroquine and azathioprine and oral anticoagulation (phenprocoumon) had normalized her right ventricular over right atrial pressure when she was diagnosed in her 5th week of pregnancy. The teratogenic drugs bosentan and phenprocoumon were stopped, the ...
http://www.zora.uzh.ch/id/eprint/31746/
Performance of the 2019 EULAR/ACR classification criteria for systemic lupus erythematosus in early disease, across sexes and...Performance of the 2019 EULAR/ACR classification criteria for systemic lupus erythematosus in early disease, across sexes and...
The European League Against Rheumatism (EULAR)/American College of Rheumatology (ACR) 2019 Classification Criteria for systemic lupus erythematosus (SLE) have been validated with high sensitivity and specificity. We evaluated the performance of the new criteria with regard to disease duration, sex and race/ethnicity, and compared its performance against the Systemic Lupus International Collaborating Clinics (SLICC) 2012 and ACR 1982/1997 criteria.Twenty-one SLE centres from 16 countries submitted SLE cases and mimicking controls to form the validation cohort. The sensitivity and specificity of the EULAR/ACR 2019, SLICC 2012 and ACR 1982/1997 criteria were evaluated.The cohort consisted of female (n=1098), male (n=172), Asian (n=118), black (n=68), Hispanic (n=124) and white (n=941) patients; with an SLE duration of 1 to ,3 years (n=196) and ≥5 years (n=879). Among patients with 1 to ,3 years disease duration, the EULAR/ACR criteria had better sensitivity than the ACR criteria (97% vs 81%). The ...
https://www.onmedica.com/posts/performance-of-the-2019-eular-acr-classification-criteria-for-systemic-lupus-erythematosus-in-early-disease-across-sexes-and-ethnicities
Comparison of structural magnetic resonance imaging findings between neuropsychiatric systemic lupus erythematosus and systemic...Comparison of structural magnetic resonance imaging findings between neuropsychiatric systemic lupus erythematosus and systemic...
Introduction: Neuropsychiatric systemic lupus erythematosus is often clinically challenging to diagnose, treat and monitor. Although brain magnetic resonance imaging is frequently performed before lumbar puncture in neuropsychiatric systemic lupus erythematosus, it is not clear from the literature whether specific brain magnetic resonance imaging findings are associated with distinct clinical features of neuropsychiatric systemic lupus erythematosus. Methods: We conducted a systematic review and meta-analysis on published studies of neuropsychiatric systemic lupus erythematosus including brain magnetic resonance imaging and the 1999 American College of Rheumatology-defined clinical neuropsychiatric systemic lupus erythematosus syndromes to determine their relationship. Pooled prevalence and risk ratio for distinct neuropsychiatric systemic lupus erythematosus associations were determined with 95% confidence intervals. Results: Of 821 studies screened, 21 fulfilled inclusion criteria. A total of ...
https://ueaeprints.uea.ac.uk/id/eprint/65654/
Neuropsychiatric Systemic Lupus Erythematosus Complicated with Acute Pericarditis in Patient with Hyperprolactinaemia: A Case...Neuropsychiatric Systemic Lupus Erythematosus Complicated with Acute Pericarditis in Patient with Hyperprolactinaemia: A Case...
Neuropsychiatric systemic lupus erythematosus (NP-SLE) is one of the major cause of morbidity in systemic lupus erythematosus patients and its treatment depends on identification of pathogenic mechanisms. We describe the rare case of neuropsychiatric systemic lupus erythematosus (NP-SLE) complicated by pericardial effusion combined to low C4 level persisting and hyperprolactinaemia. A cyclophosphamide therapy showed a good response in a 21-year old woman with disturbances in thought processes and an acute confusional state with sierositis. This paper confirms that a cyclophosphamide therapy contributes to control a disease activity by a mechanism of prolactin level reduction. Other studies occur to evaluate this hypothesis.
https://m.scirp.org/papers/27837
Signs of Bullous systemic lupus erythematosus - RightDiagnosis.comSigns of Bullous systemic lupus erythematosus - RightDiagnosis.com
Signs of Bullous systemic lupus erythematosus including medical signs and symptoms of Bullous systemic lupus erythematosus, symptoms, misdiagnosis, tests, common medical issues, duration, and the correct diagnosis for Bullous systemic lupus erythematosus signs or Bullous systemic lupus erythematosus symptoms.
http://www.rightdiagnosis.com/b/bullous_systemic_lupus_erythematosus/signs.htm
Familial congenital complete heart block and maternal systemic lupus erythematosis. | CirculationFamilial congenital complete heart block and maternal systemic lupus erythematosis. | Circulation
A family is reported in which two siblings had congenital complete heart block with resultant congestive heart failure, the father and paternal grandfather show adult-onset conduction defects, and the mother has systemic lupus erythematosis. The interaction of heredity and environment is discussed in this context. A review of the literature on familial complete heart block suggests that so-called pure congenital-onset familial heart block, originally felt to be genetic, may in fact have an important enivronmental component, specifically related to ongoing maternal factors such as systemic lupus erythematosis. ...
http://circ.ahajournals.org/content/56/6/1103
Effect of plasmapheresis on T and B lymphocyte functions in patients with systemic lupus erythematosus: A double blind study<...Effect of plasmapheresis on T and B lymphocyte functions in patients with systemic lupus erythematosus: A double blind study<...
TY - JOUR. T1 - Effect of plasmapheresis on T and B lymphocyte functions in patients with systemic lupus erythematosus. T2 - A double blind study. AU - Tsokos, G. C.. AU - Balow, J. E.. AU - Huston, David P.. AU - Wei, N.. AU - Decker, J. L.. PY - 1982/7/13. Y1 - 1982/7/13. N2 - Nine patients with active systemic lupus erythematosus entered a double-blind randomized trial to study the therapeutic effect of vigorous versus sham reinfusion plasmapheresis. Four of them received real plasmapheresis while five received sham reinfusion plasmaphersis. In the present communication we report the effects of these procedures on T lymphocytes in peripheral mononuclear cells, proliferative responses to mitogens, allogeneic mixed lymphocyte reaction and cell-mediated lympholysis, as well as the effect of plasmapheresis on the spontaneous and pokeweed mitogen induced immunoglobulin secreting cells in peripheral blood. Several mononuclear cell functions were abnormal at the beginning of the study but no ...
https://scholars.houstonmethodist.org/en/publications/effect-of-plasmapheresis-on-t-and-b-lymphocyte-functions-in-patie
Assessment of serum macrophage migration inhibitory factor (MIF), adiponectin, and other adipokines as potential markers of...Assessment of serum macrophage migration inhibitory factor (MIF), adiponectin, and other adipokines as potential markers of...
To date, the association of serum macrophage migration inhibitory factor (MIF) and serum adipokines with lupus nephritis is controversial. To assess the utility of serum MIF, leptin, adiponectin and resistin levels as markers of proteinuria and renal dysfunction in lupus nephritis. Cross-sectional study including 196 systemic lupus erythematosus (SLE) patients and 52 healthy controls (HCs). Disease activity was assessed by Systemic Lupus Erythematosus Disease Activity Index (SLEDAI). Renal SLE involvement was investigated by renal-SLEDAI. MIF, adiponectin, leptin and resistin levels were quantified by ELISA. We assessed the correlations of quantitative variables by Spearman correlation (rs). Multivariable linear regression adjusted the variables associated with the severity of proteinuria. SLE patients had higher MIF (p = 0.02) and adiponectin (p | 0.001) than HCs. Patients with renal SLE involvement (n = 43) had higher adiponectin (19.0 vs 13.3 μg/mL, p = 0.002) and resistin (10.7 vs 8.9 ng/mL, p = 0
https://biomarkerres.biomedcentral.com/articles/10.1186/s40364-020-00236-x/metrics
Accuracy of Anticardiolipin Antibodies in Identifying a History of Thrombosis Among Patients With Systemic Lupus Erythematosus<...Accuracy of Anticardiolipin Antibodies in Identifying a History of Thrombosis Among Patients With Systemic Lupus Erythematosus<...
TY - JOUR. T1 - Accuracy of Anticardiolipin Antibodies in Identifying a History of Thrombosis Among Patients With Systemic Lupus Erythematosus. AU - Escalante, Agustín. AU - L. Brey, Robin. AU - D.Mitchell Jr., Braxton. AU - Dreiner, Ute. PY - 1995/6. Y1 - 1995/6. N2 - objective: To measure the accuracy of anticardiolipin antibodies (aCL) in identifying a history of thrombosis among patients with systemic lupus erythematosus (SLE) or the primary antiphospholipid syndrome (PAPS). patients and methods: Patients with SLE or PAPS who attended our rheumatology clinic between April 1992 and March 1994 were included in a retrospective analysis of the relationship between thrombotic events and aCL. All aCL measurements were performed in the same laboratory by enzyme-linked immunosorbent assay, blinded as to the presence or absence of thrombosis. The diagnostic accuracy of IgG, IgM, and IgA aCL was quantified by means of the receiver operating characteristic area under the curve (ROC AUC) for each ...
https://scholars.uthscsa.edu/en/publications/accuracy-of-anticardiolipin-antibodies-in-identifying-a-history-o
Inherited C2 Deficiency and Systemic Lupus Erythematosus: Studies on a Family | Annals of Internal Medicine | American College...Inherited C2 Deficiency and Systemic Lupus Erythematosus: Studies on a Family | Annals of Internal Medicine | American College...
A patient is described in which an inherited defect in the synthesis of C2 complement component coexisted with the disease systemic lupus erythematosus. The family studies show evidence of the autosomal recessive nature of the inheritance of the C2 synthesis defect. Of particular interest was the finding of a great-aunt who also had homozygous C2 deficiency. This great-aunt suffered from discoid lupus erythematosus as well. The occurrence of various autoantibodies in the serum from the family members, the typing for blood groups, HL-A antigens, and some serum protein markers are reported and discussed. The C2 deficiency may be a critical defect in the host defenses to infection that predisposed to the development of autoimmune disease. ...
http://annals.org/aim/article-abstract/689206/inherited-c2-deficiency-systemic-lupus-erythematosus-studies-family
Systemic lupus erythematosus and renal tubular acidosis associated with hyperthyroidism. Case Report. - NeL.eduSystemic lupus erythematosus and renal tubular acidosis associated with hyperthyroidism. Case Report. - NeL.edu
A case of a 42-year-old female with hyperthyroidism was subsequently diagnosed to have systemic lupus erythematosus with distal RTA. The clinical examination on admission showed swelling of the knee joints and the urinalysis showed pH 6.5, pro 3+. Her blood routine results were as follows: white blood cells 1.85×109/L, platelets 100×109/L, erythrocyte 3.06×1012/L. The serum potassium was 3.11 mmol/L, 24 hour urinary electrolyte: K 68.87 mmol/24 H, antinuclear antibodies (ANA) 1:1 000, speckled pattern. The anti-double stranded DNA antibody (anti-dsDNA), anti SS-A(52) antibody and anti SS-A(60) antibody were positive. The light microscopy and immunofluorescence showed diffuse proliferative lupus nephritis. These data were compatible with the diagnosis of systemic lupus erythematosus. The diagnosis of hyperthyroidism and distal RTA is clear. This report showed that other autoimmune disease in the diagnosis of hyperthyroidism should not be ignored.. ...
http://www.nel.edu/systemic-lupus-erythematosus-and-renal-tubular-acidosis-associated-with-hyperthyroidism-case-report-107/
Frontiers | Clinical Efficacy of Routinely Administered Belimumab on Proteinuria and Neuropsychiatric Lupus | MedicineFrontiers | Clinical Efficacy of Routinely Administered Belimumab on Proteinuria and Neuropsychiatric Lupus | Medicine
Background and Objectives: Belimumab (BEL) is a monoclonal antibody approved for the treatment of active systemic lupus erythematosus (SLE) but not for lupus nephritis (LN) and neuropsychiatric systemic lupus erythematosus (NPSLE). We aimed to assess BELs effects on these severe, potentially life-threatening manifestations.Methods: Retrospective observational cohort study using routine clinical data in a case series of patients with SLE receiving BEL.Results: Sixteen patients received BEL therapy for active SLE. Nine were excluded because they had no LN or NPSLE. Six suffered from LN, and one patient had NPSLE. All LN patients received BEL in addition to standard therapy including glucocorticoids, hydroxychloroquine, and mycophenolate mofetil in five cases, and tacrolimus in one case. Three patients with proteinuria >1,000 mg/g creatinine responded well (one complete, two partial renal responses); all other patients had decreasing proteinuria and a reduction in anti-dsDNA levels. The patient with NPSLE
https://www.frontiersin.org/articles/10.3389/fmed.2020.00222/full
A retrospective study of pulmonary infarction in patients with systemic lupus erythematosus from southern Taiwan<...
TY - JOUR. T1 - A retrospective study of pulmonary infarction in patients with systemic lupus erythematosus from southern Taiwan. AU - Weng, C. T.. AU - Chung, T. J.. AU - Liu, M. F.. AU - Weng, M. Y.. AU - Lee, C. H.. AU - Chen, J. Y.. AU - Wu, A. B.. AU - Lin, B. W.. AU - Luo, C. Y.. AU - Hsu, S. C.. AU - Lee, B. F.. AU - Tsai, H. M.. AU - Chao, S. C.. AU - Wang, J. Y.. AU - Chen, T. Y.. AU - Chen, C. W.. AU - Chang, H. Y.. AU - Wang, C. R.. PY - 2011/7/1. Y1 - 2011/7/1. N2 - Since large-scale reports of pulmonary infarction in systemic lupus erythematosus (SLE) are limited, a retrospective study was performed for this manifestation in 773 hospitalized patients in southern Taiwan from 1999 to 2009. Pulmonary infarction was defined as the presence of pulmonary embolism, persistent pulmonary infiltrates, and characteristic clinical symptoms. Demographic, clinical, laboratory, and radiological images data were analyzed. There were 12 patients with pulmonary embolism and 9 of them had ...
https://researchoutput.ncku.edu.tw/en/publications/a-retrospective-study-of-pulmonary-infarction-in-patients-with-sy
Cochlear Histopathologic Findings in Patients With Systemic Lupus Erythematosus: A Human Temporal Bone Study<...
TY - JOUR. T1 - Cochlear Histopathologic Findings in Patients With Systemic Lupus Erythematosus. T2 - A Human Temporal Bone Study. AU - Kariya, Shin. AU - Kaya, Serdar. AU - Hizli, Ömer. AU - Hizli, Pelin. AU - Nishizaki, Kazunori. AU - Paparella, Michael M.. AU - Cureoglu, Sebahattin. PY - 2016/4/2. Y1 - 2016/4/2. N2 - HYPOTHESIS:: We hypothesized that, in archived human temporal bone samples from patients with systemic lupus erythematosus (SLE), a pathologic condition exists in the stria vascularis and cochlear hair cells. BACKGROUND:: Sensorineural hearing loss is a common feature in SLE patients. However, the pathophysiologic mechanism of cochlear dysfunction is unclear. METHODS:: We examined 15 temporal bone samples from 8 SLE patients, along with 17 samples from 10 age-matched healthy control patients. The samples were serially sectioned in the horizontal plane and stained with hematoxylin and eosin. We determined the area of the stria vascularis in a midmodiolar section of each cochlear ...
https://okayama.pure.elsevier.com/en/publications/cochlear-histopathologic-findings-in-patients-with-systemic-lupus
Autoimmune hepatitis with raised alpha-fetoprotein level as the presenting symptoms of systemic lupus erythematosus: A case...
TY - JOUR. T1 - Autoimmune hepatitis with raised alpha-fetoprotein level as the presenting symptoms of systemic lupus erythematosus. T2 - A case report. AU - Liu, Feng Cheng. AU - Chang, Deh Ming. AU - Lai, Jenn Haung. AU - Lin, Chih Kung. AU - Chen, Hsiang Cheng. AU - Hou, Tsung Y.. AU - Kuo, San Yuan. PY - 2007/3/1. Y1 - 2007/3/1. N2 - Systemic lupus erythematosus (SLE) and autoimmune hepatitis are distinct clinical disorders, which rarely occur, in the same patient. We describe a 59-year-old woman with coexistence of both conditions. Photosensitivity, arthritis, positive ANA, and extreme elevation of anti-dsDNA concluded the diagnosis of SLE. Hyperbilirubinemia, high serum value of liver function, and elevation of alpha-fetoprotein were also prominent. By a review of pertinent literature, clinical investigation, calculation of autoimmune hepatitis score, and pathology of liver biopsy specimen, we were in favor of autoimmune hepatitis. Awareness of this rare presentation may be beneficial to ...
https://tmu.pure.elsevier.com/en/publications/autoimmune-hepatitis-with-raised-alpha-fetoprotein-level-as-the-p
Splenectomy does not cure the thrombocytopenia of systemic lupus erythematosus<...
TY - JOUR. T1 - Splenectomy does not cure the thrombocytopenia of systemic lupus erythematosus. AU - Hall, S.. AU - McCormick, J. L.. AU - Greipp, P. R.. AU - Michet, C. J.. AU - McKenna, C. H.. PY - 1985/1/1. Y1 - 1985/1/1. N2 - Fourteen patients with systemic lupus erythematosus had splenectomies done between 1960 and 1982 for treatment of severe thrombocytopenia. Thrombocytopenia persisted or recurred within 1 month postoperatively in five patients and within 6 months in three others. Three patients had late recurrence (18, 30, and 54 months after splenectomy); in two cases it was probably related to withdrawal of immunosuppressive agents or corticosteroids. Median lowest platelet count before splenectomy and median platelet count at relapse or failure of splenectomy were both 8000/μL. Only two patients maintained normal platelet counts without need for corticosteroids or other treatment. These results differ from those in patients with idiopathic thrombocytopenic purpura. Other treatments ...
https://mayoclinic.pure.elsevier.com/en/publications/splenectomy-does-not-cure-the-thrombocytopenia-of-systemic-lupus-
Effects of vitamins C and E on oxidative stress markers and endothelial function in patients with systemic lupus erythematosus:...
TY - JOUR. T1 - Effects of vitamins C and E on oxidative stress markers and endothelial function in patients with systemic lupus erythematosus. T2 - A double blind, placebo controlled pilot study. AU - Tam, Lai S.. AU - Li, Edmund K.. AU - Leung, Vivian Y.F.. AU - Griffith, James F.. AU - Benzie, Iris F.F.. AU - Lim, Pak L.. AU - Whitney, Bruce. AU - Lee, Vivian W.Y.. AU - Lee, Kenneth K.C.. AU - Thomas, G. Neil. AU - Tomlinson, Brian. N1 - Copyright: Copyright 2010 Elsevier B.V., All rights reserved.. PY - 2005/2. Y1 - 2005/2. N2 - Objective. Patients with systemic lupus erythematosus (SLE) experience excess morbidity and mortality due to coronary artery disease (CAD) that cannot be fully explained by the classical CAD risk factors. Among emerging CAD risk factors, oxidative stress is currently being emphasized. We evaluated the effects of longterm antioxidant vitamins on markers of oxidative stress and antioxidant defense and endothelial function in 39 patients with SLE. Methods. Patients were ...
https://research.monash.edu/en/publications/effects-of-vitamins-c-and-e-on-oxidative-stress-markers-and-endot
Proteomic Analysis of Cerebrospinal Fluid: A Search for Biomarkers of Neuropsychiatric Systemic Lupus Erythematosus | Bentham...Proteomic Analysis of Cerebrospinal Fluid: A Search for Biomarkers of Neuropsychiatric Systemic Lupus Erythematosus | Bentham...
Title:Proteomic Analysis of Cerebrospinal Fluid: A Search for Biomarkers of Neuropsychiatric Systemic Lupus Erythematosus. VOLUME: 16 ISSUE: 2. Author(s):Johanna Pedroza-Díaz*, Tania Paola Luján Chavarria, Carlos Horacio Muñoz Vahos, Diego Francisco Hernández Ramírez, Elizabeth Olivares-Martínez, Gloria Vásquez, Luis Llorente, Hilda Fragoso-Loyo, Sarah Röthlisberger and Blanca Lucía Ortiz Reyes. Affiliation:Instituto Tecnologico Metropolitano-ITM-, Facultad de Ciencias Exactas y Aplicadas, Grupo de Investigacion e Innovacion Biomedica GI2B, Medellín, Universidad de Antioquia, Facultad de Medicina, Grupo de Inmunologia Celular e Inmunogenetica-GICIG-, Medellin, Universidad de Antioquia, Facultad de Medicina, Grupo de Reumatologia Universidad de Antioquia - GRUA-, Medellín, Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran, Department of Immunology & Rheumatology, Mexico DF, Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran, Department of Immunology & ...
https://www.eurekaselect.com/165304/article?trendmd-shared=3
Hypercementosis: A rare finding in a patient with systemic lupus erythematosus<...
TY - JOUR. T1 - Hypercementosis. T2 - A rare finding in a patient with systemic lupus erythematosus. AU - Shoor, Hitesh. AU - Sujir, Nitha. AU - Mutalik, Sunil. AU - Pai, Keerthilatha M.. PY - 2014/11/26. Y1 - 2014/11/26. N2 - Hypercementosis is excessive deposition of non-neoplastic cementum over normal root cementum, which alters root morphology. This cementum may be either hypocellular or cellular in nature. The aetiopathogenesis of hypercementosis is ambiguous. Although most of the cases are idiopathic, several local and systemic factors are also linked to this condition, such as Pagets disease, acromegaly, vitamin A deficiency, etc. We report two rare cases of hypercementosis associated with systemic lupus erythematosus, not previously described in the literature, and also discuss the possible aetiopathogenesis.. AB - Hypercementosis is excessive deposition of non-neoplastic cementum over normal root cementum, which alters root morphology. This cementum may be either hypocellular or ...
https://manipal.pure.elsevier.com/en/publications/hypercementosis-a-rare-finding-in-a-patient-with-systemic-lupus-e
Lupus (Systemic Lupus Erythematosus) - North Kansas City Hospital, Kansas City, MOLupus (Systemic Lupus Erythematosus) - North Kansas City Hospital, Kansas City, MO
Discusses lupus, an autoimmune disorder. Focuses on systemic lupus erythematosus (SLE). Covers symptoms and how it is diagnosed. Covers treatment with medicines like corticosteroids, NSAIDs, and antimalarials. Discusses the importance of good self-care.
http://www.nkch.org/patients-visitors/health-library/healthwise-document-viewer/?id=hw123404
Neuropsychiatric lupus: a mosaic of clinical presentations | BMC Medicine | Full TextNeuropsychiatric lupus: a mosaic of clinical presentations | BMC Medicine | Full Text
Neuropsychiatric symptoms affect nearly half of the patients with systemic lupus erythematosus; however, the effect on disease severity, quality of life, and prognosis is tremendous. Symptoms of neuropsychiatric systemic lupus erythematosus may range from mild diffuse ones, to acute life threatening events. Although the underlying mechanisms are still largely unraveled, several pathogenic pathways are identified, such as antibody-mediated neurotoxicity, vasculopathy due to anti-phospholipid antibodies and other mechanisms, and cytokine-induced neurotoxicity. In the current review, we describe the old and the new regarding epidemiology, pathophysiology, diagnosis, and management of neuropsychiatric systemic lupus erythematosus. The possible link between neuropsychiatric symptoms and specific mechanisms may help to facilitate our understanding of the disease in the future, thus allowing for better treatment strategies.
https://bmcmedicine.biomedcentral.com/articles/10.1186/s12916-015-0269-8
IgG and IgM autoantibody differences in discoid and systemic lupus patients<...
TY - JOUR. T1 - IgG and IgM autoantibody differences in discoid and systemic lupus patients. AU - Chong, Benjamin F.. AU - Tseng, Lin Chiang. AU - Lee, Thomas. AU - Vasquez, Rebecca. AU - Li, Quan Z.. AU - Zhang, Song. AU - Karp, David R.. AU - Olsen, Nancy J.. AU - Mohan, Chandra. PY - 2012/12. Y1 - 2012/12. N2 - Systemic lupus erythematosus (SLE) patients with discoid lupus erythematosus (DLE) were reported to have milder disease. To test this observation, we used sandwich arrays containing 98 autoantigens to compare autoantibody profiles of SLE subjects without DLE (DLE-SLE\+) (N = 9), SLE subjects with DLE (DLE\+SLE+) (N = 10), DLE subjects without SLE (DLE+SLE-) (N = 11), and healthy controls (N = 11). We validated differentially expressed autoantibodies using immunoassays in DLE-SLE+ (N = 18), DLE+SLE+ (N = 17), DLE+SLE-(N = 23), and healthy subjects (N = 22). Arrays showed 15 IgG autoantibodies (10 against nuclear antigens) and 4 IgM autoantibodies that were differentially expressed ...
https://utsouthwestern.pure.elsevier.com/en/publications/igg-and-igm-autoantibody-differences-in-discoid-and-systemic-lupu
Altmetric - Altered white matter microstructure in lupus patients: a diffusion tensor imaging studyAltmetric - Altered white matter microstructure in lupus patients: a diffusion tensor imaging study
The purpose of this study was to investigate whether white matter microstructure is altered in patients suffering from systemic lupus erythematosus (SLE), and if so, whether such alterations differed between patients with and without neuropsychiatric symptoms. Structural MRI and diffusion tensor imaging (DTI) were performed in 64 female SLE patients (mean age 36.9 years, range 18.2-52.2 years) and 21 healthy controls (mean age 36.7 years, range 23.3-51.2 years) in conjunction with clinical examination, laboratory tests, cognitive evaluation, and self-assessment questionnaires. The patients were subgrouped according to the American College of Rheumatology Neuropsychiatric Systemic Lupus Erythematosus case definitions into non-neuropsychiatric SLE (nonNPSLE) and neuropsychiatric SLE (NPSLE). Comparisons between the SLE group and healthy controls showed that the mean fractional anisotropy (FA) was significantly reduced in the right rostral cingulum (p = 0.038), the mid-sagittal corpus callosum (CC) ...
https://www.altmetric.com/details/32964017
Interferon-α coincides with suppressed levels of pentraxin-3 (PTX3) in systemic lupus erythematosus and regulates leucocyte...Interferon-α coincides with suppressed levels of pentraxin-3 (PTX3) in systemic lupus erythematosus and regulates leucocyte...
Systemic lupus erythematosus (SLE) is a systemic inflammatory disease. Clinically, the distinction between ongoing inflammation attributed to SLE, and organ damage due to medication or co-morbidities remains challenging. In addition, SLE is a heterogeneous disease where the various disease phenotypes complicate the search for biomarkers that adequately reflect disease activity and/or signs of increasing organ damage. The aim of the thesis was to investigate and evaluate potential new biomarkers of disease activity and/or organ damage in SLE patients.. High mobility group box protein-1 (HMGB1) is a nuclear non-histone protein that can shuttle to the cytoplasm, become secreted extracellularly, and participate in systemic inflammation. Administration of monoclonal anti-HMGB1 antibodies has been reported both to attenuate and intensify disease in animal models of arthritis and lupus. In Paper I of the thesis, circulating anti-HMGB1 was found in 23% of the SLE patients and correlated with disease ...
http://liu.diva-portal.org/smash/record.jsf?pid=diva2:1115957
Antiphospholipid Syndrome Nephropathy and Other Thrombotic Microangiopathies Among Patients With Systemic Lupus ErythematosusAntiphospholipid Syndrome Nephropathy and Other Thrombotic Microangiopathies Among Patients With Systemic Lupus Erythematosus
Publication date: September 2019Source: Advances in Chronic Kidney Disease, Volume 26, Issue 5Author(s): Elizabeth S. Kotzen, Sanjeet Roy, Koyal JainAntiphospholipid syndrome (APS) and other causes of thrombotic microangiopathy (TMA) negatively impact the renal outcomes of patients with systemic lupus erythematosus (SLE) and lupus nephritis. Here we review the diagnosis and management of occlusive...
https://medworm.com/743246738/antiphospholipid-syndrome-nephropathy-and-other-thrombotic-microangiopathies-among-patients-with-sys/
Altered type II interferon precedes autoantibody accrual and elevated type i interferon activity prior to systemic lupus...
TY - JOUR. T1 - Altered type II interferon precedes autoantibody accrual and elevated type i interferon activity prior to systemic lupus erythematosus classification. AU - Munroe, Melissa E.. AU - Lu, Rufei. AU - Zhao, Yan D.. AU - Fife, Dustin A.. AU - Robertson, Julie M.. AU - Guthridge, Joel M.. AU - Niewold, Timothy B.. AU - Tsokos, George C.. AU - Keith, Michael P.. AU - Harley, John B.. AU - James, Judith A.. N1 - Publisher Copyright: © 2016 Published by the BMJ Publishing Group Limited.. PY - 2016/11/1. Y1 - 2016/11/1. N2 - Objectives The relationship of immune dysregulation and autoantibody production that may contribute to systemic lupus erythematosus (SLE) pathogenesis is unknown. This study evaluates the individual and combined contributions of autoantibodies, type I interferon (IFN-α) activity, and IFN-associated soluble mediators to disease development leading to SLE. Methods Serial serum specimens from 55 individuals collected prior to SLE classification (average timespan=4.3a ...
https://www.researchwithnj.com/en/publications/altered-type-ii-interferon-precedes-autoantibody-accrual-and-elev
Risk factors for clinical coronary heart disease in systemic lupus erythematosus: the lupus and atherosclerosis evaluation of...Risk factors for clinical coronary heart disease in systemic lupus erythematosus: the lupus and atherosclerosis evaluation of...
Haque, Sahena, Gordon, Caroline, Isenberg, David, Rahman, Anisur, Lanyon, Peter, Bell, Aubrey, Emery, Paul, McHugh, Neil, Teh, Lee Suan, Scott, David G. I., Akil, Mohamed, Naz, Sophia, Andrews, Jacqueline, Griffiths, Bridget, Harris, Helen, Youseff, Hazem, McLaren, John, Toescu, Veronica, Devakumar, Vinodh, Teir, Jamal and Bruce, Ian N. (2010) Risk factors for clinical coronary heart disease in systemic lupus erythematosus: the lupus and atherosclerosis evaluation of risk (LASER) study. Journal of Rheumatology, 37 (2). pp. 322-329. Full text not available from this repository. (Request a copy ...
https://ueaeprints.uea.ac.uk/id/eprint/15625/
Mannose-binding lectin polymorphisms and susceptibility to infection in systemic lupus erythematosus. - MRC Weatherall...
OBJECTIVE: To determine whether variant alleles in the coding portion of the mannose-binding lectin (MBL) gene are associated with increased susceptibility to systemic lupus erythematosus (SLE) and concomitant infections. METHODS: MBL alleles and serum concentrations were determined by polymerase chain reaction and enzyme-linked immunosorbent assay, respectively, in 91 Danish patients with SLE and in 250 controls. RESULTS: Homozygosity for MBL variant alleles was observed in 7.7% of the SLE patients compared with 2.8% of the controls (P = 0.06), while no difference was seen for heterozygosity (33.0% versus 34.4%). Homozygotes had an increased risk of acquiring serious infections compared with patients who were heterozygous or homozygous for the normal allele (odds ratio 8.6, 95% confidence interval 1.5-47.6, P = 0.01). The time interval from the diagnosis of SLE to the first infectious event was shorter (P = 0.017), and the annual number of infectious events was 4 times higher, among homozygotes (P = 0
https://www.imm.ox.ac.uk/publications/929015
Health Library | Rutgers Cancer Institute of New Jersey
1. van Vollenhoven RF, Morabito LM, Engleman EG, et al. Treatment of systemic lupus erythematosus with dehydroepiandrosterone: 50 patients treated up to 12 months. J Rheumatol. 1998;25:285-289. 2. van Vollenhoven RF, Park JL, Genovese MC, et al. A double-blind, placebo-controlled, clinical trial of dehydroepiandrosterone in severe systemic lupus erythematosus. Lupus. 1999;8:181-187. 3. Mease PJ, Merrill JT, Lahita R, et al. GL701 (prasterone, dehydroepiandrosterone) improves or stabilizes disease activity in systemic lupus erythematosus. Presented at: The Endocrine Societys 82nd Annual Meeting; June 21-24, 2000; Toronto, Canada.. 4. Baulieu EE, Thomas G, Legrain S, et al. Dehydroepiandrosterone (DHEA), DHEA sulfate, and aging: contribution of the DHEAge Study to a sociobiomedical issue. Proc Natl Acad Sci USA. 2000;97:4279-4284. 5. Labrie F, Diamond P, Cusan L, et al. Effect of 12-month dehydroepiandrosterone replacement therapy on bone, vagina and endometrium in postmenopausal women. J Clin ...
http://healthlibrary.epnet.com/GetContent.aspx?token=3d2911e7-5b1e-46f2-96a2-ee479a3d0843&chunkiid=21678
Detection of Type VII Collagen Autoantibodies Before the Onset of Bullous Systemic Lupus Erythematosus | Dermatology | JAMA...Detection of Type VII Collagen Autoantibodies Before the Onset of Bullous Systemic Lupus Erythematosus | Dermatology | JAMA...
This case report finds that anti-type VII collagen autoantibodies can precede the clinical appearance of bullous systemic lupus erythematosus.
https://jamanetwork.com/journals/jamadermatology/fullarticle/2110014
Unilateral cataplexy associated with systemic lupus erythematosus | Journal of Neurology, Neurosurgery & PsychiatryUnilateral cataplexy associated with systemic lupus erythematosus | Journal of Neurology, Neurosurgery & Psychiatry
A patient with systemic lupus erythematosus (SLE) developed attacks of unilateral cataplexy precipitated by laughter. Unilateral cataplexy has not been described previously in detail and its association with SLE is unique. The clinical details, investigations, and diagnostic criteria are discussed and a causal relationship between cataplexy and SLE is suggested.. ...
https://jnnp.bmj.com/content/39/10/1023
Systemic Lupus Erythematosus - Rheumatology | Arkansas ChildrensSystemic Lupus Erythematosus - Rheumatology | Arkansas Childrens
Systemic lupus erythematosus is a rare, chronic autoimmune condition that can affect different parts of the body, such as the kidneys, skin, joints and blood.
https://www.archildrens.org/programs-and-services/rheumatology-clinic/Conditions/systemic-lupus-erythematosus
What is Lupus | Georgia Department of Community HealthWhat is Lupus | Georgia Department of Community Health
Lupus Erythematosus is a chronic autoimmune disease that causes the immune system to attack ones body. The disease is characterized by the inflammation of various healthy tissues and organs in the body, including the joints, skin, kidneys, heart, lungs, blood vessels and brain. The severity of the disease may vary because no two cases of lupus are exactly alike.. What are the different types of Lupus?. Systemic Lupus Erythematosus (SLE) is the type of the disease that can affect many parts of the body. SLE is the most common form of the disease and is most commonly characterized by inflammation to the joints, skin, kidneys, heart, lungs, blood vessels and brain.. Cutaneous Lupus Erythematosus is a chronic skin disorder than can affect the skin. Patients with Cutaneous Lupus develop photosensitivity, hair loss, skin rashes and skin lesions.. Drug-Induced Lupus Erythematosus, like SLE, can affect many parts of the body. However, Drug-Induced Lupus is caused by an overreaction to certain ...
https://dch.georgia.gov/georgia-council-lupus-education-and-awareness/what-lupus
Polymorphisms of the Fc gamma receptor type IIB gene are not associated with systemic lupus erythematosus in the Swedish...Polymorphisms of the Fc gamma receptor type IIB gene are not associated with systemic lupus erythematosus in the Swedish...
misc{08a586d2-6965-44d0-b083-93b1aacff9f7, author = {Magnusson, V and Zunec, R and Odeberg, J and Sturfelt, Gunnar and Truedsson, Lennart and Alarcon-Riquelme, ME}, issn = {1529-0131}, language = {eng}, number = {4}, pages = {1348--1350}, publisher = {John Wiley & Sons}, series = {Arthritis and Rheumatism}, title = {Polymorphisms of the Fc gamma receptor type IIB gene are not associated with systemic lupus erythematosus in the Swedish population}, url = {http://dx.doi.org/10.1002/art.20151}, volume = {50}, year = {2004 ...
https://lup.lub.lu.se/search/publication/281719
Systemic Lupus Erythematosus Global Clinical Trials Review, H2, 2016 - RnR Market ResearchSystemic Lupus Erythematosus Global Clinical Trials Review, H2, 2016 - RnR Market Research
Systemic Lupus Erythematosus Global Clinical Trials Review, H2, 2016 is a market research report available at US $2500 for a Single User PDF License from RnR Market Research Reports Library.
http://www.rnrmarketresearch.com/systemic-lupus-erythematosus-global-clinical-trials-review-h2-2016-market-report.html
CMU Intellectual Repository: Candida parapsilosis cellulitis in a patient with systemic lupus erythematosus: A case reportCMU Intellectual Repository: Candida parapsilosis cellulitis in a patient with systemic lupus erythematosus: A case report
JOURNAL OF THE MEDICAL ASSOCIATION OF THAILAND , 2019. The authors described a case of Candida parapsilosis cellulitis in a systemic lupus erythematosus patient presented with a clinical of cellulitis unresponsive to antibiotic treatment. Yeast cells and pseudohyphae were seen in tissue biopsy and C. parapsilosis were identified by tissues culture. There was excellent outcome after surgical debridement and antifungal treatment ...
http://cmuir.cmu.ac.th/handle/6653943832/65755
Polymorphisms of the ITGAM Gene Confer Higher Risk of Discoid Cutaneous Than of Systemic Lupus ErythematosusPolymorphisms of the ITGAM Gene Confer Higher Risk of Discoid Cutaneous Than of Systemic Lupus Erythematosus
Background: Lupus erythematosus (LE) is a heterogeneous disease ranging from mainly skin-restricted manifestations (discoid LE [DLE] and subacute cutaneous LE) to a progressive multisystem disease (systemic LE [SLE]). Genetic association studies have recently identified several strong susceptibility genes for SLE, including integrin alpha M (ITGAM), also known as CD11b, whereas the genetic background of DLE is less clear. Principal Findings: To specifically investigate whether ITGAM is a susceptibility gene not only for SLE, but also for cutaneous DLE, we genotyped 177 patients with DLE, 85 patients with sporadic SLE, 190 index cases from SLE families and 395 population control individuals from Finland for nine genetic markers at the ITGAM locus. SLE patients were further subdivided by the presence or absence of discoid rash and renal involvement. In addition, 235 Finnish and Swedish patients positive for Ro/SSA-autoantibodies were included in a subphenotype analysis. Analysis of the ITGAM ...
http://uu.diva-portal.org/smash/record.jsf?pid=diva2:383115
Antinuclear Antibodies (ANA) - Meritas Health, North Kansas City, MOAntinuclear Antibodies (ANA) - Meritas Health, North Kansas City, MO
An antinuclear antibody (ANA) test measures the amount and pattern of antibodies in your blood that work against your own body (autoimmune reaction).. The bodys immune system normally attacks and destroys foreign substances such as bacteria and viruses. But in disorders known as autoimmune diseases, the immune system attacks and destroys the bodys normal tissues. When a person has an autoimmune disease, the immune system produces antibodies that attach to the bodys own cells as though they were foreign substances, often causing them to be damaged or destroyed. Rheumatoid arthritis and systemic lupus erythematosus are examples of autoimmune diseases.. An ANA test is used along with your symptoms, physical examination, and other tests to find an autoimmune disease.. ...
http://www.meritashealth.com/home/resources/healthwise-document-viewer/?id=hw2297
Malar rash | definition of malar rash by Medical dictionaryMalar rash | definition of malar rash by Medical dictionary
Looking for online definition of malar rash in the Medical Dictionary? malar rash explanation free. What is malar rash? Meaning of malar rash medical term. What does malar rash mean?
http://medical-dictionary.thefreedictionary.com/Malar+rash
Diagnostic accuracy of currently available anti-double-stranded DNA antibody assays. An Italian multicentre study | IRIS...Diagnostic accuracy of currently available anti-double-stranded DNA antibody assays. An Italian multicentre study | IRIS...
Objective: An Italian multicentre study was promoted in order to assess the accuracy of four anti-double-stranded DNA (dsDNA) antibody assays for SLE diagnosis and monitoring. Methods: Two hundred and twenty-three patients with established SLE according to ACR classification criteria were enrolled from 9 centres. They included 59 patients at first evaluation (disease duration ,12 months) and 164 with longer disease duration (median disease duration 120 months). The sera from 55 healthy subjects and 161 patients with rheumatic, infectious or neoplastic diseases were tested as controls. SLE activity was measured by ECLAM score. Anti-dsDNA antibodies were detected in serum by means of FarrzymeTM assay, fluoroenzymeimmunoassay (EliATM), Crithidia luciliae indirect immunofluorescence (CLIFT) or Farr radioimmunoassay (Farr). Cut-off values of quantitative assays were chosen by ROC curves analysis. Statistics were conducted by SPSS software package. Results: Sensitivity for SLE diagnosis ranged between ...
https://iris.uniroma1.it/handle/11573/380380
Total knee replacement in a patient with lupus anticoagulant.<...
TY - JOUR. T1 - Total knee replacement in a patient with lupus anticoagulant.. AU - Bhagia, U. T.. AU - Corpe, Raymond S. AU - Steflik, D.. PY - 1997/1/1. Y1 - 1997/1/1. N2 - The lupus anticoagulant is an acquired circulating anticoagulant that was first described in patients with systemic lupus erythematosus (SLE). This rare hematologic entity is seen in about 1% to 2% of the general population and about 10% to 35% of the patients with SLE. Although associated with a prolonged partial thromboplastin time (PTT), the lupus anticoagulant does not cause bleeding complications but may be associated with an increase in thromboembolic complications. This report is presented to alert orthopedic surgeons of the increased risk of thromboembolic disease with a paradoxically prolonged PTT in patients with the lupus anticoagulant.. AB - The lupus anticoagulant is an acquired circulating anticoagulant that was first described in patients with systemic lupus erythematosus (SLE). This rare hematologic entity ...
https://augusta.pure.elsevier.com/en/publications/total-knee-replacement-in-a-patient-with-lupus-anticoagulant
Impact of belimumab on patient-reported outcomes in systemic lupus ery | PROMImpact of belimumab on patient-reported outcomes in systemic lupus ery | PROM
Impact of belimumab on patient-reported outcomes in systemic lupus erythematosus: review of clinical studies Elvira Bangert,1 Laura Wakani,2 Mehveen Merchant,3 Vibeke Strand,4 Zahi Touma2 1Division of Rheumatology, Department of Medicine, Queen’s University, Kingston, ON, Canada; 2University of Toronto Lupus Clinic, Toronto Western Hospital, Centre for Prognosis Studies in the Rheumatic Diseases, Toronto, ON, Canada; 3Division of Rheumatology, Nova Scotia Health Authority, Dalhousie University, Halifax, NS, Canada; 4Division of Immunology/Rheumatology, Stanford University, Palo Alto, CA, USA Abstract: Systemic lupus erythematosus (SLE) is a chronic autoimmune, multisystem rheumatic disease with significant impact on health-related quality of life (HRQoL). Patient-reported outcomes (PROs) provide valuable data on patient perceptions across a variety of domains, such as HRQoL, pain, fatigue, and depression. The measurement and results of PROs with respect to HRQoL in randomized controlled trials
https://www.dovepress.com/impact-of-belimumab-on-patient-reported-outcomes-in-systemic-lupus-ery-peer-reviewed-article-PROM
rs1004819 - SNPediars1004819 - SNPedia
Genetic epistasis of IL23/IL17 pathway genes in Crohns disease. [PMID 19306001] No association between interleukin 23 receptor gene polymorphisms and systemic lupus erythematosus. [PMID 19522770] Variants of the IL23R gene are associated with ankylosing spondylitis but not with Sjogren syndrome in Hungarian population samples. [PMID 19757086] Interleukin-23 receptor gene variants in Hungarian systemic lupus erythematosus patients. [PMID 19916168 ...
https://www.snpedia.com/index.php/Rs1004819
Neuropsychiatric systemic lupus erythematosusNeuropsychiatric systemic lupus erythematosus
... systemic lupus erythematosus or NPSLE refers to the neurological and psychiatric manifestations of systemic lupus erythematosus ... 2010). "EULAR recommendations for the management of systemic lupus erythematosus with neuropsychiatric manifestations: report ... "Neuropsychiatric Syndromes in Systemic Lupus Erythematosus: A Meta-Analysis". Seminars in Arthritis and Rheumatism. 41 (1): 1- ... "Management of Neuropsychiatric Systemic Lupus Erythematosus: Current Approaches and Future Perspectives". Drugs. 76 (4): 459- ...
https://en.wikipedia.org/wiki/Neuropsychiatric_systemic_lupus_erythematosus
Drug-induced lupus erythematosusDrug-induced lupus erythematosus
While these symptoms are similar to those of systemic lupus erythematosus, they are generally not as severe unless they are ... Anti-histone antibody Lupus erythematosus Hydralazine Discoid lupus erythematosus List of cutaneous conditions Rubin, Robert L ... ISBN 978-0-8089-1543-0. Lahita, Robert G. (1987). Systemic Lupus Erythematosus. New York: John Wiley & Sons. p. 859. ISBN 978-0 ... July 1983). The Clinical Management of Systemic Lupus Erythematosus. New York: Grune & Stratton. p. 221. ...
https://en.wikipedia.org/wiki/Drug-induced_lupus_erythematosus
Lupus erythematosusLupus erythematosus
... drug-induced lupus erythematosus neonatal lupus erythematosus systemic lupus erythematosus There is still no cure for lupus but ... lupus erythematosus profundus) tumid lupus erythematosus verrucous lupus erythematosus (hypertrophic lupus erythematosus) ... lupus erythematosus generalized discoid lupus erythematosus localized discoid lupus erythematosus chilblain lupus erythematosus ... 70% of lupus cases diagnosed are systemic lupus erythematosus. 20% of people with lupus will have a parent or sibling who ...
https://en.wikipedia.org/wiki/Lupus_erythematosus
Acute cutaneous lupus erythematosusAcute cutaneous lupus erythematosus
"Cutaneous lupus erythematosus: diagnosis and treatment". Best Practice & Research. Clinical Rheumatology. Systemic Lupus ... Cutaneous lupus erythematosus is associated with both lupus erythematosus-specific lesions and cutaneous manifestations that ... Because of the diagnostic criteria used to diagnose systemic lupus erythematosus, a patient with only cutaneous manifestations ... Acute cutaneous lupus erythematosus can be either localized or generalized. The localized form of the disease is most commonly ...
https://en.wikipedia.org/wiki/Acute_cutaneous_lupus_erythematosus
Lupus nephritisLupus nephritis
... is an inflammation of the kidneys caused by systemic lupus erythematosus (SLE), an autoimmune disease. It is a ... Karageorgas TP, Tseronis DD, Mavragani CP (2011). "Activation of type I interferon pathway in systemic lupus erythematosus: ... February 2004). "The classification of glomerulonephritis in systemic lupus erythematosus revisited". J. Am. Soc. Nephrol. 15 ( ... Lahita, Robert G. (2004-06-09). Systemic Lupus Erythematosus. Academic Press. ISBN 9780080474540. Greenberg, Arthur; Cheung, ...
https://en.wikipedia.org/wiki/Lupus_nephritis
MalignancyMalignancy
Papadimitraki ED, Bertsias G, Chamilos G, Boumpas DT (January 2011). "Systemic Lupus Erythematosus". Academic Press. pp. 1083- ...
https://en.wikipedia.org/wiki/Malignancy
MethylprednisoloneMethylprednisolone
Phang KF, Cho J, Lee W, Mak A (2018). "Glucocorticoid-induced osteoporosis in systemic lupus erythematosus". Rheumatology ... Methylprednisolone is used to treat several rheumatic diseases, such as Systemic Lupus Erythematosus (SLE) and Rheumatoid ... "Systemic lupus erythematosus". Nat Rev Dis Primers. 2: 16039. doi:10.1038/nrdp.2016.39. PMID 27306639. S2CID 2628865. Chan TM ( ... systemic lupus erythematosus, acute and subacute bursitis, synovitis of osteoarthritis, post-traumatic osteoarthritis, and ...
https://en.wikipedia.org/wiki/Methylprednisolone
ArthritisArthritis
ISBN 0-7216-2921-0. "Systemic Lupus Erythematosus". The Lecturio Medical Concept Library. Retrieved 22 August 2021. Wollenhaupt ... Familial Mediterranean fever Systemic lupus erythematosus An undifferentiated arthritis is an arthritis that does not fit into ... Lupus is a common collagen vascular disorder that can be present with severe arthritis. Other features of lupus include a skin ... and other systemic symptoms. Physical examination may confirm the diagnosis or may indicate systemic disease. Radiographs are ...
https://en.wikipedia.org/wiki/Arthritis
Autoimmune optic neuropathyAutoimmune optic neuropathy
Estes, Dorothy; Christian, Charles L. (1971). "The Natural History of Systemic Lupus Erythematosus by Prospective Analysis". ... Tsokos, George C. (2011). "Systemic Lupus Erythematosus". New England Journal of Medicine. 365 (22): 2110-21. doi:10.1056/ ... may be a forme fruste of systemic lupus erythematosus (SLE) associated optic neuropathy. AON is more than the presence of any ... "Optic Neuropathy and Chiasmopathy in the Diagnosis of Systemic Lupus Erythematosus". Journal of Neuro-Ophthalmology. 21 (3): ...
https://en.wikipedia.org/wiki/Autoimmune_optic_neuropathy
IRAK1IRAK1
Deng Y, Hahn BH, Tsao BP (2013). "Systemic Lupus Erythematosus". Emery and Rimoin's Principles and Practice of Medical Genetics ...
https://en.wikipedia.org/wiki/IRAK1
List of patient-reported quality of life surveysList of patient-reported quality of life surveys
Systemic lupus erythematosus. The Systemic Lupus Erythematosus Quality of Life measure (L-QoL or SLEQoL) was published in 2009 ... Systemic Lupus Erythematosus-Specific Quality of Life Questionnaire (SLEQOL), and Systemic Lupus Erythematosus Quality of Life ... Yazdany J (November 2011). "Health-related quality of life measurement in adult systemic lupus erythematosus: Lupus Quality of ... a quality-of-life instrument specific to systemic lupus erythematosus". Annals of the Rheumatic Diseases. 68 (2): 196-200. doi: ...
https://en.wikipedia.org/wiki/List_of_patient-reported_quality_of_life_surveys
Nuclear bodiesNuclear bodies
Jones JM, Martinez AJ, Joshi VV, McWilliams N (March 1975). "Systemic lupus erythematosus". Archives of Pathology. 99 (3): 152- ... These, or similar, bodies have been found increased in the presence of lymphoid cancers and SLE (lupus). They are also observed ...
https://en.wikipedia.org/wiki/Nuclear_bodies
Connective tissue diseaseConnective tissue disease
... such as systemic lupus erythematosus or scleroderma. Latent lupus and incomplete lupus are alternative terms that have been ... such as systemic lupus erythematosus (SLE); systemic sclerosis (SSc); dermatomyositis (DM); polymyositis (PM); anti-synthetase ... It can occur alone or with rheumatoid arthritis, scleroderma, or systemic lupus erythematosus. Nine out of 10 cases occur in ... "Systemic lupus erythematosus". Genetics Home Reference. Retrieved 2019-11-19. Reference, Genetics Home. "Rheumatoid arthritis ...
https://en.wikipedia.org/wiki/Connective_tissue_disease
Autoimmune diseaseAutoimmune disease
Systemic lupus erythematosus is associated with focal cancers throughout the body and lymphoproliferative cancers. Systemic ... Conversely, systemic lupus erythematosus is correlated with a decrease in some cancers. This is best explained by increased ... This test is most useful for diagnosing systemic lupus erythematosus, having a 95% positive test rate. A test taking ... Tsokos GC (December 2011). "Systemic lupus erythematosus". The New England Journal of Medicine. 365 (22): 2110-21. doi:10.1056/ ...
https://en.wikipedia.org/wiki/Autoimmune_disease
Chronic diarrhea of infancyChronic diarrhea of infancy
... and pancreatic disorders in systemic lupus erythematosus.". Systemic Lupus Erythematosus. Academic Press. pp. 391-401. doi: ... and Pancreatic Disorders in Systemic Lupus Erythematosus", Systemic Lupus Erythematosus, Elsevier, pp. 391-401 Gosemann JH, ...
https://en.wikipedia.org/wiki/Chronic_diarrhea_of_infancy
Obstructive shockObstructive shock
García-Carrasco M, Pinto CM, Poblano JC, Morales IE, Cervera R, Anaya JM (2013-07-18). "Systemic lupus erythematosus". In Anaya ... Thrombolysis can be systemic via IV alteplase (tPA) or catheter-directed. tPA works to break up the clot. A major risk of tPA ...
https://en.wikipedia.org/wiki/Obstructive_shock
Complement deficiencyComplement deficiency
"Systemic Lupus Erythematosus. Lupus treatment; information , Patient". Patient. Retrieved 21 September 2016. " ... Systemic lupus erythematosus is associated with low C3 and C4. Membranoproliferative glomerulonephritis usually has low C3. The ... C4: C4 deficiency is highly associated with systemic lupus erythematosus. Aβ42, a protein involved in Alzheimer's disease, can ...
https://en.wikipedia.org/wiki/Complement_deficiency
ZAP70ZAP70
In systemic lupus erythematosus, the Zap-70 receptor pathway is missing and the homolog Syk takes its place. ZAP-70 deficiency ... Tsokos GC (December 2011). "Systemic lupus erythematosus". The New England Journal of Medicine. 365 (22): 2110-21. doi:10.1056/ ...
https://en.wikipedia.org/wiki/ZAP70
Robert G. LahitaRobert G. Lahita
Lahita is the editor of the standard textbook Systemic Lupus Erythematosus (5th edition), now Lahita's Systemic Lupus ... "Systemic Lupus Erythematosus - 4th Edition". www.elsevier.com. Retrieved 2018-08-20. "Why The Body Attacks Itself". Retrieved ... Neuropsychiatric Manifestations of Systemic Lupus Erythematosus. Annals of the New York Academy of Sciences, 1999. Lahita, ... Novel Treatments for Systemic Lupus Erythematosus. Vol 3, no 5, pp255-266. Therapeutic Advances in Musculoskeletal Disease. ...
https://en.wikipedia.org/wiki/Robert_G._Lahita
Mycophenolic acidMycophenolic acid
... systemic lupus erythematosus (SLE), scleroderma (systemic sclerosis or SSc), and pemphigus vulgaris (PV) with success for some ... D'Cruz DP, Khamashta MA, Hughes GR (February 2007). "Systemic lupus erythematosus". Lancet. 369 (9561): 587-96. CiteSeerX 10.1. ... Walsh proposed that mycophenolate should be considered as a first-line induction therapy for treatment of lupus nephritis in ... Its increasing application in treating lupus nephritis has demonstrated more frequent complete response and less frequent ...
https://en.wikipedia.org/wiki/Mycophenolic_acid
Lee GoldmanLee Goldman
"Systemic Lupus Erythematosus". PracticeUpdate. 26 February 2021. "Lee Goldman, MD - Taiwan Society of Internal Medicine". ...
https://en.wikipedia.org/wiki/Lee_Goldman
Lumleian LecturesLumleian Lectures
Hill, L. C. (1957). "Systemic Lupus Erythematosus". BMJ. 2 (5046): 655-660 contd. doi:10.1136/bmj.2.5046.655. PMC 1962315. PMID ... Systemic Lupus Erythematosus 1958 John St. Clair Elkington, Cerebral Vascular Disease in the light of Modern Techniques 1959 ...
https://en.wikipedia.org/wiki/Lumleian_Lectures
Apolipoprotein HApolipoprotein H
Anti-β2-GP1 antibodies are found in both infectious and some systemic autoimmune diseases (eg. systemic lupus erythematosus ( ... Anti-β2-GP1 antibodies are strongly associated with thrombotic forms of lupus. In molecular biology, the protein domain Sushi 2 ... Lupus. 1 (2): 75-81. doi:10.1177/096120339200100204. PMID 1301967. S2CID 35296154. Shi T, Giannakopoulos B, Iverson GM, ... "Beta2-glycoprotein I dependent anticardiolipin antibodies and lupus anticoagulant in patients with recurrent pregnancy loss". ...
https://en.wikipedia.org/wiki/Apolipoprotein_H
Protein losing enteropathyProtein losing enteropathy
Systemic lupus erythematosus (SLE). Ménétrier's disease. Zollinger-Ellison syndrome. Eosinophilic gastroenteritis. Coeliac ... Swelling of the legs due to peripheral edema can also occur, however, if the PLE is related to a systemic disease such as ...
https://en.wikipedia.org/wiki/Protein_losing_enteropathy
Lupus headacheLupus headache
... from other headache types in people with lupus. Cuadrado MJ, Sanna G (2003). "Headache and systemic lupus erythematosus". Lupus ... "Lupus headaches in childhood-onset systemic lupus erythematosus: relationship to disease activity as measured by the systemic ... Lupus headache is an important item in the Systemic Lupus Erythematosus Disease Activity Index (SLEDAI), a scoring system often ... Lupus headache is a proposed, specific headache disorder in patients with systemic lupus erythematosus (SLE). Research shows ...
https://en.wikipedia.org/wiki/Lupus_headache
Aseptic meningitisAseptic meningitis
Autoimmune diseases Systemic lupus erythematosus. Cancer-caused aseptic meningitis such as neoplastic meningitis This affects ...
https://en.wikipedia.org/wiki/Aseptic_meningitis
Vacuolar interface dermatitisVacuolar interface dermatitis
"Skin inflammatory (nontumor) > Lichenoid and interface reaction patterns > Lupus: systemic lupus erythematosus (SLE)". ... lupus erythematosus and dermatomyositis. Bolognia, Jean L.; et al. (2007). Dermatology. St. Louis: Mosby. p. 11. ISBN 1-4160- ...
https://en.wikipedia.org/wiki/Vacuolar_interface_dermatitis
Antinuclear antibodyAntinuclear antibody
This allows the use of ANAs in the diagnosis of some autoimmune disorders, including systemic lupus erythematosus, Sjögren ... These disorders include: systemic lupus erythematosus (SLE), rheumatoid arthritis, Sjögren syndrome, scleroderma, polymyositis ... Mok, CC; Lau, CS (July 2003). "Pathogenesis of systemic lupus erythematosus". Journal of Clinical Pathology. 56 (7): 481-90. ... A significant number of patients are diagnosed as systemic lupus erythematosus or undifferentiated connective tissue disease ...
https://en.wikipedia.org/wiki/Antinuclear_antibody
Histopathologic diagnosis of dermatitisHistopathologic diagnosis of dermatitis
"Skin inflammatory (nontumor) > Lichenoid and interface reaction patterns > Lupus: systemic lupus erythematosus (SLE)". ... lupus erythematosus and dermatomyositis. Interface dermatitis with lichenoid inflammation, not otherwise specified, can be ... lichenoid lupus erythematosus, lichenoid GVHD (chronic GVHD), pigmented purpuric dermatosis, pityriasis rosea, and pityriasis ...
https://en.wikipedia.org/wiki/Histopathologic_diagnosis_of_dermatitis
Anti-dsDNA antibodiesAnti-dsDNA antibodies
They are highly diagnostic of systemic lupus erythematosus (SLE) and are implicated in the pathogenesis of lupus nephritis. The ... Mok CC, Lau CS (July 2003). "Pathogenesis of systemic lupus erythematosus". J. Clin. Pathol. 56 (7): 481-90. doi:10.1136/jcp. ... Rekvig OP, Nossent JC (February 2003). "Anti-double-stranded DNA antibodies, nucleosomes, and systemic lupus erythematosus: a ... Graham KL, Utz PJ (September 2005). "Sources of autoantigens in systemic lupus erythematosus". Current Opinion in Rheumatology ...
https://en.wikipedia.org/wiki/Anti-dsDNA_antibodies
CKLF-like MARVEL transmembrane domain-containing 5CKLF-like MARVEL transmembrane domain-containing 5
... the CMTM5 gene in the DNA isolated from the blood of individuals with the autoimmune diseases of systemic lupus erythematosus ...
https://en.wikipedia.org/wiki/CKLF-like_MARVEL_transmembrane_domain-containing_5
Follicular dendritic cellsFollicular dendritic cells
Deficit of this factor in mice leads to a state resembling systemic lupus erythematosus (SLE). Furthermore, mice lacking LT or ...
https://en.wikipedia.org/wiki/Follicular_dendritic_cells
Pulmonary-renal syndromePulmonary-renal syndrome
Other causes include systemic lupus erythematosus, eosinophilic granulomatosis with polyangiitis, microscopic polyangiitis, ... and systemic sclerosis. Less common causes also include IgA vasculitis and cryoglobulinemic vasculitis. Other etiologies ...
https://en.wikipedia.org/wiki/Pulmonary-renal_syndrome
Jan AasethJan Aaseth
Common rheumatic diseases include rheumatoid arthritis, Sjögren's syndrome, systemic lupus erythematosus, and also fibromyalgia ...
https://en.wikipedia.org/wiki/Jan_Aaseth
HLA A1-B8-DR3-DQ2HLA A1-B8-DR3-DQ2
In systemic lupus erythematosus (SLE) patients HLA DR3-DQ2.5-C4AQ0, which was strongly associated with SLE (odds ratio [OR] 2.8 ... The "HL-A1,8 phenotype" was found to be associated with severe systemic lupus erythematosus (SLE) (renal and central nervous ... Goldberg MA, Arnett FC, Bias WB, Shulman LE (1976). "Histocompatibility antigens in systemic lupus erythematosus". Arthritis ... 1993). "Polymorphism of the tumor necrosis factor beta gene in systemic lupus erythematosus: TNFB-MHC haplotypes". ...
https://en.wikipedia.org/wiki/HLA_A1-B8-DR3-DQ2
Lichen planusLichen planus
Cutaneous lupus erythematosus Discoid lupus erythematosus Lichenoid drug eruptions may be caused by a variety of systemic ... For example: Lupus erythematosus overlap syndrome. Lesions of this syndrome share features of both lupus erythematosus and ... ISBN 978-1-4377-0314-6. Ebrahimi M, Lundqvist L, Wahlin YB, Nylander E (October 2012). "Mucosal lichen planus, a systemic ... Asch S, Goldenberg G (March 2011). "Systemic treatment of cutaneous lichen planus: an update". Cutis. 87 (3): 129-34. PMID ...
https://en.wikipedia.org/wiki/Lichen_planus
60S ribosomal protein L760S ribosomal protein L7
... such as systemic lupus erythematosus. As is typical for genes encoding ribosomal proteins, there are multiple processed ... The protein has been shown to be an autoantigen in patients with systemic autoimmune diseases, ... of eukaryotic protein L7 as a novel autoantigen which frequently elicits an immune response in patients suffering from systemic ...
https://en.wikipedia.org/wiki/60S_ribosomal_protein_L7
MAGEB2MAGEB2
1998). "MAGE Xp-2: a member of the MAGE gene family isolated from an expression library using systemic lupus erythematosus sera ...
https://en.wikipedia.org/wiki/MAGEB2
HemolysisHemolysis
... itself more common in diseases such as systemic lupus erythematosus, rheumatoid arthritis, Hodgkin's lymphoma, and chronic ... systemic release of hemoglobin is associated with pulmonary and systemic hypertension,17,20,53-55 decreased organ perfusion, ... The systemic removal of nitric oxide has been shown to contribute to clinical morbidities, including severe esophageal spasm ... This can lead to esophageal spasm and dysphagia, abdominal pain, erectile dysfunction, systemic hypertension, decreased organ ...
https://en.wikipedia.org/wiki/Hemolysis
Moraxella atlantaeMoraxella atlantae
uniProt Buchman, A. L.; Pickett, M. J. (1991). "Moraxella atlantae bacteraemia in a patient with systemic lupus erythematosus ...
https://en.wikipedia.org/wiki/Moraxella_atlantae
Peripheral neuropathyPeripheral neuropathy
Immune-mediated diseases, such as rheumatoid arthritis, systemic lupus erythematosus (SLE) Infections: leprosy, lyme disease, ... systemic lupus erythematosus, leprosy, Sjögren's syndrome, Babesiosis, Lyme disease, vasculitis, sarcoidosis. Multiple ... Common causes include systemic diseases (such as diabetes or leprosy), hyperglycemia-induced glycation, vitamin deficiency, ... Wood-allum, Clare A.; Shaw, Pamela J. (2014). "Thyroid disease and the nervous system". Neurologic Aspects of Systemic Disease ...
https://en.wikipedia.org/wiki/Peripheral_neuropathy
Michael D. LockshinMichael D. Lockshin
Lockshin's long-term research interest is in the clinical aspects of systemic lupus erythematosus (SLE), antiphospholipid ... studies on neurologic lupus, including treatment and cognitive dysfunction; pregnancy and lupus; atherosclerosis and lupus, and ... Lockshin received the Lupus Foundation of America's 2012 National Leadership Award for Lupus Medical Advancement and a Lifetime ... He is a researcher of autoimmune diseases, with focus on antiphospholipid syndrome and lupus. He is currently professor of ...
https://en.wikipedia.org/wiki/Michael_D._Lockshin
Gerald WeissmannGerald Weissmann
His laboratory found that crises in systemic lupus erythematosus are provoked by intravascular complement activation. Using a ... Complement activation and vascular injury in systemic lupus erythematosus. Journal of Rheumatology. 14:43-46, 1987. Kimmel, S.C ...
https://en.wikipedia.org/wiki/Gerald_Weissmann
ACTH receptorACTH receptor
... and systemic lupus erythematosus. This is problematic long-term and can lead to ACTH-receptor pathway-related side effects ...
https://en.wikipedia.org/wiki/ACTH_receptor
2009 swine flu pandemic in Malaysia2009 swine flu pandemic in Malaysia
A 10-year-old school girl, who was diagnosed with Systemic lupus erythematosus was sent to ICU after she had breathing ... Despite on medicine, she died on 13 August due to Systemic lupus erythematous with severe pneumonia with renal impairment. A 71 ...
https://en.wikipedia.org/wiki/2009_swine_flu_pandemic_in_Malaysia
EpiscleritisEpiscleritis
... systemic lupus erythematosus), psoriatic arthritis, ankylosing spondylitis, Cogan syndrome, rosacea, gout, atopy, Crohn's ... Most cases of episcleritis have no identifiable cause, although about a third of cases are associated with various systemic ... Akpek, EK; Uy, HS; Christen, W; Gurdal, C; Foster, CS (April 1999). "Severity of episcleritis and systemic disease association ... Several diseases are associated with episcleritis, including systemic vasculitis (polyarteritis nodosa, granulomatosis with ...
https://en.wikipedia.org/wiki/Episcleritis
Granuloma annulareGranuloma annulare
It has also been associated with auto-immune diseases such as systemic lupus erythematosus, rheumatoid arthritis, Lyme disease ... If local treatment fails it may be treated with systemic corticosteroids. Treatment success varies widely, with most patients ...
https://en.wikipedia.org/wiki/Granuloma_annulare
BelimumabBelimumab
... is primarily used in patients with systemic lupus erythematosus. When it was introduced in 2011, it was the first new ... BLISS-52 Study Group) (February 2011). "Efficacy and safety of belimumab in patients with active systemic lupus erythematosus: ... Hahn BH (April 18, 2013). "Belimumab for Systemic Lupus Erythematosus". N Engl J Med. 368 (16): 1528-1535. doi:10.1056/ ... NICE publishes draft guidance on belimumab for systemic lupus erythematosus, press release, 26 April 2012 Vugmeyster Y, ...
https://en.wikipedia.org/wiki/Belimumab
Chromosome 6Chromosome 6
COL11A2 Systemic lupus erythematosus Diabetes mellitus type 1, HLA-DR, DQA1 & DQB1 X-linked sideroblastic anemia Epilepsy ...
https://en.wikipedia.org/wiki/Chromosome_6
German Center for Pediatric and Adolescent RheumatologyGerman Center for Pediatric and Adolescent Rheumatology
... but also systemic lupus erythematosus, juvenile dermatomyositis, scleroderma and other connective tissue disorders. Patients, ...
https://en.wikipedia.org/wiki/German_Center_for_Pediatric_and_Adolescent_Rheumatology
PharmacoepigeneticsPharmacoepigenetics
... such as systemic lupus erythematosus, rheumatoid arthritis, and systemic onset juvenile idiopathic arthritis. They have also ...
https://en.wikipedia.org/wiki/Pharmacoepigenetics
XerostomiaXerostomia
... primary form but with the addition of a combination of other connective tissue disorders such as systemic lupus erythematosus ... Dysphonia (voice changes). There may also be other systemic signs and symptoms if there is an underlying cause such as ... Important factors in determining systemic and oral health". Journal of Medicine and Life. 2 (3): 303-7. PMC 5052503. PMID ...
https://en.wikipedia.org/wiki/Xerostomia
Diffuse proliferative nephritisDiffuse proliferative nephritis
The most common associated disease of DPGN is severe systemic lupus erythematosus(SLE). Specifically, Lupus nephritis class IV ... "The Classification of Glomerulonephritis in Systemic Lupus Erythematosus Revisited". Journal of the American Society of ... "Mycophenolate mofetil combined with prednisone for diffuse proliferative lupus nephritis: a histopathological study". Lupus. 13 ... Immune-complexes are combinations of DNA, anti-dsDNA ubiquitin, and other proteins in DPGN that are associated with lupus ...
https://en.wikipedia.org/wiki/Diffuse_proliferative_nephritis
HypersensitivityHypersensitivity
... systemic lupus erythematosus, farmers' lung (hypersensitivity pneumonitis), and rheumatoid arthritis.[citation needed] The ...
https://en.wikipedia.org/wiki/Hypersensitivity
Carbonic anhydrase III, muscle specificCarbonic anhydrase III, muscle specific
... systemic lupus erythematosus, and type 1 diabetes. The gene spans 10.3 kb and contains seven exons and six introns. GRCh38: ... systemic lupus erythematosus, diabetes, hypertensive renal disease, and heart failure". Clinical and Developmental Immunology. ...
https://en.wikipedia.org/wiki/Carbonic_anhydrase_III,_muscle_specific
CalcineurinCalcineurin
... adult and juvenile systemic lupus erythematosus, adult lupus membranous nephritis, systemic sclerosis, aplastic anemia, steroid ...
https://en.wikipedia.org/wiki/Calcineurin
Antiphospholipid syndromeAntiphospholipid syndrome
Secondary antiphospholipid syndrome occurs with other autoimmune diseases, such as systemic lupus erythematosus. In rare cases ... most frequently systemic lupus erythematosus, SLE), and catastrophic (when there is simultaneous multi-organ failure with small ... syndrome is responsible for most of the miscarriages in later trimesters seen in concomitant systemic lupus erythematosus and ... Lupus and Pregnancy Archived 2013-02-18 at the Wayback Machine by Michelle Petri. The Johns Hopkins Lupus Center. Retrieved May ...
https://en.wikipedia.org/wiki/Antiphospholipid_syndrome
UveitisUveitis
... arthritis reactive arthritis Behçet's disease inflammatory bowel disease Whipple's disease systemic lupus erythematosus ... List of systemic diseases with ocular manifestations Intermediate uveitis Uveitis-Glaucoma-Hyphema syndrome Jabs DA, ... Occasionally, uveitis is not associated with a systemic condition: the inflammation is confined to the eye and has unknown ... Shah IA, Zuberi BF, Sangi SA, Abbasi SA (1999). "Systemic Manifestations of Iridocyclitis". Pak J Ophthalmol. 15 (2): 61-64. ...
https://en.wikipedia.org/wiki/Uveitis
CCL8CCL8
2008). "CCL genes in multiple sclerosis and systemic lupus erythematosus". J. Neuroimmunol. 200 (1-2): 145-52. doi:10.1016/j. ...
https://en.wikipedia.org/wiki/CCL8
NEGR1NEGR1
2008). "Association of systemic lupus erythematosus with C8orf13-BLK and ITGAM-ITGAX". N. Engl. J. Med. 358 (9): 900-9. doi: ...
https://en.wikipedia.org/wiki/NEGR1
Systemic Lupus Erythematosus (SLE) | CDCSystemic Lupus Erythematosus (SLE) | CDC
... is the most common type of lupus. SLE is an autoimmune disease in which the immune system attacks its own tissues, causing ... Systemic lupus erythematosus (SLE), is the most common type of lupus. SLE is an autoimmune disease in which the immune system ... Lupus QoL-US benchmarks for US patients with systemic lupus erythematosus. J Rheumatol. 2010;37(9):1828-1833. doi:10.3899/ ... The incidence and prevalence of systemic lupus erythematosus in New York County (Manhattan), New York: The Manhattan Lupus ...
https://www.cdc.gov/lupus/facts/detailed.html
Headache and Systemic Lupus ErythematosusHeadache and Systemic Lupus Erythematosus
Headache occurs frequently in patients with systemic lupus erythematosus. This review describes the epidemiology, differential ... Diagnosis and Optimal Treatment for Systemic Lupus Erythematosus and Lupus Nephritis 1.5 CME / CE / ABIM MOC Credits Clinical ... systemic lupus erythematosus (SLE), Behçets syndrome and other systemic or focal (e.g., limbic encephalitis) autoimmune ... Table 1. Summary of controlled studies relating headaches and systemic lupus erythematosus. Primary author/Year. Sample. Data ...
http://www.medscape.com/viewarticle/990983
Systemic lupus erythematosus: MedlinePlus GeneticsSystemic lupus erythematosus: MedlinePlus Genetics
Systemic lupus erythematosus (SLE) is a chronic disease that causes inflammation in connective tissues, such as cartilage and ... SYSTEMIC LUPUS ERYTHEMATOSUS WITH HEMOLYTIC ANEMIA, SUSCEPTIBILITY TO, 1. *SYSTEMIC LUPUS ERYTHEMATOSUS WITH NEPHRITIS, ... SYSTEMIC LUPUS ERYTHEMATOSUS WITH NEPHRITIS, SUSCEPTIBILITY TO, 2. *SYSTEMIC LUPUS ERYTHEMATOSUS WITH NEPHRITIS, SUSCEPTIBILITY ... medlineplus.gov/genetics/condition/systemic-lupus-erythematosus/ Systemic lupus erythematosus. ...
https://medlineplus.gov/genetics/condition/systemic-lupus-erythematosus/
Prognosis and treatment of systemic lupus erythematosusPrognosis and treatment of systemic lupus erythematosus
This article summarizes the evidence for the improved prognosis in patients with systemic lupus erythematosus (SLE). It ... Prognosis and treatment of systemic lupus erythematosus Curr Opin Rheumatol. 1996 Sep;8(5):430-7. doi: 10.1097/00002281- ... This article summarizes the evidence for the improved prognosis in patients with systemic lupus erythematosus (SLE). It ... Lupus Erythematosus, Systemic / diagnosis* * Lupus Erythematosus, Systemic / mortality * Lupus Erythematosus, Systemic / ...
https://pubmed.ncbi.nlm.nih.gov/8941446/?dopt=Abstract
Increased frequencies of Sm and nRNP autoantibodies in American blacks compared to whites with systemic lupus erythematosusIncreased frequencies of Sm and nRNP autoantibodies in American blacks compared to whites with systemic lupus erythematosus
... in 106 whites and 60 blacks with systemic lupus erythematosus. Anti-Sm occurred significantly more frequently in blacks (25 … ... Increased frequencies of Sm and nRNP autoantibodies in American blacks compared to whites with systemic lupus erythematosus J ... in 106 whites and 60 blacks with systemic lupus erythematosus. Anti-Sm occurred significantly more frequently in blacks (25%) ...
https://pubmed.ncbi.nlm.nih.gov/3230562/?dopt=Abstract
Lupus (Systemic Lupus Erythematosus): Lifestyle ManagementLupus (Systemic Lupus Erythematosus): Lifestyle Management
Additional and alternative methods for treating lupus and heart disease. ... Such lifestyle changes, combined with medication, can control lupus symptoms in most people living with lupus. ... Many people with lupus have found support groups to be very useful. Besides providing support, taking part in a support group ... It is also important to find ways to cope with the stress of having lupus. Exercising and finding ways to relax may make it ...
https://www.nationaljewish.org/conditions/lupus-sle/lifestyle
Immunoinflammatory markers and disease activity in systemic lupus erythematosus: something old, something newImmunoinflammatory markers and disease activity in systemic lupus erythematosus: something old, something new
Elwy, M.A., Galal, Z.A. & Hasan, H.E. (‎2010)‎. Immunoinflammatory markers and disease activity in systemic lupus erythematosus ... Immunoinflammatory markers and disease activity in systemic lupus erythematosus: something old, something new. ... of some novel inflammatory markers compared with traditional laboratory markers in patients with systemic lupus erythematosus ... scored using the British Isles Lupus Assessment Group index. Inflammatory markers neopterin and soluble intercellular adhesion ...
https://apps.who.int/iris/handle/10665/117956
Are BCL6 and EZH2 novel therapeutic targets for systemic lupus erythematosus? | Cellular & Molecular ImmunologyAre BCL6 and EZH2 novel therapeutic targets for systemic lupus erythematosus? | Cellular & Molecular Immunology
As a chronic systemic autoimmune disease, systemic lupus erythematosus (SLE) can influence multiple organs and systems. ... Ding, S., Rao, Y. & Lu, Q. Are BCL6 and EZH2 novel therapeutic targets for systemic lupus erythematosus?. Cell Mol Immunol 19, ... Are BCL6 and EZH2 novel therapeutic targets for systemic lupus erythematosus?. *Shu Ding1, ... 6 in circulating follicular helper-like T cells positively correlates with the disease activity in systemic lupus erythematosus ...
https://www.nature.com/articles/s41423-022-00882-1?error=cookies_not_supported
Browsing by Subject Lupus Erythematosus, SystemicBrowsing by Subject "Lupus Erythematosus, Systemic"
Systemic lupus erythematosus and Epstein-Barr virus]‎  Tazi, I.; Fehri, S.; Elghrari, K.; Ouazzani, T.; Benchemsi, N. (‎2009)‎ ... We determined the prevalence of antibodies to Epstein-Barr virus [‎EBV]‎ in 44 patients with systemic lupus erythematosus [‎SLE ... Immunoinflammatory markers and disease activity in systemic lupus erythematosus: something old, something new  ... of some novel inflammatory markers compared with traditional laboratory markers in patients with systemic lupus erythematosus ...
https://extranet.who.int/iris/restricted/browse?authority=Lupus+Erythematosus%2C+Systemic&type=mesh
Glucocorticoids Withdrawal in Early Systemic Lupus Erythematosus - Full Text View - ClinicalTrials.govGlucocorticoids Withdrawal in Early Systemic Lupus Erythematosus - Full Text View - ClinicalTrials.gov
Glucocorticoids Withdrawal in Early Systemic Lupus Erythematosus. The safety and scientific validity of this study is the ... Systemic Lupus Erythematosus Glucocorticoids Therapy Withdrawal Drug: oral Prednisone 5mg Not Applicable ... Lupus Erythematosus, Systemic. Connective Tissue Diseases. Autoimmune Diseases. Immune System Diseases. Prednisone. Anti- ... Glucocorticoids Withdrawal in Early Systemic Lupus Erythematosus: a Randomized Placebo-controlled Equivalence Trial. ...
https://clinicaltrials.gov/ct2/show/NCT03804723
Systemic Lupus Erythematosus (Lupus)Systemic Lupus Erythematosus (Lupus)
... What is lupus?. Systemic lupus erythematosus, also known as SLE, or simply lupus, is a ... Treatment for lupus. There is no cure for lupus. Specific treatment for lupus will be determined by your doctor based on:. *. ... Lupus can potentially be fatal.. The majority of people who have lupus are young women (late teens to 45). This may be due to ... How is lupus diagnosed?. Lupus is difficult to diagnose because of the vagueness of the symptoms each person might have. There ...
https://baycare.org/health-library/systemic-lupus-erythematosus-lupus
AZ's Saphnelo scores US approval for systemic lupus erythematosus - PharmaTimes
AZs Saphnelo scores US approval for systemic lupus erythematosus. 2nd August 2021. ... for the treatment of moderate to severe systemic lupus erythematosus (SLE).. The FDA has specifically cleared Saphnelo for the ... a central driver in systemic lupus erythematosus pathophysiology. This ground-breaking medicine has the potential to ... SLE is the most common form of lupus, affecting up to 300,000 people in the US alone and disproportionately affects the African ...
https://www.pharmatimes.com/news/azs_saphnelo_scores_us_approval_for_systemic_lupus_erythematosus_1373970
Bullous Systemic Lupus Erythematosus (BSLE) Medication: Antimycobacterial Agents, Corticosteroids, Immunosuppressive Agents,...Bullous Systemic Lupus Erythematosus (BSLE) Medication: Antimycobacterial Agents, Corticosteroids, Immunosuppressive Agents,...
... lupus erythematosus is an autoantibody-mediated subepidermal blistering disease that occurs in patients with systemic lupus ... erythematosus (see the image below). {file27914}The diagnosis of bullous systemic lupus erythematosus requires the following ... encoded search term (Bullous Systemic Lupus Erythematosus (BSLE)) and Bullous Systemic Lupus Erythematosus (BSLE) What to Read ... A 12-year retrospective review of bullous systemic lupus erythematosus in cutaneous and systemic lupus erythematosus patients. ...
https://emedicine.medscape.com/article/1065402-medication
Validation of the automated neuropsychological assessment metrics for assessing cognitive impairment in systemic lupus...Validation of the automated neuropsychological assessment metrics for assessing cognitive impairment in systemic lupus...
... in patients with systemic lupus erythematosus (SLE) and developed composite indices for interpreting ANAM results. Our ... of the automated neuropsychological assessment metrics for assessing cognitive impairment in systemic lupus erythematosus ...
https://iwh.on.ca/journal-articles/validation-of-automated-neuropsychological-assessment-metrics-for-assessing-cognitive-impairment-in-systemic-lupus-erythematosus
Systemic lupus erythematosus disease activity index 2000. | The Journal of RheumatologySystemic lupus erythematosus disease activity index 2000. | The Journal of Rheumatology
Systemic lupus erythematosus disease activity index 2000. Message Subject (Your Name) has forwarded a page to you from The ... Systemic lupus erythematosus disease activity index 2000.. Dafna D Gladman, Dominique Ibañez and Murray B Urowitz ... OBJECTIVE: To describe the Systemic Lupus Erythematosus Disease Activity Index 2000 (SLEDAI-2K), a modification of SLEDAI to ... A subgroup of 212 patients with SLE followed at the Lupus Clinic who had 5 regular visits, 3-6 months apart, in 1991-93 was ...
https://www.jrheum.org/content/29/2/288?ijkey=f952a14ed93ebf09ede85862dcd08b4697a9055a&keytype2=tf_ipsecsha
Course Content - #76042: Psychologic Services for Patients with Systemic Lupus Erythematosus - NetCECourse Content - #76042: Psychologic Services for Patients with Systemic Lupus Erythematosus - NetCE
Systemic lupus erythematosus (SLE) is a multi-system, chronic, rare orphan disease that impacts physical and psychologic ... Four different forms of lupus have been identified: cutaneous lupus erythematosus (CLE), drug-induced lupus, neonatal lupus, ... Coping with Lupus: A Practical Guide to Alleviating the Challenges of Systemic Lupus Erythematosus. 4th ed. New York, NY: ... that result in lupus-like symptoms. Neonatal lupus is a rare, non-systemic condition affecting infants of women with lupus; ...
https://www.netce.com/coursecontent.php?courseid=2174
Systemic Lupus Erythematosus (SLE) in Dogs - Veterinary Partner - VINSystemic Lupus Erythematosus (SLE) in Dogs - Veterinary Partner - VIN
Systemic lupus erythematosus (SLE) is a fairly rare chronic and potentially-fatal autoimmune disease. ...
https://veterinarypartner.vin.com/default.aspx?pid=19239&catId=102899&id=4952585&ind=297&objTypeID=1007
Biological Databases and Tools - Systemic Lupus Erythematosus| Protein LoungeBiological Databases and Tools - Systemic Lupus Erythematosus| Protein Lounge
SLE (Systemic lupus erythematosis) is a chronic autoimmune disease characterized by the production of autoantibodies and the ... Systemic lupus erythematosis) is a chronic autoimmune disease characterized by the production of autoantibodies and the ... Systemic Lupus Erythematosus. Description:. SLE (Systemic lupus erythematosis) is a chronic autoimmune disease characterized by ... Systemic lupus erythematosus.. Kaul A, Gordon C, Crow MK, Touma Z, Urowitz MB, van Vollenhoven R, Ruiz-Irastorza G, Hughes G.. ...
https://proteinlounge.com/systemic-lupus-erythematosus-pg-928.html
Fatal Stevens-Johnson syndrome following urography with iopamidol in systemic lupus erythematosus. | Postgraduate Medical...Fatal Stevens-Johnson syndrome following urography with iopamidol in systemic lupus erythematosus. | Postgraduate Medical...
A 46 year old white woman with active systemic lupus erythematosus developed a skin rash 8 hours after intravenous urography ... Fatal Stevens-Johnson syndrome following urography with iopamidol in systemic lupus erythematosus. ... Fatal Stevens-Johnson syndrome following urography with iopamidol in systemic lupus erythematosus. ...
https://pmj.bmj.com/content/64/751/392
High mortality in North American Natives with systemic lupus erythematosusHigh mortality in North American Natives with systemic lupus erythematosus
JavaScript is disabled for your browser. Some features of this site may not work without it ...
https://mspace.lib.umanitoba.ca/xmlui/handle/1993/24059
Low bone mineral density is present in newly diagnosed paediatric systemic lupus erythematosus patients | Annals of the...Low bone mineral density is present in newly diagnosed paediatric systemic lupus erythematosus patients | Annals of the...
The influence of lean mass in trabecular and cortical bone in juvenile onset systemic lupus erythematosus. Lupus 2008;17:787-92 ... Bone mineral density in children and adolescents with systemic lupus erythematosus, juvenile dermatomyositis, and systemic ... Osteoporosis in juvenile systemic lupus erythematosus: a longitudinal study on the effect of steroids on bone mineral density. ... Prevalence and etiology of low bone mineral density in juvenile systemic lupus erythematosus. Arthritis Rheum 2007;56:1966-73. ...
https://ard.bmj.com/content/70/11/1991?ijkey=6f656f04be546dd371e395e75151813d67882385&keytype2=tf_ipsecsha
Septic arthritis caused by Mycoplasma hominis in a patient with systemic lupus erythematosus | BMJ Case ReportsSeptic arthritis caused by Mycoplasma hominis in a patient with systemic lupus erythematosus | BMJ Case Reports
Septic arthritis caused by Mycoplasma hominis in a patient with systemic lupus erythematosus ... Septic arthritis caused by Mycoplasma hominis in a patient with systemic lupus erythematosus ... hominis in a 27-year-old woman with systemic lupus erythematosus (SLE), who presented with a 2-week history of left elbow ...
https://casereports.bmj.com/content/15/1/e247675
WHO EMRO | Immunoinflammatory markers and disease activity in systemic lupus erythematosus: something old, something new |...
Immunoinflammatory markers and disease activity in systemic lupus erythematosus: something old, something new ... Lupus, 2002, 11(12):770-773.. *Kyttaris VC, Juang YT, Tsokos GC. Immune cells and cytokines in systemic lupus erythematosus: an ... Systemic lupus erythematosus glomerulonephritis (lupus nephritis). In: Cluskey RT, Andres GA, eds. Immunologically Mediated ... Serum soluble markers of immune activation and disease activity in systemic lupus erythematosus. Lupus, 1995, 4(1):29-32. ...
https://www.emro.who.int/emhj-volume-16-2010/volume-16-issue-8/article-12.html
Have you any suggestions as to diet or alternative treatment for systemic lupus erythematosus (SLE)? - Ask the Dietitian®Have you any suggestions as to diet or alternative treatment for systemic lupus erythematosus (SLE)? - Ask the Dietitian®
Have you any suggestions as to diet or alternative treatment for systemic lupus erythematosus (SLE)? I have just received an " ... Have you any suggestions as to diet or alternative treatment for systemic lupus erythematosus (SLE)?. By ... Home Nutrition Therapy Autoimmune Disease Have you any suggestions as to diet or alternative treatment for systemic... ... Lupus is an autoimmune disease. It is treated with aspirin for mild cases or steroids like prednisone for severe cases. ...
https://www.dietitian.com/nutrition-therapy/autoimmune-disease/have-you-any-suggestions-as-to-diet-or-alternative-treatment-for-systemic-lupus-erythematosus-sle/
Recurrent podocytopathy in a patient with systemic lupus erythematosus.<...
title = "Recurrent podocytopathy in a patient with systemic lupus erythematosus.",. abstract = "Podocytopathy in systemic lupus ... Paramalingam, S, Wong, D, Dogra, GK & Nossent, J 2017, Recurrent podocytopathy in a patient with systemic lupus erythematosus. ... Recurrent podocytopathy in a patient with systemic lupus erythematosus. In: SAGE Open Medical Case Reports . 2017 ; Vol. 5. pp ... Recurrent podocytopathy in a patient with systemic lupus erythematosus.. Shereen Paramalingam, Daniel Wong, G.K. Dogra, ...
https://research-repository.uwa.edu.au/en/publications/recurrent-podocytopathy-in-a-patient-with-systemic-lupus-erythema
Systemic lupus erythematosus -diagnosis and management - Medical IndependentSystemic lupus erythematosus -diagnosis and management - Medical Independent
Systemic lupus erythematosus -diagnosis and management. By Dr Wan Lin Ng, SpR in Rheumatology; and Dr Laura Durcan, Consultant ... Systemic lupus erythematosus (SLE) is a multisystem autoimmune disease characterised by the presence of autoantibodies, which ... a) Lupus nephritis. Lupus nephritis occurs in up to 60 per cent of SLE patients, is most marked in non-Caucasians and is a ... To diagnose SLE based on the Systemic Lupus International Collaborating Clinics (SLICC) 2012 criteria, the patient needs to ...
https://www.medicalindependent.ie/societies/isr/systemic-lupus-erythematosus-diagnosis-and-management/
ATR-mediated DNA damage responses underlie aberrant B cell activity in systemic lupus erythematosus - Research Highlights -...
Research Highlights :ATR-mediated DNA damage responses underlie aberrant B cell activity in systemic lupus erythematosus ... ATR-mediated DNA damage responses underlie aberrant B cell activity in systemic lupus erythematosus. Manolakou T, Nikolopoulos ...
http://www.bioacademy.gr/research-highlights-details/XsaOsDbS/atr-mediated-dna-damage-responses-underlie-aberrant-b-cell-a
Whole-genome sequencing identifies complex contributions to genetic risk by variants in genes causing monogenic systemic lupus...Whole-genome sequencing identifies complex contributions to genetic risk by variants in genes causing monogenic systemic lupus...
Systemic lupus erythematosus (SLE, OMIM 152700) is a systemic autoimmune disease with a complex etiology. The mode of ... Systemic lupus erythematosus (SLE, OMIM 152700) is a systemic autoimmune disease with a complex etiology. The mode of ... article{d5fdf66f-7a3d-4321-8cc0-6de4c60d232c, abstract = {{,p,Systemic lupus erythematosus (SLE, OMIM 152700) is a systemic ... Whole-genome sequencing identifies complex contributions to genetic risk by variants in genes causing monogenic systemic lupus ...
https://lup.lub.lu.se/search/publication/d5fdf66f-7a3d-4321-8cc0-6de4c60d232c
DERMATOMYOSITIS AND SYSTEMIC LUPUS ERYTHEMATOSUS: I. A CLINICAL REPORT OF TRANSITIONAL CASES, WITH A CONSIDERATION OF LEAD AS A...DERMATOMYOSITIS AND SYSTEMIC LUPUS ERYTHEMATOSUS: I. A CLINICAL REPORT OF TRANSITIONAL CASES, WITH A CONSIDERATION OF LEAD AS A...
Conception of Lupus Erythematosus and Its Morphologic Variants, with Particular Reference to Systemic Lupus Erythematosus , ... 36:729 ( (Oct.) ) 1937 3. Relation Between Systemic Lupus Erythematosus and a Peculiar Form of Thrombocytopenic Purpura , ... This is also References 1. Keil, H.: (a) Relationship Between Lupus Erythematosus and Tuberculosis: A Critical Review Based on ... Ludy, J. B., and Corson, E. F.: Lupus Erythematosus: Increased Incidence, Hematoporphyrinuria and Spectroscopic Findings , Arch ...
https://www.deepdyve.com/lp/american-medical-association/dermatomyositis-and-systemic-lupus-erythematosus-i-a-clinical-report-NE3yr0iY9N?key=JAMA
Diffuse myometrium thinning and placenta accreta spectrum in a patient with systemic lupus erythematosus (SLE): a case report...Diffuse myometrium thinning and placenta accreta spectrum in a patient with systemic lupus erythematosus (SLE): a case report...
A twenty-nine-year-old primigravida with a history of lupus enteritis and paralytic ileus had a natural conception after less ... Cases of uterine wall thinning and placental abnormalities complicated with systemic lupus erythematosus (SLE) during pregnancy ... From: Diffuse myometrium thinning and placenta accreta spectrum in a patient with systemic lupus erythematosus (SLE): a case ...
https://bmcpregnancychildbirth.biomedcentral.com/articles/10.1186/s12884-022-04864-z/figures/1
ChronicRheumatoid arthritisInclude systemic lupus erythemPatients with lupusBritish Isles Lupus Assessment GroupRheumatologyAutoimmune diseases2020International Collaborating ClinicsNephritisInflammatory2017ArthritisSymptomsSclerodermaDiseasesManifestationsCutaneous lupusDiseaseInfectionInflammationOutcomesDiagnosis and treatmentAbstractMortalityPathophysiologySevereFoundation of AmericaNeutrophilTherapyImpairmentPrognosisPaediatricType of lupusCentersInvolvementStudyPeople with lupusAutoimmunityClinical trialClassificationVariantsTuberculosisManage lupus
Chronic13
  • Systemic lupus erythematosus (SLE) is a chronic autoimmune and potentially fatal disease. (medscape.com)
  • Systemic lupus erythematosus (SLE) is a chronic disease that causes inflammation in connective tissues, such as cartilage and the lining of blood vessels, which provide strength and flexibility to structures throughout the body. (medlineplus.gov)
  • As a chronic systemic autoimmune disease, systemic lupus erythematosus (SLE) can influence multiple organs and systems. (nature.com)
  • Lupus symptoms are usually chronic and relapsing. (baycare.org)
  • Systemic lupus erythematosus (SLE) is a multi-system, chronic, rare orphan disease that impacts physical and psychologic functioning. (netce.com)
  • SLE (Systemic lupus erythematosis) is a chronic autoimmune disease characterized by the production of autoantibodies and the deposition of immune complexes, affecting a wide range of organs. (proteinlounge.com)
  • Systemic lupus erythematosus (SLE) is an autoimmune disease characterized by affecting predominantly woman of childbearing age in a chronic, relapsing-remitting course. (efim.org)
  • Systemic lupus erythematosus (SLE) is a chronic, heterogeneous systemic autoimmune disease, with a prevalence in Hungary of 70.5 per 100,000 people, depending on both sex (women are affected nine to ten times more often than men) and age (onset of SLE peaks from the second to the fourth decade of life) ( 1 ). (iiarjournals.org)
  • This article presents the report of psychological intervention in the pediatric ward of a school hospital, referring to the recent statement of diagnosis and early treatment of a chronic disease called Juvenile Systemic Lupus Erythematosus. (bvsalud.org)
  • Introduction: Systemic lupus erythematosus (SLE ) is a chronic inflammatory disease of unknown cause and autoimmune nature. (bvsalud.org)
  • Treatment of chronic discoid lupus erythematosus in adults. (nih.gov)
  • Systemic lupus erythematosus (SLE) is a multisystemic chronic autoimmune disease with a varied clinical history. (2pressrelease.net)
  • Inform your doctor if you have or have had had kidney or liver illness, high cholesterol, diabetes, asthma, gout, or systemic lupus erythematosus (SLE), a chronic inflammatory disease. (prescriptiongiant.com)
Rheumatoid arthritis3
  • No role for the TNF gene cluster in the genetic predisposition to rheumatoid arthritis or systemic lupus erythematosus. (ox.ac.uk)
  • There were 24 people with rheumatoid arthritis, one with scleroderma, and one with systemic lupus erythematosus. (cdc.gov)
  • who are latently infected with an on- Certain pharmaceutical drugs, Immunosuppression as a medi- cogenic virus are at greatly increased ionizing and ultraviolet radiation, cal therapy is used to treat autoim- risk for developing virus-related or infection with certain viruses mune diseases such as lupus ery- cancers when they become immu- and parasites can cause immu- thematosus or rheumatoid arthritis. (who.int)
Include systemic lupus erythem2
  • They include systemic lupus erythematosus (SLE), antiphospholipid syndrome (APS), or renal disease. (alale.co)
  • Systemic conditions-those that attack multiple systems-include systemic lupus erythematosus, also known as lupus or SLE, Sjögren's syndrome , and scleroderma , which all affect tissues and organs throughout the body. (medlineplus.gov)
Patients with lupus2
  • The severity of the kidney involvement can alter the survival rate of patients with lupus. (baycare.org)
  • The U.S. National Institutes of Health (NIH) is conducting a research study for patients with lupus. (lupustrials.org)
British Isles Lupus Assessment Group3
  • In a cohort of 43 SLE patients [‎19 with inactive and 24 with active SLE]‎ and 20 healthy controls, serial measures of soluble vascular cell adhesion molecule [‎sVCAM-1]‎ were significantly associated with SLE disease activity, scored using the British Isles Lupus Assessment Group index. (who.int)
  • Ces mesures ont été effectuées selon l'indice du British Isles Lupus Assessment Group (Groupe d'évaluation du lupus des îles britanniques). (who.int)
  • It comprises criteria from 3 indices, SELENA-SLE Disease Activity Index (SELENA-SLEDAI), Physician Global Assessment, and the British Isles Lupus Assessment Group (BILAG). (clinicalstudydatarequest.com)
Rheumatology1
  • SLICC/ACR, Systemic Lupus International Collaborating Clinics/American College of Rheumatology. (rheumatologynetwork.com)
Autoimmune diseases2
  • Moreover, the importance of the interaction between BCL-6 and IL-21 in Tfh cell differentiation and autoantibody production should not be ignored, especially in lupus and some autoimmune diseases. (nature.com)
  • For example, many kinds of autoimmune diseases such as lupus, scleroderma, and Sjögren's syndrome are far more common among women than among men. (medlineplus.gov)
20201
  • Lung involvement during hospitalization for systemic lupus erythematosus (SLE) may be associated with greater inpatient mortality, according to study results presented at the 2020 CHEST Annual Meeting, held virtually October 18 to 21. (pulmonologyadvisor.com)
International Collaborating Clinics1
  • To diagnose SLE based on the Systemic Lupus International Collaborating Clinics (SLICC) 2012 criteria, the patient needs to meet four criteria with at least one clinical and at least one immunologic (autoantibodies or low complement) in the absence of biopsy-proven nephritis. (medicalindependent.ie)
Nephritis8
  • Poojary S, Rais S. Bullous systemic lupus erythematosus with lupus nephritis: a rare case of a subepidermal bullous disorder in a child. (medscape.com)
  • Lupus podocytopathy falls outside the scope of the current International Society of Nephrology and the Renal Pathology Society classification of lupus nephritis. (edu.au)
  • However, it allows lupus nephritis to be the sole criterion in the presence of anti-dsDNA or ANA antibodies. (medicalindependent.ie)
  • In our case report in this article, the patient had biopsy-proven lupus nephritis along with meeting five-of-11 clinical criteria and four-of-six immunologic criteria of the SLICC criteria. (medicalindependent.ie)
  • Belimumab is FDA-approved for the treatment of active lupus nephritis. (mhmedical.com)
  • Voclosporin, a novel calcineurin inhibitor, is FDA-approved to treat active lupus nephritis when used in combination with mycophenolate mofetil. (mhmedical.com)
  • In 2019 and 2021, the European League for Rheumatism (EULAR) jointly with the European Renal Association (ERA) and the Kidney Disease: Improving Global Outcomes (KDIGO), respectively, released updated guidelines on the management of lupus nephritis (LN). The Immunology Working Group of the ERA reviewed and compared both updates. (medscape.com)
  • Lupus nephritis (LN) is a frequent complication of systemic lupus erythematosus (SLE), a systemic autoimmune disease affecting mostly young women. (medscape.com)
Inflammatory4
  • This case report describes the occurrence of septic arthritis secondary to M. hominis in a 27-year-old woman with systemic lupus erythematosus (SLE), who presented with a 2-week history of left elbow swelling and tenderness, elevated inflammatory markers and joint aspiration findings consistent with infection. (bmj.com)
  • Systemic inflammatory response syndrome developed in 64% of patients, 35% needed intensive care unit admission, and 22.8% had multi-organ failure. (rheumatologynetwork.com)
  • Background/Aim: Despite remission or low disease activity non-inflammatory complaints like exhaustion, fatigue, and pain persist in a significant proportion of patients with systemic lupus erythematosus (SLE) and have a considerable impact on health-related quality of life. (iiarjournals.org)
  • The drug is a monoclonal antibody that blocks BDCA2 cells which inhibit the production of major inflammatory mediators in lupus. (lupus.org)
20171
  • Mansi has been suffering from Systemic Lupus Erythematosus (SLE) since 2017. (milaap.org)
Arthritis4
  • According to the Arthritis Foundation, about 25,000 children and adolescents have lupus or a related disorder. (baycare.org)
  • Background: The application of more sensitive imaging techniques, such as ultrasonography (US), changed the concept of non-erosive arthritis in systemic lupus erythematosus (SLE), underlining the need for biomarkers to identify patients developing the erosive phenotype. (uniroma1.it)
  • For Dr. Kaposi to group together patients with such varied manifestations as arthritis, pleurisy and coma, all of whom also had cutaneous lupus, was bold and prescient. (the-rheumatologist.org)
  • This study was approved by the nile idiopathic arthritis or systemic lupus erythematosus). (bvsalud.org)
Symptoms10
  • Learn more about lupus symptoms . (cdc.gov)
  • Learn more about lupus triggers and how to control your symptoms on the Managing Lupus page . (cdc.gov)
  • Such lifestyle changes, combined with medication, can control lupus symptoms in most people living with lupus. (nationaljewish.org)
  • What are the symptoms of lupus? (baycare.org)
  • The following are the most common symptoms of lupus. (baycare.org)
  • The symptoms of lupus may resemble other medical conditions or problems. (baycare.org)
  • Lupus is difficult to diagnose because of the vagueness of the symptoms each person might have. (baycare.org)
  • It is a systemic disease, with a large spectrum of signs and symptoms. (pharmafile.com)
  • Stevens Johnson syndrome, toxic epidermal necrolysis, drug reaction with eosinophilia and systemic symptoms, acute generalized exanthematous pustulosis have been reported. (nih.gov)
  • Leg pain that has different characteristics such as localized, persistent or intensifying pain, pain that occurs at different times of the day, obvious joint involvement, limb swelling or erythema or systemic symptoms demand a more extensive history and laboratory and/or radiological investigation. (pediatriceducation.org)
Scleroderma1
  • The prevalence of scleroderma was 0.2% (RR 15.65, 95% CL 0.21-87.03) and the prevalence of systemic lupus erythematosus was 0.2% (RR 11.37, 95% CL 0.15-63.23). (cdc.gov)
Diseases8
  • Accumulating evidence now indicates that the presence of faecal haemoglobin, in the absence of gastrointestinal bleeding, may be an indicator of systemic inflammation and is linked to the development of human diseases. (biomedcentral.com)
  • Of note, patients with a poor corneal surface, especially those with systemic diseases in whom keratoconjunctivitis sicca (dry eye syndrome) often is also present, are at increased risk for corneal infection. (medscape.com)
  • Conclusion: The oral health of the patients is poor, there is great variability in systemic diseases, use of various drugs with negative side effects and immunosuppressants for the general condition of patients with SLE. (bvsalud.org)
  • Despite the controversy, researchers continue to investigate the effects of mercury poisoning and have now linked it to many other diseases including MS, CFS and lupus. (fibromyalgia-symptoms.org)
  • We could not elucidate pathophysiology of systemic diseases like lupus without first looking for commonalities and distinctions among patients," says Dr. Salmon. (the-rheumatologist.org)
  • To better understand how it affects the ones with auto-immune diseases, as well as how to better protect ourselves, the Lupus Foundation of America has done a great job consolidating the latest info. (lupushope.org)
  • In systemic diseases with microvasculature damage as a prominent feature, abnormalities of nailfold capillaries can be appreciated before the onset of clinical disease. (cdriadvlkn.org)
  • 4] Thenceforth, nailfold capillaroscopy become an important diagnostic tool for diagnosing progressive connective tissue diseases such as systemic sclerosis, mixed connective tissue disease, lupus erythematosus, dermatomyositis, and polymyositis, and also in patients with Raynaud's phenomenon. (cdriadvlkn.org)
Manifestations2
  • Systemic lupus erythematosus (SLE) is an autoimmune disorder with heterogeneous clinical manifestations and target tissue damage. (elsevier.com)
  • Objective: Incomplete lupus erythematosus (ILE) involves clinical and/or serologic manifestations consistent with but insufficient for systemic lupus erythematosus (SLE) classification. (elsevier.com)
Cutaneous lupus2
  • This provides an antibody-mediated blockade of Fas-Fas ligand interactions involved in the epidermal necrosis of toxic epidermal necrolysis-like cutaneous lupus erythematosus. (medscape.com)
  • The drug demonstrated statistically significant reduction of disease activity in people with cutaneous lupus (CLE) and systemic lupus erythematosus (SLE) compared to those who received placebo. (lupus.org)
Disease24
  • Although used in disease activity scores, the concept of lupus headache is controversial. (medscape.com)
  • This is a 36 months, randomized, double-blind, placebo-controlled, parallel-groups, equivalence multicenter trial in patients with inactive Systemic Lupus Erythematosus to evaluate if low disease activity can be sustained with withdrawal of glucocorticoids in patients on stable clinical remission or low disease activity. (clinicaltrials.gov)
  • Concomitant ongoing conditions (e.g. asthma, Crohn's disease) that require treatment with systemic GC (excluding topical or inhaled GC). (clinicaltrials.gov)
  • Systemic lupus erythematosus disease activity index 2000. (jrheum.org)
  • OBJECTIVE: To describe the Systemic Lupus Erythematosus Disease Activity Index 2000 (SLEDAI-2K), a modification of SLEDAI to reflect persistent, active disease in those descriptors that had previously only considered new or recurrent occurrences, and to validate SLEDAI-2K against the original SLEDAI as a predictor for mortality and as a measure of global disease activity in the clinic. (jrheum.org)
  • Pathways leading to an immunological disease: systemic lupus erythematosus. (proteinlounge.com)
  • Home Nutrition Therapy Autoimmune Disease Have you any suggestions as to diet or alternative treatment for systemic. (dietitian.com)
  • Lupus is an autoimmune disease. (dietitian.com)
  • We present a case of relapsing podocytopathy with nephrotic syndrome occurring simultaneously with two extra-renal and serological disease flares, which makes it likely that podocytopathy was related to systemic lupus erythematosus activity. (edu.au)
  • Systemic lupus erythematosus (SLE) is a multisystem autoimmune disease characterised by the presence of autoantibodies, which can cause inflammation in various organs. (medicalindependent.ie)
  • Systemic lupus erythematosus (SLE, OMIM 152700) is a systemic autoimmune disease with a complex etiology. (lu.se)
  • Early in the course of my studies on lupus erythematosus1 it became apparent to me that there were resemblances between that disease and dermatomyositis. (deepdyve.com)
  • Systemic Lupus Erythematosus (SLE) is an autoimmune disease, characterised by an autoantibody response to nuclear and cytoplasmic antigens. (pharmafile.com)
  • Interstitial lung disease associated with systemic lupus erythematosus : a monocentric study of 23 cases. (ers-education.org)
  • We have typed 64 Japanese patients with mixed connective tissue disease (MCTD) and 53 Japanese patients with systemic lupus erythematosus (SLE) for HLA‐DRB1, DRB3, DRB4, DRB5, DQA1, DQB1, and DPB1 genes by the HLA‐DNA typing method using the PCR‐SSOP technique. (elsevier.com)
  • Background: Systemic lupus erythematosus (SLE) is a multi-system autoimmune disease with a great variability in disease presentation and course. (who.int)
  • The frequency, types of systemic damage, use of controlled medications used to treat this disease that undertake dental treatment. (bvsalud.org)
  • Transmission an incidence rate of 1.5 cases/1,000 live births and a of T. gondii can occur through food items and the en- burden of disease of 1.2 million disease-adjusted life vironment. (cdc.gov)
  • She also emphasizes the importance of Kaposi's contribution in recognizing SLE as a systemic disease, because that enabled the search for underlying mechanisms. (the-rheumatologist.org)
  • Systemic lupus erythematosus (SLE), a complex and heterogeneous autoimmune disease, represents a significant challenge for both diagnosis and treatment. (bvsalud.org)
  • Lupus, technically known as systemic lupus erythematosus (SLE), is an autoimmune disease in which. (onionsearchengine.com)
  • Lewy body (ies) (disease) (G31.8) · multiple sclerosis (G35) · neurosyphilis (A52.1) · niacin deficiency [pellagra] (E52) · polyarteritis nodosa (M30.0) · systemic lupus erythematosus (M32. (who.int)
  • ABSTRACT Objective: to learn the perception of individuals with Systemic Lupus Erythematosus about living with the disease. (bvsalud.org)
  • The functional prediction results indicated that T2 treatment inhibited some carbohydrate metabolism pathways and induced certain disease-related pathways (e.g., those related to systemic lupus erythematosus, Vibrio cholerae infection, hypertrophic cardiomyopathy, and shigellosis). (bvsalud.org)
Infection3
  • Updates from the 2018 European Lupus Society Meeting focus on the risk infection poses to patients with SLE. (rheumatologynetwork.com)
  • Simard J, Rossides M, Arkema E. Serious infection rates in systemic lupus erythematosus: a Swedish population-based assessment. (rheumatologynetwork.com)
  • Objective: To evaluate Pneumocystis jirovecii pneumonia (PJP) infection risk in patients with systemic lupus erythematosus (SLE) in Taiwan. (elsevier.com)
Inflammation1
  • 3 Many patients with posterior uveitis or panuveitis depend on systemic steroids to achieve longterm control of intraocular inflammation. (touchophthalmology.com)
Outcomes5
  • Clinical, histological, immunological presentations and outcomes of bullous systemic lupus erythematosus: 10 New cases and a literature review of 118 cases. (medscape.com)
  • Bacteremia in systemic lupus erythematosus patients from Relesser Registry: risk factors, clinical and microbiological characteristics and outcomes. (rheumatologynetwork.com)
  • Systemic lupus erythematosus (SLE) has a high female predominance with a 9:1 female-to-male sex ratio, but males have poorer clinical outcomes than females. (ox.ac.uk)
  • Results: Adverse perinatal outcomes increase in pregnancies with lupus. (ac.ir)
  • 4 These patients may suffer worse outcomes than patients treated with systemic steroids due to visual loss in the interval between steroid injections. (touchophthalmology.com)
Diagnosis and treatment1
  • Learn more about lupus diagnosis and treatment . (cdc.gov)
Abstract2
  • abstract = "Podocytopathy in systemic lupus erythematosus is characterised by diffuse foot process effacement without significantperipheral capillary wall immune deposits as seen on electron microscopy. (edu.au)
  • Abstract Introduction Glucocorticoid (GC) therapy remains important in improving the prognosis of patients with systemic lupus erythematosus (SLE). (escholarship.org)
Mortality3
  • Lung involvement during hospitalization for systemic lupus erythematosus may be associated with greater inpatient mortality. (pulmonologyadvisor.com)
  • Edigin E, Prado V, Salazar M, and Shaka H. Lung involvement in systemic lupus erythematosus increases inpatient mortality: analysis of the national inpatient sample . (pulmonologyadvisor.com)
  • The pathobiology of the autoimmune neutropenia in Felty's syndrome and systemic lupus erythematosus is complex, and it could be a major cause of morbidity and mortality due to increased risk of sepsis. (nebraska.edu)
Pathophysiology1
  • Today's landmark approval of Saphnelo is the culmination of years of AstraZeneca's pioneering research in the type I interferon pathway, a central driver in systemic lupus erythematosus pathophysiology. (pharmatimes.com)
Severe2
  • Lupus affects each individual differently and the effects of the illness range from mild to severe. (baycare.org)
  • The US Food and Drug Administration (FDA) has approved AstraZeneca's Saphnelo (anifrolumab) for the treatment of moderate to severe systemic lupus erythematosus (SLE). (pharmatimes.com)
Foundation of America2
  • Continue to follow the Lupus Foundation of America for updates on BIIB059 and learn more about medications used to treat lupus . (lupus.org)
  • The Lupus Foundation of America works to improve the quality of life for all people affected by lupus through programs of research, education, support and advocacy. (lupus.org)
Neutrophil3
  • Neutrophil Extracellular Traps and Systemic Lupus Erythematosus. (proteinlounge.com)
  • Autoimmune neutropenia, caused by neutrophil-specific autoantibodies is a common phenomenon in autoimmune disorders such as Felty's syndrome and systemic lupus erythematosus. (nebraska.edu)
  • Recombinant human granulocyte colony-stimulating factor is a safe and effective therapeutic modality in management of autoimmune neutropenia associated with Felty's syndrome and systemic lupus erythematosus, which stimulates neutrophil production. (nebraska.edu)
Therapy4
  • Bullous systemic lupus erythematosus generally responds well to medical therapy. (medscape.com)
  • Relevant differences in the recommended management relate to the recognition of lupus podocytopathies, uncertainties in steroid dosing, drug preferences in specific populations and maintenance therapy, treatment of pure class V LN, therapy of recurrent LN, evolving alternative drug options and diagnostic work-up of thrombotic microangiopathy. (medscape.com)
  • Topical steroid drops and ointment are primarily useful for anterior uveitis or as adjunct therapy along with systemic treatment for panuveitis, as penetration into the posterior segment is minimal. (touchophthalmology.com)
  • 3 The relatively low systemic concentration of steroids achieved by this method spares patients from the usual complications of systemic steroid therapy. (touchophthalmology.com)
Impairment2
  • OBJECTIVE: We previously demonstrated the utility of the Automated Neuropsychological Assessment Metrics (ANAM) for screening cognitive impairment (CI) in patients with systemic lupus erythematosus (SLE) and developed composite indices for interpreting ANAM results. (iwh.on.ca)
  • Pre-validated survey instruments including Lupus Quality of Life (LupusQoL), Short-Form Health Survey (SF-36), Work Productivity, and Activity Impairment-Lupus (WPAI-Lupus) questionnaires were used. (iiarjournals.org)
Prognosis1
  • This article summarizes the evidence for the improved prognosis in patients with systemic lupus erythematosus (SLE). (nih.gov)
Paediatric1
  • Objectives The objectives of this study were to (1) determine the prevalence of low bone mineral density (BMD) in a large prospective cohort of newly diagnosed patients with paediatric systemic lupus erythematosus (pSLE) and (2) identify risk factors associated with low BMD. (bmj.com)
Type of lupus3
  • Systemic lupus erythematosus (SLE), is the most common type of lupus. (cdc.gov)
  • Click here to search lupus trials by where you live and the type of lupus you have. (lupustrials.org)
  • Use this tool to search all lupus trials and create a personalized list of studies by the type of lupus you have and where you live. (lupustrials.org)
Centers1
  • The Lupus Clinical Investigators Network (LuCIN), is comprised of leading lupus experts at academic research centers throughout North America. (lupustrials.org)
Involvement2
  • Children with lupus can have a large degree of kidney involvement. (baycare.org)
  • Systemic lupus erythematosus (SLE): Cyto- and chemokines as possible serum markers for pulmonary involvement? (ers-education.org)
Study2
  • This was a retrospective inception cohort study of newly diagnosed pSLE patients seen at the SickKids Lupus Clinic between December 2001 and December 2007. (bmj.com)
  • Associations between clinically diagnosed testicular hypofunction and systemic lupus erythematosus: a record linkage study. (ox.ac.uk)
People with lupus4
  • People with lupus that get proper medical care, preventive care, and education can significantly improve function and quality of life. (cdc.gov)
  • As mentioned above, recent evidence also suggests that people with lupus may have an increased risk of heart attacks as compared with the general population. (nationaljewish.org)
  • Many people with lupus have found support groups to be very useful. (nationaljewish.org)
  • This test is done to detect for certain antibodies that are present in most people with lupus. (baycare.org)
Autoimmunity2
  • Newman, KA & Akhtari, M 2011, ' Management of autoimmune neutropenia in Felty's syndrome and systemic lupus erythematosus ', Autoimmunity Reviews , vol. 10, no. 7, pp. 432-437. (nebraska.edu)
  • Nonetheless, it is increasingly recognised that the human intestine also serves as an active organ, playing a pivotal role in the development of systemic autoimmunity [ 1 ]. (biomedcentral.com)
Clinical trial1
  • Lupus Therapeutics has an unprecedented network of clinical trial sites. (lupustrials.org)
Classification1
  • Neutropenia is also common in systemic lupus erythematosus and it is included in the current systemic lupus classification criteria. (nebraska.edu)
Variants1
  • Conception of Lupus Erythematosus and Its Morphologic Variants, with Particular Reference to 'Systemic' Lupus Erythematosus , Keil Arch. (deepdyve.com)
Tuberculosis1
  • Keil, H.: (a) Relationship Between Lupus Erythematosus and Tuberculosis: A Critical Review Based on Observations at Necropsy , Arch. (deepdyve.com)
Manage lupus2
  • Learn what you can do to manage lupus . (cdc.gov)
  • Join SELF, our online self-management program to help you better manage lupus. (lupus.org)